WO2002020530A1 - Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors - Google Patents

Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors Download PDF

Info

Publication number
WO2002020530A1
WO2002020530A1 PCT/SE2001/001880 SE0101880W WO0220530A1 WO 2002020530 A1 WO2002020530 A1 WO 2002020530A1 SE 0101880 W SE0101880 W SE 0101880W WO 0220530 A1 WO0220530 A1 WO 0220530A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbamoyl
thieno
dichloro
alkyl
pyrrole
Prior art date
Application number
PCT/SE2001/001880
Other languages
French (fr)
Inventor
Julie B. Bartlett
Sue Freeman
Peter Kenny
Andrew Morley
Paul Whittamore
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL01361024A priority Critical patent/PL361024A1/en
Priority to CA002417594A priority patent/CA2417594A1/en
Priority to KR1020037003265A priority patent/KR100802369B1/en
Priority to MXPA03001512A priority patent/MXPA03001512A/en
Priority to DK01961577T priority patent/DK1317459T3/en
Priority to JP2002525151A priority patent/JP2004508376A/en
Priority to AU2001282833A priority patent/AU2001282833B2/en
Priority to SI200130112T priority patent/SI1317459T1/en
Priority to BR0113606-2A priority patent/BR0113606A/en
Priority to HU0400784A priority patent/HUP0400784A3/en
Priority to AU8283301A priority patent/AU8283301A/en
Priority to NZ524011A priority patent/NZ524011A/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to EEP200300083A priority patent/EE200300083A/en
Priority to US10/344,506 priority patent/US20030232875A1/en
Priority to SK259-2003A priority patent/SK2592003A3/en
Priority to DE60102710T priority patent/DE60102710T2/en
Priority to IL15429101A priority patent/IL154291A0/en
Priority to UA2003021026A priority patent/UA73781C2/en
Priority to EP01961577A priority patent/EP1317459B1/en
Priority to AT01961577T priority patent/ATE263772T1/en
Publication of WO2002020530A1 publication Critical patent/WO2002020530A1/en
Priority to IS6727A priority patent/IS2110B/en
Priority to NO20031024A priority patent/NO20031024D0/en
Priority to BG107624A priority patent/BG107624A/en
Priority to HK03107519A priority patent/HK1055299A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to heterocyclic amide derivatives, pharmaceutically acceptable salts and in vivo hydrolysable esters thereof. These heterocyclic amides possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity and thus are potentially useful in methods for the treatment of a warm-blooded animal such as man.
  • the invention also relates to processes for the manufacture of said heterocyclic amide derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments to inhibit glycogen phosphorylase activity in a warm-blooded animal such as man.
  • the liver is the major organ regulating glycaemia in the post-absorptive state. Additionally, although having a smaller role in the contribution to post-prandial blood glucose levels, the response of the liver to exogenous sources of plasma glucose is key to an ability to maintain euglycaemia.
  • An increased hepatic glucose output (HGO) is considered to play an important role in maintaining the elevated fasting plasma glucose (FPG) levels seen in type 2 diabetics; particularly those with a FPG >140mg/dl (7.8mM).
  • HGO glycogenolysis
  • gluconeogenic precursors Hellerstein et al (1997) Am J Physiol, 272: E163).
  • Glycogen phosphorylase is a key enzyme in the generation by glycogenolysis of glucose- 1 -phosphate, and hence glucose in liver and also in other tissues such as muscle and neuronal tissue.
  • Liver glycogen phosphorylase activity is elevated in diabetic animal models including the db/db mouse and the fa/fa rat (Aiston S et al (2000). Diabetalogia 43, 589-597). Inhibition of hepatic glycogen phosphorylase with chloroindole inhibitors (CP91149 and CP320626) has been shown to reduce both glucagon stimulated glycogenolysis and glucose output in hepatocytes (Hoover et al (1998) J Med Chem 41, 2934-8; Martin et al (1998) PNAS 95, 1776-81, WO 96/39384 and WO 96/39385). Additionally, plasma glucose concentration is reduced, in a dose related manner, in db/db and ob/ob mice following treatment with these compounds.
  • Bay K 3401 Studies in conscious dogs with glucagon challenge in the absence and presence of another glycogen phosphorylase inhibitor, Bay K 3401, also show the potential utility of such agents where there is elevated circulating levels of glucagon, as in both Type 1 and Type 2 diabetes. In the presence of Bay R 3401, hepatic glucose output and arterial plasma glucose levels following a glucagon challenge were reduced significantly (Shiota et al, (1997), Am J Physiol, 273: E868).
  • ES 2,081,747 discloses that certain amide derivatives of 4H-thieno[3,2-b]pyrroles and 4H-thieno[2,3-b]pyrroles are CCK antagonists and are useful in the treatment of gastric secretion disorders and in the regulation of appetite.
  • the compounds disclosed in this document are disclaimed from the compound claims of the present invention.
  • US 3,706,810 discloses that certain N-(aminoalkyl) derivatives of thieno[3,2- b]pyrrole-5-carboxamide are useful as analgesic and anti-depressant agents.
  • the compounds disclosed in this document are disclaimed from the compound claims of the present invention.
  • US 4,751,231 discloses that certain thieno[2,3-b]pyrrole-5-sulfonamides are useful in the treatment of elevated intraocular pressure and glaucoma. Certain amides are disclosed as intermediates. The compounds disclosed in this document are disclaimed from the compound claims of the present invention.
  • Q is aryl, substituted aryl, heteroaryl, or substituted heteroaryl; each z and X are independently (C, CH or CH 2 ), N, O or S;
  • X 1 is NR a , -CH 2 -, O or S; each — is independently a bond or is absent, provided that both — are not simultaneously bonds;
  • R 1 is hydrogen, halogen, -OC C 8 alkyl, -SC C 8 alkyl, -C ⁇ . -C 8 alkyl, -CF 3 , -NH 2 -
  • each R a and R b is independently hydrogen or -C ⁇ . -C 8 alkyl; Y is
  • R 2 and R 3 are independently hydrogen, halogen, -C ⁇ .-C 8 alkyl, -CN, -C ⁇ C-Si(CH 3 ) 3 , -Od-Csalkyl, -SQ-Qalkyl, -CF 3 , -NH 2 , -NHC r C 8 alkyl,
  • A is -NR d R d , -NR a CH 2 CH 2 OR a ,
  • the heterocyclic amides of the present invention possess glycogen phosphorylase inhibitory activity and accordingly are expected to be of use in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia and obesity, particularly type 2 diabetes.
  • the present invention provides a compound of formula (I):
  • R and R are independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C 1-6 alkyl, C 2 . 6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C ⁇ -6 alkanoyl, C ⁇ .
  • R 6 alkylsulphonyl-N-(C 1 _ 6 alkyl)amino
  • R 6 is hydrogen or d- ⁇ alkyl
  • R 1 is selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C 1-6 alkyl, C 2 - 6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N-(d- 6 alkyl)amino, N,N-(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N-(C 1-6 alkyl)carbamoyl, NN-(C 1 .
  • R 1 may be optionally substituted on carbon by one or more groups selected from P and wherein if said heterocyclic group contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R;
  • R is selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C 1-6 alkyl, C .
  • R a and R b are independently selected from hydrogen or C 1-6 alkyl which is optionally substituted by a group V ;
  • F is C 1-6 alkylene optionally substituted by one or more Q or a direct bond
  • H is selected from aryl, C 3-8 cycloalkyl and heterocyclic group; wherein H may be optionally substituted on carbon by one or more groups selected from S and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from T;
  • R 3 is hydrogen or C ⁇ -6 alkyl; n is selected from 0-4; wherein the values of R 1 may be the same or different; and wherein the values of R may be the same or different;
  • P, S and Q are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, d- 6 alkanoyl, d_ 6 alkanoyloxy, N-(C ⁇ _ 6 alkyl)amino, NN-(C 1 _ 6 alkyl) 2 amino, d-ealkanoylamino, N-(d- 6 alkyl)carbamoyl, NN-(C 1-6 alkyl) 2 carbamoyl, N-(C 1 .
  • V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl,
  • NN-diefhylcarbamoyl N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl, N-methyl-N-ethylsulphamoyl, morpholino, morpholinocarbonyl, N- benzylcarbamoyl, and 4- hydroxypiperidinocarbonyl;
  • R, T and U are independently selected from C 1-4 alkyl, C 1-4 alkanoyl, C 1-4 alkylsulphonyl, C 1-4 alkoxycarbonyl, carbamoyl, N-(d- 4 alkyl)carbamoyl, NN-(C 1 .
  • R 6 is hydrogen or C 1-6 alkyl
  • R 1 is selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, d- 6 alkanoyloxy, N-(d- 6 alkyl)amino, NN-(C 1-6 alkyl) 2 amino, d- 6 alkanoylamino, N-(C 1-6 alkyl)carbamoyl, NN-(C 1 .
  • R 2 is selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C 1-6 alkyl, C 2 - 6 alkenyl, d ⁇ alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C ⁇ -6 alkanoyloxy, N-(C 1-6 alkyl)amino, NN-(C 1 . 6 alkyl) 2 amino, C 1-6 alkanoylamino, NN-(C 1 .
  • alkyl) 2 carbamoyl, N-(C 1-6 alkyl)-N-(C 1-6 alkoxy)carbamoyl, C 1-6 alkylS(O) a wherein a is 0 to 2, C 1-6 alkoxycarbonyl, d- 6 alkoxycarbonylamino, N-(C 1-6 alkyl)sulphamoyl, NN-(C 1 .
  • E and G are independently selected from a direct bond, -O-, -S-, -SO-, -SO 2 -, -OC(O)-, -C(O)O-, -C(O)-, - ⁇ R ⁇ -NR a C(O)-, -C(O)NR a -, -SO 2 NR a -, -NR a SO 2 -, -NR a C(O)NR
  • R a and R b are independently selected from hydrogen or C 1-6 alkyl; F is C 1-6 alkylene optionally substituted by one or more Q or a direct bond; H is selected from aryl, C 3 . 8 cycloalkyl and heterocyclic group; wherein H may be optionally substituted on carbon by one or more groups selected from S and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from T;
  • R 3 is hydrogen or C 1-6 alkyl; n is selected from 0-4; wherein the values of R 1 may be the same or different; and wherein the values of R 3 may be the same or different; P, S and Q are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N-(C 1-6 alkyl)amino, NN-(C 1 .
  • V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl,
  • alkyl includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only.
  • d. 6 alkyl includes d_ 4 alkyl, propyl, isopropyl and t-butyl.
  • references to individual alkyl groups such as 'propyl' are specific for the straight chained version only and references to individual branched chain alkyl groups such as
  • arylC 1-6 alkyl includes arylC 1-4 alkyl, benzyl, 1-phenylethyl and 2-phenylethyl.
  • halo refers to fluoro, chloro, bromo and iodo.
  • a “heterocyclic group” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH 2 - group can optionally be replaced by a -C(O)-and a ring sulphur atom may be optionally oxidised to form the S-oxide(s).
  • heterocyclic group examples and suitable values of the term "heterocyclic group" are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, imidazolyl, thiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, 1,3-dioxolanyl, thiadiazolyl, piperazinyl, isothiazolidinyl, 1,3,4-triazolyl, tetrazolyl, pyrrolidinyl, 2-oxazolidinonyl, 5-isoxazolonyl, benz-3-azepinyl, 1,4-benzodioxanyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, 3-pyrazolin-5-onyl, tetrahydropyranyl, benzimidazolyl,
  • a "heterocyclic group” is pyridyl, imidazolyl, thiazolyl, quinolyl, thienyl, 1,3-benzodioxolyl, 1,3-dioxolanyl, isothiazolidinyl, 1,3,4-triazolyl, tetrazolyl, 2-oxazolidinonyl, 5-isoxazolonyl, benz-3-azepinyl, hydantoinyl, 1,4-benzodioxanyl, thiomorpholino, 3-pyrazolin-5-onyl, benzimidazolyl, benzthiazolyl, imidazo[l,2-a]pyridyl, pyrimidyl, pyrazinyl, and 2,3-dihydro-l,5-benzothiazepin-4(5H)-one
  • Aryl is a partially saturated or unsaturated, mono or bicyclic ring
  • aryl is phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl (tetralinyl) or indanyl. More preferably aryl is phenyl, naphthyl or 1,2,3,4-tetrahydronaphthyl. Most preferably aryl is phenyl, or naphthyl.
  • An example of "C 1-6 alkanoyloxy” is acetoxy.
  • Examples of "C 1-6 alkoxycarbonyl” include C 1-4 alkoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl.
  • C 1-6 alkoxycarbonylamino examples include methoxycarbonylamino, ethoxycarbonylamino, n- and t-butoxycarbonylamino.
  • Examples of “C 1-6 alkoxy” include methoxy, ethoxy and propoxy.
  • Examples of “C 1-6 alkanoylamino” include formamido, acetamido and propionylamino. Examples of “C 1 .
  • 6 alkylS(O) a wherein a is 0 to 2" include C 1-4 alkylsulphonyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl.
  • Examples of "C 1-6 alkylsulphonylamino” include methylsulphonylamino, ethylsulphonylamino and propylsulphonylamino.
  • C 1-6 alkylsulphonyl-N-(C 1-6 alkyl)amino examples include methylsulphonyl-N-methylamino, ethylsulphonyl-N-methylamino and propylsulphonyl-N-ethylamino.
  • C 1-6 alkanoyl examples include C 1-4 alkanoyl, propionyl and acetyl.
  • N-(C ⁇ -6 alkyl)amino include methylamino and ethylamino.
  • 6 alkyl) 2 amino include di-N-methylamino, di-(N-ethyl)amino and N-ethyl-N-methylamino.
  • C 2 _6alkenyl are vinyl, allyl and 1-propenyl.
  • C 2 . 6 alkynyl are ethynyl, 1-propynyl and 2-propynyl.
  • N-(Ci. 6 alkyl)sulphamoyl are N-(methyl)sulphamoyl and N-(ethyl)sulphamoyl.
  • N-(C 1-6 alkyl) 2 sulphamoyl are N,N-(dimethyl)sulphamoyl and N-(methyl)-N-(ethyl)sulphamoyl.
  • N-(d.. 6 alkyl)carbamoyl are N-(C 1-4 alkyl)carbamoyl, methylaminocarbonyl and ethylaminocarbonyl.
  • Examples of "NN-(d_ 6 a ⁇ kyl) 2 carbamoyl” are NN-(C 1-4 alkyl)carbamoyl, dimethylaminocarbonyl and methylethylaminocarbonyl.
  • C 3-8 cycloalkyl ring are cyclopropyl and cyclohexyl.
  • (heterocyclic group)d. 6 alkyl) include pyridylmethyl, 3-morpholinopropyl and 2-pyrimid-2-ylethyl.
  • Examples of "C 3 _ 8 cycloarkyld- 6 cycloalkyr' include cyclopropylmethyl and 2-cyclohexylpropyl.
  • ''N-td-ealky ⁇ sulphamoylamdno'' are N-(methyl)sulphamoylamino and N-(ethyl)sulphamoylamino.
  • Examples of "N-(C 1-6 alkyl) 2 sulphamoylamino” are
  • C 1-6 alkylsulphonylaminocarbonyl include methylsulphonylaminocarbonyl, ethylsulphonylaminocarbonyl and propylsulphonylaminocarbonyl.
  • a suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid.
  • a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
  • an alkali metal salt for example a sodium or potassium salt
  • an alkaline earth metal salt for example a calcium or magnesium salt
  • an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation
  • a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxye
  • An in vivo hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol.
  • Suitable pharmaceutically acceptable esters for carboxy include C 1-6 alkoxymethyl esters for example methoxymethyl, C 1-6 alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters,
  • C 3-8 cycIoalkoxycarbonyloxyd_ 6 alkyl esters for example 1-cyclohexylcarbonyloxyethyl; l,3-dioxolen-2-onylmethyl esters for example 5-methyl-l,3-dioxolen-2-onylmethyl; and d_ 6 alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.
  • An in vivo hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
  • inorganic esters such as phosphate esters and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
  • ⁇ -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy.
  • a selection of in vivo hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.
  • substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl ring.
  • Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess glycogen phosphorylase inhibitory activity.
  • the invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess glycogen phosphorylase inhibitory activity.
  • R 1 , R 2 , R 3 , -X-Y-Z-and n are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
  • R 4 and R 5 are independently selected from hydrogen, halo or d- 6 alkyl.
  • R 4 and R 5 are independently selected from hydrogen, chloro, bromo or methyl.
  • R 4 and R 5 are independently selected from hydrogen or chloro. More particularly R 4 and R 5 are both chloro.
  • R 6 is hydrogen
  • R 6 is C 1-6 alkyl.
  • R 1 is selected from hydrogen, hydroxy, d_ 6 alkyl, d- 6 alkoxycarbonyl, arylCj-ealkyl and (heterocyclic group)C]. 6 alkyl; wherein R 1 may be optionally substituted on carbon by one or more groups selected from P; and
  • P is selected from hydroxy and C 1 . 6 alkylsulphonyl-N-(C 1 . 6 alkyl)amino.
  • R 1 is selected from hydrogen, hydroxy, methyl, methoxycarbonyl, benzyl and imidazol-4-ylmethyl; wherein R 1 may be optionally substituted on carbon by one or more groups selected from P; and
  • P is selected from hydroxy and mesyl-N-(methyl)amino.
  • R 1 is selected from hydrogen, hydroxy, methyl, methoxycarbonyl, mesyl-N-(methyl)aminomethyl, benzyl, hydroxymethyl and imidazol-4-ylmethyl.
  • R 1 is selected from hydrogen, mesyl-N-(methyl)aminomethyl or benzyl.
  • R 2 is selected from N,N-(C 1 . 4 alkyl) 2 carbamoyl,
  • F is C 1-6 alkylene optionally substituted by one or more Q or a direct bond
  • H is selected from aryl, C 3-8 cycloalkyl and heterocyclic group; wherein H may be optionally substituted on carbon by one or more groups selected from S and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from T;
  • S is selected from halo, hydroxy, trifluoromethyl, sulphamoyl, ureido, C 1-6 alkyl, C 1-6 alkoxy, NN-(C 1 . 6 alkyl) 2 amino, C 1 . 6 alkanoylamino and aryl; wherein S may be optionally substituted on carbon by one or more groups selected from V;
  • N is carbamoyl
  • T is independently selected from C 1- alkyl or phenyl. More preferably R 2 is selected from NN-dimethylcarbamoyl,
  • E and G are independently selected from a direct bond, -O-, -S-, -C(O)-, - ⁇ R a -, -C(O)NR a -, -NR a SO 2 - and -NR a C(O)O-; wherein R a is hydrogen;
  • F is methylene optionally substituted by one or more Q or a direct bond
  • H is selected from phenyl, naphthyl, cyclopropyl, thiomorpholino, pyridyl, thiazolyl, isothiazolyl, morpholinyl, 2,3-dihydro-l,5-benzothiazepin-4(5H)-onyl, 5-oxo-3-pyrazolinyl, 2-oxazolidinonyl, 5-hydroxy-l,3,4,5-tetrahydro-benzo[b]azepin-2-onyl, 5-oxo-2-isoxazolinyl, imidazo[l,2-a]pyridinyl, benzothiazolyl, 2,5-dioxoimidazolidinyl, pyrazinyl, pyridazinyl, imidazolyl, benzimidazolyl, tetrazolyl, quinolyl, 1,3-
  • T is independently selected from methyl or phenyl.
  • R is selected from NN-dimethylcarbamoyl, NN-dimethylsulphamoyl- amino, mesylaminocarbonyl, 2-methoxyphenyl, phenoxy, 2-phenylcyclopropyl, thien-2-yl, 4- fluorophenyl, benzoyl, thiomorpholino, anilinocarbonyl, pyrid-2-ylamino, thiazol-2-yl, benzylsulphonylamino, 2,3-dihydro-l,5-benzothiazepin-4(5H)-one-3-yl, l-phenyl-2,3- dimethyl-5-oxo-3-pyrazolin-4-yl, 3-phenyl-2-oxazolidinon-5-yl, 5-hydroxy-l,3,4,5-tetrahydro- benzo[b]azepin-2-onyl, 3-phenyl-5-oxo-2-isoxazolin-4
  • R 2 is selected from NN-dimethylcarbamoyl, NN-dimethylsulphamoylamino, mesylaminocarbonyl, 2-methoxyphenyl, phenoxy, 2- phenylcyclopropyl, thien-2-yl, 4-fluorophenyl, benzoyl, thiomorpholino, anilinocarbonyl, pyrid-2-ylamino, thiazol-2-yl, benzylsulphonylamino, 2,3-dihydro-l,5-benzothiazepin-4(5 ⁇ )- one-3-yl, l-phenyl-2,3-dimethyl-5-oxo-3-pyrazolin-4-yl, 3-phenyl-2-oxazolidinon-5-yl, 5- hydroxy- 1 ,3,4,5-tetrahydro-benzo[b]azepin-2-onyl, 3-phenyl-5-oxo-2-iso
  • R 2 is selected from NN-dimethylcarbamoyl, phenoxy, 2- phenylcyclopropyl, thien-2-yl, 4-fluorophenyl, benzoyl, thiomorpholino, anilinocarbonyl, pyrid-2-ylamino or thiazol-2-yl.
  • R 3 is hydrogen
  • n is selected from 0-3; wherein the values of R 1 may be the same or different; and wherein the values of R 3 may be the same or different.
  • n is selected from 0-2; wherein the values of R 1 may be the same or different; and wherein the values of R 3 may be the same or different.
  • n is 2; wherein the values of R 1 may be the same or different; and wherein the values of R 3 may be the same or different. In one aspect of the invention preferably n is i.
  • n 0.
  • preferred compounds of the invention are any one of the Examples or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
  • R 4 and R 5 are independently selected from hydrogen, halo or C 1-6 alkyl
  • R 1 is selected from hydrogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxycarbonyl, aryld- 6 alkyl and (heterocyclic group)C 1-6 alkyl; wherein R 1 may be optionally substituted on carbon by one or more groups selected from P; and
  • P is selected from hydroxy and C 1-6 alkylsulphonyl-N-(C 1 . 6 alkyl)amino;
  • R 2 is selected from NN-(C 1-4 alkyl) 2 carbamoyl, NN-(C 1 . 6 alkyl) 2 sulphamoylamino, Ci- 6 alkylsulphonylaminocarbonyl and a group -E-F-G-H; wherein E and G are independently selected from a direct bond, -O-, -S-, -C(O)-, -NR a -, -C(O)NR a -, -NR a SO 2 - and -NR a C(O)O-; wherein R a is hydrogen;
  • F is C ⁇ -6 alkylene optionally substituted by one or more Q or a direct bond
  • H is selected from aryl, C -8 cycloalkyl and heterocyclic group; wherein H may be optionally substituted on carbon by one or more groups selected from S and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from T;
  • S is selected from halo, hydroxy, trifluoromethyl, sulphamoyl, ureido, d-ealkyl, d_ alkoxy, N ) N-(C 1 _ 6 alkyl) 2 amino, C 1-6 alkanoylamino and aryl; wherein S may be optionally substituted on carbon by one or more groups selected from N; Q is hydroxy; V is carbamoyl; and
  • X 1 is NR a , -CH 2 -, O or S.
  • R 1 is selected from hydrogen, hydroxy, methyl, methoxycarbonyl, mesyl-N-(methyl)aminomethyl and hydroxymethyl ;
  • R 2 is selected from NN-dimethylcarbamoyl, NN-dimethylsulphamoylamino, mesylaminocarbonyl, 2-methoxyphenyl, phenoxy, 2-phenylcyclopropyl, thien-2-yl, 4- fluorophenyl, benzoyl, thiomorpholino, anilinocarbonyl, pyrid-2-ylamino, thiazol-2-yl, benzylsulphonylamino, 2,3-dihydro- 1 ,5-benzothiazepin-4(5H)-one-3-yl, 1 -phenyl-2,3- dimethyl-5-oxo-3-pyrazolin-4-yl, 3-phenyl-2-oxazolidinon-5-yl, 5-hydroxy-l ,3, 4,5-tetrahydro- benzo[B]azepin-2-onyl, 3-phenyl-5-oxo-2-isoxa
  • R 3 is hydrogen; and n is selected from 0-3; wherein the values of R 1 may be the same or different; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
  • the present invention provides a compound of formula (I) (as depicted above) wherein:
  • R 2 is a group -E-F-G-H; wherein E, F and G are each a direct bond; H is a C 3 _ 12 cycloalkyl which is optionally fused to a benz ring wherein H may be optionally substituted on carbon by one or more groups S which are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C 1-6 alkyl, d ⁇ alkenyl, C 2 - 6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N-(C 1-6 alkyl)amino, NN-(C 1-6 alkyl) 2 amino, C ⁇ -6 alkanoylamino, N-(C 1-6 alkyl)carbamoyl, NN-(C 1 -
  • N is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl,
  • R 2 , R 4 , and R 5 are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
  • R 4 and R 5 are independently selected from hydrogen, halo or d- ⁇ alkyl.
  • H is indanyl, 1,2,3,4-tetrahydronaphthyl or cyclopropyl. More preferably H is indanyl or 1,2,3,4-tetrahydronaphthyl. Most preferably H is indanyl.
  • S is independently selected from from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, d- 6 alkyl, d_ 6 alkoxy, C 1-6 alkanoyl, d_ 6 alkanoyloxy, N-(d- 6 alkyl)amino, NN-(C 1 . 6 alkyl) 2 amino, d- 6 alkanoylamino, N-(C 1-6 alkyl)carbamoyl, NN-(C 1 . 6 alkyl) 2 carbamoyl, N-(C 1 . 6 alkyl)-N-(C 1-6 alkoxy)carbamoyl, C ⁇ .
  • R 2 is a group -E-F-G-H; wherein E, F and G are each a direct bond; and
  • H is a cyclic amide of formula
  • k is 0, 1, 2 or 3 and 1 is 0, 1, 2 or 3 such that the sum of k and 1 is 2 or 3 and wherein one of the carbon atoms governed by k or 1 may be replaced by sulphur and wherein H is optionally substituted on carbon by one or more groups selected from S and may be independently optionally substituted on nitrogen by a group selected from T;
  • S is selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, d_ 6 alkyl, C 2 - 6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1 . 6 alkanoyloxy, N ⁇ d- ⁇ alk amino, NN-(C 1-6 alkyl) 2 amino, C 1-6 alkanoylamino, N-(C 1-6 alkyl)carbamoyl, NN-(C 1 .
  • T and U are independently selected from C 1-4 alkyl, C 1-4 alkanoyl, C ⁇ _ 4 alkylsulphonyl, C 1- alkoxycarbonyl, carbamoyl, N-(C 1 . 4 alkyl)carbamoyl, NN-(C 1 . 4 alkyl)carbamoyl, phenyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl wherein T and U may be optionally and independently substituted on carbon by one or more groups selected from V;
  • V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl,
  • R 4 , R 5 and H are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
  • R 4 and R 5 are independently selected from hydrogen, halo or C 1-6 alkyl.
  • H is 1,2,3,4-tetrahydroquinolyl, 2-oxo- 1,2,3,4-tetrahydroquinolyl, 4-oxo-2,3,4,5-tetrahydrobenz[l,5]thiazepin-3-yl, 2-oxo-2,3,4,5- tetrahydro-lH-benz[t>]azepinyl, 2,3,4,5-tetrahydro-lH-benz[6]azepinyl or 3-oxo-2,3,4,5- tetrahydro-lH-benz[c]azepinyl each optionally substituted on carbon by one or more groups selected from S wherein S is selected from hydroxy, d_ 6 a ⁇ kyl or d- 6 alkoxy, and each independently optionally substituted on nitrogen by a group selected from T wherein T is selected from d- 4 alkyl or C 1-4 alkanoyl.
  • H is 2-oxo-l,2,3,4-tetrahydroquinol-3-yl, l-methyl-2-oxo-l,2,3,4- tetrahydroquinol-3-yl, 4-oxo-2,3,4,5-tetrahydrobenz[l,5]thiazepin-3-yl, 5-hydroxy-2-oxo- 2,3,4,5-tetrahydro-lH-benz[Z>]azepin-4-yl, 2-oxo-2,3,4,5-tetrahydro-lH-benz[ ⁇ ]azepin-3-yl or 3-oxo-2,3 ,4,5-tetrahydro- lH-benz[c]azepin-4-yl.
  • the present invention provides a compound of formula (I)
  • R is selected from a group -E-F-G-H; wherein E, F and G are each a direct bond;
  • H is an unsaturated five membered heterocyclic group containing at least one nitrogen atom and one or two ring atoms selected from oxygen and sulphur and wherein H may be optionally substituted on carbon by one or more groups S which are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C ⁇ -6 alkanoyl, C 1-6 alkanoyloxy, N-(d_ 6 alkyl)amino, NN-(C 1 .
  • groups S which are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ure
  • R 3 is hydrogen or C 1-6 alkyl; or a pharmaceutically acceptable salt thereof.
  • R 1 , R 3 and H are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
  • R 1 is selected from hydrogen or benzyl and more preferably benzyl.
  • R is hydrogen
  • H is 1,3,4-oxadiazolyl, isoxazolyl, oxazolyl or 1,2,4-oxadiazolyl. More preferably H is 5-ethoxycarbonyl-l,3,4-oxadiazol-2-yl, 4- phenylisoxazol-3-yl, 3-phenyl-l,2,4-oxadiazol-5-yl, 4-methoxycarbonyloxazol-5-yl or 3- methylisoxazol-5-yl.
  • H may be optionally substituted on carbon by one or more groups S which are independently selected from halo, carboxy, C 1-6 alkyl, d- ⁇ alkoxy, d- ⁇ alkanoyloxy, N-(d. 6 alkyl)amino, NN-(C 1 . 6 alkyl) 2 amino, C 1-6 alkanoylamino, d- 6 alkoxycarbonyl, C 3 _ 8 cycloalkyl and aryl groups.
  • S is C 1-6 alkoxy, d- ⁇ aikoxycarbonyl or phenyl.
  • R 2 is a group -E-F-G-H; wherein E is a direct bond; F is methylene; wherein G is -C(O) ⁇ R a -, wherein R a is selected from hydrogen or C ⁇ _ 6 alkyl which is optionally substituted by a group V ; H is aryl which may be optionally substituted on carbon by one or more groups selected from S;
  • S is selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C 1-6 alkyl, C 2-6 alkenyl, C 2 - 6 alkynyl, C 1-6 alkoxy, C ⁇ -6 alkanoyl, C 1-6 alkanoyloxy, N-(C 1-6 alkyl)amino, NN-(C ⁇ -6 alkyl) 2 amino, d_ 6 alkanoylamino, N ⁇ d-ealky carbamoyl, NN-(C ⁇ .
  • V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl,
  • NN-diethylcarbamoyl N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl, N-methyl-N-ethylsulphamoyl, morpholino, morpholinocarbonyl, N- benzylcarbamoyl , and 4- hydroxypiperidinocarbonyl; or a pharmaceutically acceptable salt thereof.
  • R 1 , R 2 , R 3 , -X-Y-Z-and n are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
  • H is aryl.
  • V is cyano or hydroxy.
  • Specific compounds of the present invention are: 2 ,3 -dichloro-5- [N-(2-phenoxyethyl)carbamoyl] -4H-thieno [3 ,2-b] pyrrole ; 2,3-dichloro-5- ⁇ N-[2-(2-thienyl)ethyl]carbamoyl ⁇ -4H-thieno[3,2-b]pyrrole; 2,3-dichloro-5- ⁇ N-[2-(2-methoxyphenyl)ethyl]carbamoyl ⁇ -4H-thieno[3,2-t3]pyrrole; 2,3-dichloro-5-[N-(2-phenyl-l-cyclopropyl)carbamoyl]-4H-thieno[3,2-t)]pyrrole; 2,3-dichloro-5- ⁇ N-[2-(4-fluorophenyl)ethyl]carbam
  • Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof which process (wherein R 1 , R 2 , R 3 , -X-Y-Z-and n are, unless otherwise specified, as defined in formula (I)) comprises of: a) reacting an acid of the formula (II):
  • Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, or for example carbonyldiimidazole, l-ethyl-3-(3-dimethylaminopropyl)carbodi-imide hydrochloride and dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as 1- hydroxybenzotriazole, dimethylaminopyridine or 4-pynOlidinopyridine, optionally in the presence of a base for example triethylamine, di-isopropylethylamine, pyridine, or 2,6-di- ⁇ /£y/-pyridines such as 2,6-lutidine or 2,6-di-tert-butylpyridine.
  • Suitable solvents include dimethylacetamide, dichloromethane, benzene, tetrahydrofuran and dimethylformamide.
  • the coupling reaction may conveniently be performed at a temperature in the range
  • Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters.
  • the reaction of these types of compounds with amines is well known in the art, for example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those described above. The reaction may conveniently be performed at a temperature in the range of -40 to 40°C.
  • the acids of formula (II) may be prepared according to Scheme 1:
  • aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group.
  • modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
  • a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylrnethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
  • the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
  • a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
  • a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
  • the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a base such as sodium hydroxide
  • a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
  • the compounds defined in the present invention possesses glycogen phosphorylase inhibitory activity. This property may be assessed, for example, using the procedure set out below.
  • the activity of the compounds is determined by measuring the inhibitory effect of the compounds in the direction of glycogen synthesis, the conversion of glucose- 1 -phosphate into glycogen with the release of inorganic phosphate, as described in EP 0 846464 A2.
  • the reactions were in 96well microplate format in a volume of lOO ⁇ l.
  • the change in optical density due to inorganic phosphate formation was measured at 620nM in a Labsystems iEMS Reader MF by the general method of (Nordlie R.C and Arion W.J, Methods of Enzymology, 1966, 619-625).
  • the reaction is in 50mM HEPES, 2.5mM MgCl 2 , 2.25mM ethylene glycol- bis(b-aminoethyl ether) NNN',N'-tetraacetic acid, lOOmM KC1, 2mM D-(+)-glucose pH7.2, containing 0.5mM dithiothreitol, the assay buffer solution, with 0. lmg type HI glycogen,
  • glycogen phosphorylase a from rabbit muscle and 0.5mM glucose- 1 -phosphate.
  • GP is pre-incubated in the assay buffer solution with the type HI glycogen at 2.5 mg ml "1 for 30 minutes.
  • 40 ⁇ l of the enzyme solution is added to 25 ⁇ l assay buffer solution and the reaction started with the addition of 25 ⁇ l 2mM glucose- 1 -phosphate.
  • Compounds to be tested are prepared in lO ⁇ l 10% DMSO in assay buffer solution, with final concentration of 1% DMSO in the assay.
  • the non-inhibited activity of GP ⁇ is measured in the presence of lO ⁇ l 10% DMSO in assay buffer solution and maximum inhibition measured in the presence of 30 ⁇ M CP320626 (Hoover et al (1998) J Med Chem 41, 2934-8; Martin et al (1998) P ⁇ AS 95, 1776-81).
  • the reaction is stopped after 30min with the addition of 50 ⁇ l acidic ammonium molybdate solution, 12ug ml "1 in 3.48% H 2 SO 4 with 1% sodium lauryl sulphate and lOug ml "1 ascorbic acid. After 30 minutes at room temperature the absorbency at 620nm is measured.
  • the activity of the compounds is alternatively determined by measuring the inhibitory effect of the compounds on glycogen degradation, the production of glucose- 1 -phosphate from glycogen is monitored by the multienzyme coupled assay, as described in EP 0 846464 A2, general method of Pesce et al ( Pesce, M A, Bodourian, S H, Harris, R C, and Nicholson, J F (1977) Clinical Chemistry 23, 1171 - 1717).
  • the reactions were in 384well microplate format in a volume of 50 ⁇ l.
  • the change in fluorescence due to the conversion of the co-factor NAD to NADH is measured at 340nM excitation, 465nm emission in a Tecan Ultra Multifunctional Microplate Reader.
  • the reaction is in 50mM HEPES, 3.5mM KH 2 PO 4, 2.5mM MgCl 2 , 2.5mM ethylene glycol-bis(b-aminoethyl ether) NNN'N-tetraacetic acid, lOOmM KC1, 8mM D-(+)-glucose pH7.2, containing 0.5mM dithiothreitol, the assay buffer solution.
  • Human recombinant liver glycogen phosphorylase a (hrl GP ⁇ ) 20nM is pre-incubated in assay buffer solution with 6.25mM NAD, 1.25mg type HI glycogen at 1.25 mg ml "1 the reagent buffer, for 30 minutes.
  • the coupling enzymes phosphoglucomutase and glucose-6-phosphate dehydrogenase ( Sigma) are prepared in reagent buffer, final concentration 0.25Units per well. 20 ⁇ l of the hrl GPa solution is added to lO ⁇ l compound solution and the reaction started with the addition of 20ul coupling enzyme solution. Compounds to be tested are prepared in lO ⁇ l 5% DMSO in assay buffer solution, with final concentration of 1% DMSO in the assay. The non-inhibited activity of GP ⁇ is measured in the presence of lO ⁇ l 5% DMSO in assay buffer solution and maximum inhibition measured in the presence of 5mgs ml "1 N- ethylmaleimide. After 6 hours at 30°C Relative Fluoresence Units (RFUs) are measured at 340nM excitation, 465nm emission .
  • REUs Relative Fluoresence Units
  • the assay is performed at a test concentration of inhibitor of lO ⁇ M or lOO ⁇ M. Compounds demonstrating significant inhibition at one or both of these concentrations may be further evaluated using a range of test concentrations of inhibitor to determine an IC 50 , a concentration predicted to inhibit the enzyme reaction by 50%. Activity is calculated as follows :-
  • % inhibition (1 - (compound RFUs - fully inhibited RFUs)/ (non-inhibited rate RFUs - fully inhibited RFUs)) * 100.
  • Typical IC 50 values for compounds of the invention when tested in the above assay are in the range lOO ⁇ M to InM.
  • the inhibitory activity of compounds was further tested in rat primary hepatocytes.
  • Rat hepatocytes were isolated by the collagenase perfusion technique, general method of Seglen (P.O. Seglen, Methods Cell Biology (1976) 13 29-83). Cells were cultured on Nunclon six well culture plates in DMEM with high level of glucose containing 10% foetal calf serum, NEAA, Glutamine, penicillin /streptomycin ((100units/100ug)/ml) for 4 to 6 hours. The hepatocytes were then cultured in the DMEM solution without foetal calf serum and with lOnM insulin and lOnM dexamethasone.
  • a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.
  • composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
  • parenteral injection including intravenous, subcutaneous, intramuscular, intravascular or infusion
  • sterile solution emulsion
  • topical administration as an ointment or cream or for rectal administration as a suppository.
  • compositions may be prepared in a conventional manner using conventional excipients.
  • the compound of formula (I) will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.1-100 mg/kg, and this normally provides a therapeutically-effective dose.
  • a unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient.
  • a daily dose in the range of 1-50 mg/kg is employed.
  • the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
  • R 1 may be optionally substituted on carbon by one or more groups selected from P and wherein if said heterocyclic group contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from R;
  • R 2 is selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, d.
  • E and G are independently selected from a direct bond, -O-, -S-, -SO-, -SO2-, -OC(O)-, -C(O)O-, -C(O)-, - ⁇ R a -, -NR a C(O)-, -C(O)NR a -, -SO 2 NR a -, -NR a SO 2 -, -NR a C(O)NR b -, -OC(O)NR a -, -NR a C(O)O-, -NR a SO 2 NR b -, -SO 2 NR a C(O)- and -C(O)NR a SO 2 -; wherein R a and R b are independently selected from hydrogen or C 1-6 alkyl which is optionally substituted by a group V ;
  • F is d- 6 alkylene optionally substituted by one or more Q or a direct bond
  • H is selected from aryl, C 3 . 8 cycloalkyl and heterocyclic group; wherein H may be optionally substituted on carbon by one or more groups selected from S and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from T;
  • R 3 is hydrogen or C 1-6 alkyl; n is selected from 0-4; wherein the values of R 1 may be the same or different; and wherein the values of R 3 may be the same or different;
  • P, S and Q are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C 1-6 alkyl, C 2 . 6 alkenyl, C 2-6 alkynyl, d_ 6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, N-(C 1-6 alkyl)amino, NN-(d_ 6 alkyl) 2 amino, d.
  • V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamo
  • X 1 is NR a , -CH 2 -, O or S; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of a glycogen phosphorylase inhibitory effect in a warm-blooded animal such as man.
  • a compound of the formula (I'), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof as defined hereinbefore in the manufacture of a medicament for use in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal such as man.
  • a compound of the formula (I'), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof as defined hereinbefore in the manufacture of a medicament for use in the treatment of type 2 diabetes in a warm-blooded animal such as man.
  • a method of producing a glycogen phosphorylase inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I').
  • a method of treating type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity which comprises administering to said animal an effective amount of a compound of formula (I').
  • a method of treating type 2 diabetes in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (V).
  • the size of the dose required for the therapeutic or prophylactic treatment of a particular cell-proliferation disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated.
  • a unit dose in the range, for example, 1-100 mg/kg, preferably 1-50 mg/kg is envisaged.
  • the compounds of formula (I) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
  • the alternative and preferred embodiments of the compounds of the invention described herein also apply. Examples
  • temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C and under an atmosphere of an inert gas such as argon;
  • Example #5 2.3-Dichloro-5- ⁇ N-r2-(4-fluorophenyl)ethyllcarbamoyl
  • Example #6 2.3-dichloro-5-rN-(N-phenylcarbamoylmethyl)carbamoyll-4H-thienor3.2-
  • Example #11 The following compounds were made by the process of Example #11 using 5-carboxy- 3-chloro-4H-thieno[3,2-_7]pyrrole (Method #7) and the appropriate amine:
  • Example #12 3-Chloro-5- ⁇ N-r2-(thiomorpholino)ethvncarbamoyll-4H-thieno[3,2-&lpyrrole
  • Example #13 3-Chloro-5- ⁇ N-r2-(N-methylmethanesulphonamido)-l-(thiazol-2- vDethyllcarbamoyl I -4H-thieno F3 ,2-fclpyrrole
  • Example #14 3-Chloro-5-rN-(benzoylmethyl)carbamoyll-4H-thienor3,2-&lpyrrole
  • Example #15 3-Chloro-5- ⁇ N-r2-(2-methoxyphenyl)ethyllcarbamoyli-4H-thienor3.2- bl pyrrole
  • Example #16 3-Chloro-5- ⁇ N-r2-(2-thienyl)ethyllcarbamoyl)-4H-thienor3,2-tjlpyrrole
  • Example #17 3-Chloro-5-rN-(2-phenyl-l-cvclopropyl)carbamoyll-4H-thienor3.2-t>1pyrrole
  • Example #18 3-Chloro-5- ⁇ N-r2-(4-fluorophenyl)ethyllcarbamoyl ⁇ -4H-thienor3.2-61pyrrole
  • Example #19 3-Chloro-5-rN-(2-phenoxyethyl)carbamoyll-4H-thienor3,2-b1pyrrole
  • Example #20 3-Chloro-5-(N-r2-(l-phenylmethanesulphonamido)ethyllcarbamoyll-4H- thieno ⁇ 3,2-b pyrrole
  • Example #21 3-Chloro-5-rN-(4-oxo-2,3,4.5-tetrahydrobenzri,51thiazepin-3-yl)carbamoyll- 4H-thienor3.2
  • Example #22 The following compounds were made by the process of Example #22 using 5-carboxy- 2-chloro-4H-thieno[3,2-b]pyrrole (Method #8) and the appropriate amine:
  • Example #23 2-Chloro-5-rN-(2-phenyl-l-cvclopropyl)carbamoyll-4H-thienor3.2-/j1pyrrole
  • Example #24 2-Chloro-5-rN-(N-phenylcarbamoylmethyl)carbamovn-4H-thienor3 1 2- fclpyrrole
  • Example #27 2-Chloro-5-rN-(2-phenoxyethyl)carbamoyll-4H-thienor3.2-61pyrrole
  • Example #28 2-Chloro-5- IN- r2-(2-thienyl)ethyllcarbamoyl 1 -4H-thieno ⁇ 3 ,2- ⁇ lpyrrole
  • Example #29 2-Chloro-5-(N-r2-(4-fluorophenyl)ethyllcarbamoyll-4H-thienor3.2-t>l ⁇ yrrole
  • Example #30 2-Chloro-5- ⁇ N-r2-(N-methylmethanesulphonamido)-l-(thiazol-2- yl)ethyl1carbamoyl)-4H-thienor3,2-/j1pyrrole
  • Example #31 2-Chloro-5- ⁇ N-r2-(thiomorpholino)ethyllcarbamoyl
  • Example #32 2.3-Dichloro-5-rN-(2,3-dimethyl-5-oxo-l-phenyl-2.5-dihvdro-lH-pyrazol-4- yl)carbamoyl1-4H-thieno[ ⁇ 3,2-t31pyrrole
  • Example #33 2,3-Dichloro-5-rN-(4-sulphamoylphenylmethyl)carbamovn-4H-thienor3,2- ⁇ lpyrrole
  • Example #37 2,3-Dichloro-5-rN-(5-oxo-3-phenyl-4.5-dihvdroisoxazol-4-yl)carbamoyll-4H- thieno
  • Example #38 2.3-Dichloro-5-rN-(5-hvdroxy-2-oxo-2.3.4.5-tetrahvdro- ! ⁇ -benzr61azepin-4- yl)carbamoyl1-4H-thienor3.2-t>1pyrrole
  • Example #40 2.3-Dichloro-5-IN-r(4-dimethylaminophenyl)methyllcarbamoyl
  • Example #41 5-
  • Example #42 2,3-Dichloro-5-
  • Example #43 2,3-Dichloro-5-rN-( ⁇ -(K)-hydroxy- -methylphenethyl)carbamoyll-4H- thieno ⁇ 3 ,2-blpyrrole
  • Example #45 2,3-Dichloro-5- ⁇ N-r2-(4-hvdroxyphenyl)ethyllcarbamoyl ⁇ 4H-thieno[3,2- t>l pyrrole
  • Example #46 2,3-Dichloro-5- ⁇ N-r(benzimidazol-2-yl)methyllcarbamoyl ⁇ -4H-thienor3,2- t>lpyrrole
  • Example #50 2,3-Dichloro-5- ⁇ N-[(6-trifluoromethylpyrid-3-yl)methyllcarbamoyl)-4H- thieno ⁇ 32-b ⁇ pyrrole
  • Example #51 2.3-Dichloro-5-fN-(2-r(2-pyridazinyl)methyllcarbamoyl ⁇ -4H-thienor3.2- ⁇ lpyrrole
  • Example #55 2-Chloro-5-(N- ⁇ 2-r(3-trifluoromethylpyrid-2-yl)aminolethyl ⁇ carbamoyl)-4H- thieno ⁇ ,2-61 pyrrole
  • Example #56 2.3-Dichloro-5- ⁇ N-r2-(4-sulphamoylphenyl)ethyllcarbamoyl)-4H-thienor3.2- ⁇ lpyrrole
  • Example #57 2.3-Dichloro-5-(N-r2-( ' 2-pyridyl)ethyllcarbamoyll-4H-thienor3.2-t31pyrrole
  • Example #58 2.3-Dichloro-5- ⁇ N-(2-f 1 -hvdroxymethyl-2-(4-imidazolyl)ethyllcarbamoyl ⁇ -
  • Example #59 2.3-Dichloro-5-(N-(2-r(3-quinolyl)methyllcarbamoyll-4H-thienor3,2- fclpyrrole
  • Example #60 5-(N-r3-(4-Acetamidophenoxy)-2-hvdroxypropyl1carbamoyl)-2,3-dichloro-
  • Example #64 5- ⁇ N-r2-Benzylthio-l-(hydroxymethyl)ethyllcarbamoyl ⁇ -2.3-dichloro-4H- thienor3.2-/31pyrrole
  • Example #65 2.3-Dichloro-5- ⁇ N-r2-(dimethvaminosulphonylamino)ethyllcarbamoyl)-4H- thienof3 ,2-_jlpyrrole
  • Example #75 2.3-Dichloro-5-rN-(l-phenylcvclobutyl)methyl)carbamoyll-4H-thienor3,2- b ⁇ pyrrole
  • Example #76 2.3-Dichloro-5-rN-( ⁇ -methylphenethyl)carbamoyll-4H-thienor3.2-Z>lpyrrole
  • Example #78 5- r N-(N-Benzylcarbamoylmethyl)carbamovH- 2,3-dichloro-4H-thienor3,2- t>lpyrrole
  • Example #79 5-rN-(N-Benzyl-N-methylcarbamoylmethyl)carbamoyll-2.3-dichloro-4H- thienor3,2-&lpyrrole
  • Example #86 2,3-dichloro-5-(N-[N-methyl-N-(4-methylphenyl)carbamoylmethyll- carbamoyl ⁇ -4H-thienor3 ,2-_>1pyrrole
  • Example #87 2.3-dichloro-5-
  • Example #91 2.3-dichloro-5-
  • Example #92 2,3-dichloro-5- ⁇ N-rN-(2-hvdroxyethyl)carbamoylmethyllcarbamoyl ) -4H- thienor3.2-t>lpyrrole
  • Example #93 2,3-dichloro-5- ⁇ N-rN-(3-hvdroxypropyl)carbamoylmethyllcarbamoyll-4H- thienor3,2-Z>lpyrrole
  • Example #96 2.3-dichloro-5- ⁇ N-rN-(2.3-dihvdroxypropyl)carbamoylmethyllcarbamoyl)-
  • Example #97 The following compounds were made by the process of Example #97 using 5-(N- carboxymethylcarbamoyl)-2,3-dichloro-4H-thieno[3,2-b]pyrrole (Method #12) and the appropriate commercially available amine:
  • Example #98 2.3-dichloro-5- ⁇ N-[N-(5-isoquinolyl)carbamoylmethyllcarbamoyl)-4H- thieno ⁇ 32-b ⁇ pyrrole
  • Example #101 2.3-dichloro-5- ⁇ N-rN-(2.4-difluorophenyl)-N-methyl-carbamoylmethyll- carbamoyl ⁇ -4H-thieno ⁇ 3 ,2-/31pyrrole
  • Example #102 2.3-dichloro-5- ⁇ N-r(L2.3.4-tetrahydro-l-quinolyl)carbonylmethyl1- carbamoyl
  • Example #103 2.3-dichloro-5- ⁇ N-rN-(2-cvanoethyl)-N-methylcarbamoylmethyll- carbamoyl ⁇ -4H-thienoF3,2-&1pyrrole
  • Example #104 2.3 -dichloro-5 - ⁇ N- rN-(4-hvdroxypiperidino carbamoylmethyll carbamoyl ) -
  • Example #106 2,3-dichloro-5-rN-(N-isopropylcarbamoylmethyl)carbamoyn-4H-thienor3,2- /J>lpyrrole
  • Example #107 2.3-dichloro-5-rN-(N-isopropyl-N-methylcarbamoylmethyl)carbamoyll-4H- thieno ⁇ 3.2-bl pyrrole
  • the two component mixture was separated using bond-elute silica column chromatography (eluent: dichloromethane-dichloromethane/methanol 5% gradient) to afford the less polar product (sulfone) as a white powder (57mg 33%) and the more polar product (sulfoxide) as a white solid (62mg, 37%).
  • Example #113 The following compounds were made by the process of Example #113 using 5- carboxy-2,3-dichloro-4H-thieno[3,2-b]pyrrole (Method #9) and the appropriate amine:
  • Example #115 2.3-Dichloro-5-rN-(4-phenylisoxazol-3-ylmethyl)carbamoyll-4H-thienor3.2- tjlpyrrole
  • Example #116 2.3-Dichloro-5-('N-(2-r2-(2-morpholinoethoxy)phenyllethyllcarbamoyl)-4H- thieno ⁇ 3 ,2-/31 pyrrole
  • Example #117 2,3-Dichloro-5-(N- ⁇ 2-r2-(methoxycarbonylmethoxy)phenyllethyl ⁇ - carbamoyl)-4H-thienoF3,2-/j1pyrrole
  • Example #123 2.3-Dichloro-5-(N-(2-r2-(N-methylcarbamoylmethoxy)phenyllethyll- carbamoyl)-4H-thienor3 1 2-/jlpyrrole
  • Example #125 2.3-Dichloro-5-(N- ⁇ 2-r2-(morpholinocarbonylmethoxy)phenyllethyl
  • Example #126 5-(N- ⁇ 2-r2-(N-Benzylcarbamoylmethoxy)phenyllethyl ⁇ carbamoyl)-2.3- dichloro-4H-thieno[3,2-&lpyrrole
  • Example #127 2,3-Dichloro-5-(N- ⁇ 2-r2-(4-hvdroxypiperidinocarbonylmethoxy)phenvn- ethyl)carbamoyl)-4H-thienor3,2-/J>lpyrrole
  • the reaction mixture was diluted with ethyl acetate (75ml) washed with dilute citric acid, water and brine, dried over magnesium sulphate and concentrated.
  • the crude material was purified by bond elute silica column chromatography (eluent - DCM/Ethyl acetate gradient 0-50%) to give the title compound (147mg, 34%).
  • the reaction mixture was diluted with ethyl acetate (50ml), water (20ml) was added and the p ⁇ adjusted to 7 with dilute hydrochloric acid.
  • the organic fraction was separated washed with water and brine, dried over magnesium sulphate and concentrated.
  • the crude material was purified by bond elute silica column chromatography (eluent - Ethyl acetate ) to give the title compound as a solid (128mg, 67%).
  • the reaction mixture was diluted with ethyl acetate (100ml), water (20ml) was added and the p ⁇ adjusted to 7 with dilute hydrochloric acid.
  • the organic fraction was separated washed with water and brine, dried over magnesium sulphate and concentrated.
  • the crude material was purified by bond elute silica column chromatography (eluent - Ethyl acetate ) to give the title compound as a solid (72mg, 34%)
  • 2,3-Dichloro-5- [N-( 1 -hydroxyindan-2-yl)carbamoyl] -4H-thieno[3 ,2-t)]pyrrole (Example #133) was subject to preparative ⁇ PLC under the following conditions to give 2,3- dichloro-5-[N-((-/S,2S)-l-hydroxyindan-2-yl)carbamoyl]-4H-thieno[3,2-t3]pyrrole as a white solid (9 mg) and 2,3-dichloro-5-[N-((H-,2i-)-l-hydroxyindan-2-yl)carbamoyl]-4H- thieno[3,2-t)]pyrrole as a white solid (12 mg).
  • Example #141 2,3-Dichloro-5-[N-(3-methylisoxazol-5-yl)methyllcarbamoyll-4H- thienor3.2-/jlpyrrole
  • Example #142 2,3-Dichloro-5-rN-(4-hvdroxy-l,l-dioxotetrahvdrothiophen-3-yl)carbamoyll-
  • Example #143 2.3-dichloro-5-(N- ⁇ N-methyl-N-r(l-oxo-1.2.3.4-tetrahvdronaphth-2- yl)methyllcarbamoylmethyllcarbamoyl)-4H-thieno[3,2-t)lpyrrole
  • Triethylamine (lOlmg, l.Ommol) was added to a suspension 5-[N-(l-aminoindan-2- yl)carbamoyl]-2,3-dichloro-4H-thieno[3,2-j]pyrrole trifluoroacetic acid salt (Example #150, 240mg, 0.5mmol) in dichloromethane (4ml), followed by acetyl chloride (47mg, 0.6mmol) dissolved in dichloromethane (1ml) and the reaction stirred at room temperature for 6 hours during which a white solid precipitated.
  • the starting materials for the Examples above are either commercially available or are readily prepared by standard methods from known materials. For example the following reactions are illustrations but not limitations of the preparation of some of the starting materials used in the above reactions.
  • Methanolic sodium methoxide solution (28%) (5 ml, 25.9 mmol) was diluted with MeO ⁇ (5 ml) and was cooled to -25°C under nitrogen.
  • Aldehyde Aldehyde ref. Gronowitz et al. Tetrahedron Vol.32 1976 p.1403
  • N-(tert-Butoxycarbonyl)glycine (875mg, 5mmol) was dissolved in DMF (7ml) containing DIPEA (3.5ml, 20mmol) and benzylamine (536mg, 5mmol). The mixture was allowed to stand for one minute before addition of 0-(7-Azabenzotriazol-l-yl)-NNN',N'- tetramethyluronium hexafluorophosphate (HATU) (2.09g, 5.5mmol). The solution was allowed to stand for approximately 18 hours before being partitioned between ethyl acetate (50ml) and water (50ml).
  • HATU 0-(7-Azabenzotriazol-l-yl)-NNN',N'- tetramethyluronium hexafluorophosphate
  • Aqueous ammonium chloride (10%, 200 ml) was added and the solution was extracted using diethyl ether.
  • the aqueous layer was acidified and re-extracted using diethyl ether.
  • the combined organic layers were dried, filtered and concentrated under reduced pressure.
  • the residue (5.30 g, 22.6 mmol) was dissolved in ethanol (100 ml) containing pyridine (18 ml) and hydroxylamine hydrochloride (1.88 g, 27.1 mmol).
  • the mixture was heated under reflux in an inert atmosphere for 2.5 hours before being cooled and concentrated under reduced pressure.
  • the residue was suspended in water and cooled to 0°C.
  • the mixture was acidified to pH 4 using aqueous hydrochloric acid (2.0 M).
  • the resulting solid (9.2 g, 42.8 mmol) was dissolved in dry DMF (30 ml) and the solution was heated on a steam bath for 2 hours. Ammonium chloride (2.22 g, 41.5 mmol) was added to the hot solution along with sodium azide (2.68 g, 56.3 mmol). The mixture was cooled and left to stir for over 48 hours. The solution was filtered and basified to p ⁇ 8 using aqueous potassium bicarbonate. The aqueous layer was washed using EtOAc before being acidified using dilute aqueous hydrochloric acid. A white solid was filtered off.
  • N-Benzyloxycarbonylglycine (2.09 g) was dissolved in toluene (40 ml) and DMF (5 drops).
  • Oxalyl chloride (1.3 ml) was added and the mixture was stirred at ambient temperature for 2 hours.
  • the solution was diluted with diethyl ether (25 ml) and was added dropwise to a solution of l-amino-3-phenoxy-2-propanol (1.67 g) in diethyl ether (25 ml).
  • Sodium hydroxide (0.4 g) was dissolved in water (1.5 ml) and was added to the mixture. The solution was stirred for greater than 48 hours before being filtered.
  • N-t-Butoxycarboylglycine (1.92 g, 1.1 mmol) was dissolved in dry EtOAc (20 ml) and the solution was cooled to -25°C.
  • N-Methyl morpholine (1.1 g, 1.1 mmol) was added and the mixture was stirred for 2 minutes before the addition of ethyl chloroformate (1.08 g, 1.0 mmol).
  • a suspension of 5-amino-3- methylisothiazole hydrochloride (1.5 g, 1.0 mmol) was added in triethylamine (1.01 g, 1.0 mmol) and dry EtOAc (10 ml). The mixture was stirred at ambient temperature for 17 hours before being filtered.
  • Ethanolamine (6.0 ml) was suspended in dry xylene (100 ml) and the mixture was stirred at ambient temperature with sodium hydride (3 g). After 20 minutes the solution was cooled to 0°C. 3,6-Dichloropyridazine (15.0 g) was added. The solution was warmed to ambient temperature and was stirred for 15 hours before being extracted with chloroform. The chloroform was concentrated and the residue was taken up in EtOAc before being filtered. Ethanolic HCl was added and a white solid was filtered off. This compound (550 mg) was dissolved in MeOH (130 ml) and palladium on charcoal (5%, 200 mg) was added. The suspension was stirred under an atmosphere of hydrogen for 6 hours before being filtered. The filtrate was concentrated and the residue was triturated using diethyl ether. The title compound was isolated as a white solid (340 mg).
  • Ethylene diamine (30 ml) was dissolved in DCM (130 ml) with di-t-Zmtyl dicarbonate (13.5 g). The mixture was stirred at ambient temperature for 30 minutes before the solvent was decanted off. The residue was washed with water and dried. The product (6.1 g) was dissolved in ethanol (15 ml). Chloroacetic acid (5.77 g) solution in aqueous sodium hydroxide (1 M, 61 ml) was added dropwise, followed by more aqueous sodium hydroxide (1 M, 31 ml). The mixture was stirred for 17 hours before being washed with diethyl ether.
  • Benzyl chloroformate (5 g) was added to the aqueous phase and the mixture was stirred at ambient temperature for 4 hours. The solution was washed with diethyl ether and the aqueous layer was acidified using aqueous citric acid (30%). The solution was extracted using EtOAc. The combined organic layers were washed with brine, then water before being dried, filtered and concentrated. The residue was triturated using diethyl ether/petrol mixture and the required intermediate was isolated as a white solid. Following repeated procedure on a larger scale, this solid (28 g) was dissolved in ethanol (250 ml) containing palladium on charcoal (10%, 4.6 g). The suspension was stirred under an atmosphere of hydrogen until the reaction was complete.
  • the mixture was filtered and the filtrate was concentrated.
  • the residue (3 g, was treated with potassium cyanate (1.3 g) in water (30 ml) and the mixture was heated under reflux for 2 hours. An excess of concentrated hydrochloric acid was added and the mixture was heated for a short time before being concentrated.
  • the residue was taken up in water (50 ml) and was loaded onto basic Amberlite® IRA resin. The resin was washed with water until the eluent was found to be neutral. Dilute aqueous hydrochloric acid was used to elute the crude product from the resin. The acidic fractions were concentrated and the residue was triturated with ethanol. The title compound was isolated as orange crystals (950 mg).
  • 3-Hydroxyphenylacetic acid (30.4 ml) was dissolved in MeOH (160 ml). Concentrated sulphuric acid (1.6 ml) was added and the mixture was heated under reflux for 6 hours. The mixture was concentrated to low bulk before the addition of toluene (120 ml). The mixture was washed with water, saturated aqueous sodium bicarbonate and brine. The combined organic layers were reduced in volume by one half before being stirred with ammonia solution (180 ml) for 16 hours. The mixture was concentrated and filtered. The solid was washed with water and was dried.
  • the mixture was filtered and the filtrate was concentrated.
  • the residual oil was purified by flash column chromatography, using a gradient of MeOH in EtOAc as eluent, to afford both cis- and trans- isomers of the required intermediate.
  • the trans- isomer (1.6 g) was dissolved in dry diethyl ether (180 ml). The solution was heated under reflux using Soxhlet equipment with lithium aluminium hydride (2.0 g) for 16 hours. The solution was cooled and water (2 ml) was added with sodium hydroxide solution (3 M, 2 ml), followed by more water (6 ml). The metal residues were removed by filtration and the filtrate was extracted using DCM. The combined organic layers were dried, filtered and concentrated. The residue was triturated using ethanol to afford the title compound as a white solid.
  • N-(Benzyloxycarbonyl)-2-(2-hydroxyphenyl)ethylamine (542mg, 2mmol) dissolved in DMF 5ml was treated with potassium carbonate (325 mesh, 350mg, 2.5mmol) and 2- chloroethyl p-toluenesulphonate (484ul,2.6mmol) and the mixture was stirred at 60C overnight.
  • Isoamyl nitrite (15 ml, 108 mmol) was added to a solution of indan-l,2-dione (12 g, 90 mmol) in methanol (380 ml) at 45°C followed by concentrated HCl (12 ml) dropwise over 5 minutes. The reaction mixture was stirred for 3 hours at room temperature. Excess isoamyl nitrite (1 ml) and concentrated HCl (1 ml) was added and the suspension stirred for a further 15 minutes. On cooling to room temperature a white precipitate formed.
  • Tetralone (1 eq, 100 mmol, 15 g) and methylamine hydrochloride (2.5 eq, 250 mmol, 15 g) and paraformaldehyde (1 eq, 100 mmol, 3 g) in ethanol (100 ml) were heated under reflux for 16 hours.
  • the reaction mixture was cooled and filtered to afford 2- (methylaminomethyl)-3,4,dihydro-l-(2H)-naphthalenone as a solid (14 g).
  • the filtrate was concentrated and the residue was taken up in ethyl acetate before being washed with aqueous sodium bicarbonate, dried, filtered and concentrated.
  • the residue was left to stand in a solution of hydrogen bromide in acetic acid for 30 minutes.
  • the mixture was triturated with diethyl ether and the solvent was decanted off.
  • the residue was treated with ammonia solution and this was extracted with chloroform.
  • the chloroform was concentrated and the residue was recrystallised from ethanol to afford the title compound.
  • (+/-) tr ⁇ 7M-2-bromo ⁇ l-hydroxyindan (21.0g, O.lmol) and potassium phthalimide (42.0g, 0.22 mol ) in dry DMF (120ml) was heated at 100°C for 5 hours.
  • the reaction mixture was cooled and evaporated to an oil which was triturated with ethyl acetate and filtered.
  • the filtrates were evaporated and purified by chromatography on silica with 2: 1 iso- hexane:ethyl acetate as eluent to give (+l-)-trans -l-hydroxy-2-phthalimido indan as a pale yellow amorphous powder (17.7g, 63%).
  • the crade product was purified by chromatography on silica with 4: 1 w ⁇ -hexane: ethyl acetate as eluent to give the title compound as a white solid (16.1g, 96%); NMR 1.42(9H, s), 2.78(1H, dd), 3.0(1H, dd), 4.3-4.42(lH, m), 4.78-4.9(lH, m), 4.9-5.0(lH, m), 6.3(1H, d), 7.0-7.25(4H, m).
  • the above formulations may be obtained by conventional procedures well known in the pharmaceutical art.
  • the tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Heterocyclic amide derivatives, of formula (I): wherein -X-Y-Z- is selected from -S-CR?4=CR5-, -CR4=CR5¿-S-, -O-CR?4=CR5-, -CR4=CR5¿-O-, -N=CR4-S-, -S-CR4=N-, -NR?6-CR4=CR5¿- and -CR?4=CR5-NR6¿-; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof; (with provisos); possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.

Description

Bicyclic pyrrolyl amides as glucogen phos phorylase inhibitors
The present invention relates to heterocyclic amide derivatives, pharmaceutically acceptable salts and in vivo hydrolysable esters thereof. These heterocyclic amides possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity and thus are potentially useful in methods for the treatment of a warm-blooded animal such as man. The invention also relates to processes for the manufacture of said heterocyclic amide derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments to inhibit glycogen phosphorylase activity in a warm-blooded animal such as man.
The liver is the major organ regulating glycaemia in the post-absorptive state. Additionally, although having a smaller role in the contribution to post-prandial blood glucose levels, the response of the liver to exogenous sources of plasma glucose is key to an ability to maintain euglycaemia. An increased hepatic glucose output (HGO) is considered to play an important role in maintaining the elevated fasting plasma glucose (FPG) levels seen in type 2 diabetics; particularly those with a FPG >140mg/dl (7.8mM). (Weyer et al, (1999), J Clin Invest 104: 787-794; Clore & Blackgard (1994), Diabetes 43: 256-262; De Fronzo, R. A., et al, (1992) Diabetes Care 15; 318 - 355; Reaven, G.M. (1995) Diabetologia 38; 3-13). Since current oral, anti-diabetic therapies fail to bring FPG levels to within the normal, non-diabetic range and since raised FPG (and glycHbAlc) levels are risk factors for both macro- (Charles, M.A. et al (1996) Lancet 348, 1657-1658; Coutinho, M. et al (1999) Diabetes Care 22; 233-240; Shaw, J.E. et al (2000) Diabetes Care 23, 34-39) and micro-vascular disease (DCCT Research Group (1993) New. Eng. J. Med. 329; 977-986); the reduction and normalisation of elevated FPG levels remains a treatment goal in type 2 diabetes.
It has been estimated that, after an overnight fast, 74% of HGO is derived from glycogenolysis with the remainder derived from gluconeogenic precursors (Hellerstein et al (1997) Am J Physiol, 272: E163). Glycogen phosphorylase is a key enzyme in the generation by glycogenolysis of glucose- 1 -phosphate, and hence glucose in liver and also in other tissues such as muscle and neuronal tissue.
Liver glycogen phosphorylase activity is elevated in diabetic animal models including the db/db mouse and the fa/fa rat (Aiston S et al (2000). Diabetalogia 43, 589-597). Inhibition of hepatic glycogen phosphorylase with chloroindole inhibitors (CP91149 and CP320626) has been shown to reduce both glucagon stimulated glycogenolysis and glucose output in hepatocytes (Hoover et al (1998) J Med Chem 41, 2934-8; Martin et al (1998) PNAS 95, 1776-81, WO 96/39384 and WO 96/39385). Additionally, plasma glucose concentration is reduced, in a dose related manner, in db/db and ob/ob mice following treatment with these compounds.
Studies in conscious dogs with glucagon challenge in the absence and presence of another glycogen phosphorylase inhibitor, Bay K 3401, also show the potential utility of such agents where there is elevated circulating levels of glucagon, as in both Type 1 and Type 2 diabetes. In the presence of Bay R 3401, hepatic glucose output and arterial plasma glucose levels following a glucagon challenge were reduced significantly (Shiota et al, (1997), Am J Physiol, 273: E868).
ES 2,081,747 discloses that certain amide derivatives of 4H-thieno[3,2-b]pyrroles and 4H-thieno[2,3-b]pyrroles are CCK antagonists and are useful in the treatment of gastric secretion disorders and in the regulation of appetite. The compounds disclosed in this document are disclaimed from the compound claims of the present invention.
US 3,706,810 discloses that certain N-(aminoalkyl) derivatives of thieno[3,2- b]pyrrole-5-carboxamide are useful as analgesic and anti-depressant agents. The compounds disclosed in this document are disclaimed from the compound claims of the present invention. US 4,751,231 discloses that certain thieno[2,3-b]pyrrole-5-sulfonamides are useful in the treatment of elevated intraocular pressure and glaucoma. Certain amides are disclosed as intermediates. The compounds disclosed in this document are disclaimed from the compound claims of the present invention.
US 4,794,120 discloses 4H-thieno[3,2-b]pyrrole-5-carboxylic acid hydrazide and 6H- thieno[2,3-b]pyrrole-5-carboxylic acid hydrazide as intermediates in the preparation of corresponding (5-nitro-2-furanyl)methylenehydrazides which are antibacterials, fungicides and protozoacides. The compounds disclosed in this document are disclaimed from the compound claims of the present invention. Co-pending application EP 1088824 discloses that a compound of Formula A: a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically
Figure imgf000004_0001
acceptable salt of the prodrug, wherein
Q is aryl, substituted aryl, heteroaryl, or substituted heteroaryl; each z and X are independently (C, CH or CH2), N, O or S;
X1 is NRa, -CH2-, O or S; each — is independently a bond or is absent, provided that both — are not simultaneously bonds;
R1 is hydrogen, halogen, -OC C8alkyl, -SC C8alkyl, -Cι.-C8alkyl, -CF3, -NH2-
-NHd-C8alkyl, -N(C,.-C8alkyl)2, -NO2, -CN, -CO2H, -COz - alkyl,
-C2-C8alkenyl, or -C2-C8alkynyl; each Ra and Rb is independently hydrogen or -Cι.-C8alkyl; Y is
OH
/
\
H
or absent;
R2 and R3 are independently hydrogen, halogen, -Cι.-C8alkyl, -CN, -C≡C-Si(CH3)3, -Od-Csalkyl, -SQ-Qalkyl, -CF3, -NH2, -NHCrC8alkyl,
-N(Cι-C8alkyl)2, -NO2, -CO2H, -CO2Cι-C8alkyl, -C2-C8alkenyl, or -C2-C8alkynyl, or R2 and R3 together with the atoms on the ring to which they are attached form a five or six membered ring containing from 0 to 3 heteroatoms and from 0 to 2 double bonds;
R4 is -C(=O)-A;
A is -NRdRd, -NRaCH2CH2ORa,
Figure imgf000005_0001
each Rd is independently hydrogen, Cι.-C8alkyl, Cι-C8alkoxy, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; each Rc is independently hydrogen, -C(=O)ORa, -ORa, -SRa, or -NRaRa; and each n is independently 1-3, are useful in treating diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, or tissue ischemia. These compounds are disclaimed from the present application.
The heterocyclic amides of the present invention possess glycogen phosphorylase inhibitory activity and accordingly are expected to be of use in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia and obesity, particularly type 2 diabetes. The present invention provides a compound of formula (I):
Figure imgf000005_0002
(I) wherein:
-X-Y-Z- is selected from -S-CR =CR5-, -CR =CR5-S-, -O-CR4=CR5-, -CR4=CR -O-,
-N=CR4-S-, -S-CR =N-, -NR -CR4=CR - and -CR =CR -NR6-; wherein R and R are independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2.6alkenyl, C2-6alkynyl, C1-6alkoxy, Cι-6alkanoyl, Cι.6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1.6alkyl)2amino, C1-6alkanoylamino,
Figure imgf000006_0001
NN-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, C1-6alkoxycarbonylamino, N-(Cι-6alkyl)sulphamoyl, NN-(C1.6alkyl)2sulphamoyl, d-βalkylsulphonylamino and C1.6alkylsulphonyl-N-(C1_6alkyl)amino; R6 is hydrogen or d-βalkyl; R1 is selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(d-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, NN-(C1.4alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, d-6alkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, NN-(C1-6alkyl)2sulphamoyl, d-6alkylsulphonylamino, C1.6alkylsulphonyl-N-(C1-6alkyl)amino, C3-8cycloalkyl, C3.8cycloalkylCι..6alkyl, aryl, aryld.6alkyl, heterocyclic group and (heterocyclic group)d„6alkyl; wherein R1 may be optionally substituted on carbon by one or more groups selected from P and wherein if said heterocyclic group contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R; R is selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C .6alkenyl, C2-6alkynyl, Cι-6alkoxy, d-βalkanoyl, C1-6alkanoyloxy, N-(Cι_6alkyl)amino, NN-(C1.6alkyl)2amino, d-δalkanoylamino, N-(d.6alkyl)carbamoyl, N,N-(C1.4alkyl)2carbamoyl, N-(C1-6alkyl)-N-(Cι.6alkoxy)carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, d-6alkoxycarbonyl, d-6alkoxycarbonylamino, N-(d.6alkyl)sulphamoyl, NN-(d_6alkyl)2sulphamoyl, sulphamoylamino,
Figure imgf000006_0002
C1-6alkylsulphonylamino, C1-6alkylsulphonylaminocarbonyl, C1.6alkylsulphonyl-N-(C1.6alkyl)amino and a group -E-F-G-H; wherein E and G are independently selected from a direct bond, -O-, -S-, -SO-, -SO2-,
-OC(O)-, -C(O)O-, -C(O)-, -ΝR\ -NRaC(O)-, -C(O)NR\ -SO2NRa-, -NRaSO2-, -NRaC(O)NRb-, -OC(O)NRa-, -NRaC(O)O-, -NRaSO NRb-, -SO2NRaC(O)- and -C(O)NRaSO2-; wherein Ra and Rb are independently selected from hydrogen or C1-6alkyl which is optionally substituted by a group V ;
F is C1-6alkylene optionally substituted by one or more Q or a direct bond;
H is selected from aryl, C3-8cycloalkyl and heterocyclic group; wherein H may be optionally substituted on carbon by one or more groups selected from S and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from T;
R3 is hydrogen or Cι-6alkyl; n is selected from 0-4; wherein the values of R1 may be the same or different; and wherein the values of R may be the same or different;
P, S and Q are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, d-6alkanoyl, d_6alkanoyloxy, N-(Cι_6alkyl)amino, NN-(C1_6alkyl)2amino, d-ealkanoylamino, N-(d-6alkyl)carbamoyl, NN-(C1-6alkyl)2carbamoyl, N-(C1.6alkyl)-N-(C1.6alkoxy)carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, d_6alkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, NN-(C1_6alkyl)2sulphamoyl, d_6alkylsulphonylamino, C1.6alkylsulphonyl-N-(C1-6alkyl)amino, C3.8cycloalkyl, aryl and heterocyclic group; wherein P, S and Q may be optionally and independently substituted on carbon by one or more groups selected from V and wherein if said heterocyclic group contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from U;
V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl,
NN-diefhylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl, N-methyl-N-ethylsulphamoyl, morpholino, morpholinocarbonyl, N- benzylcarbamoyl, and 4- hydroxypiperidinocarbonyl;
R, T and U are independently selected from C1-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N-(d-4alkyl)carbamoyl, NN-(C1.4alkyl)carbamoyl, phenyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl wherein R, T and U may be optionally and independently substituted on carbon by one or more groups selected from V; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof; with the provisos: i) when -X-Y-Z- is -S-CH=CH-, R2-(CR1R3)n- cannot be amino, l-phenyl-5-methyl-lH-l,5- benzodiazepine-2,4(3H,5H)dion-3-yl, l-methyl-5-phenyl-2-oxo-2,3-dihydro-lH- benzo(E)( 1 ,4)diazepin-3-yl, 2-(4-phenyl- 1 ,2,5 ,6-tetrahydropyrid- 1 -yl)ethyl, 3-(4- phenyl- 1 ,2,5 ,6-tetrahydropyrid- 1 -yl)propyl, 2-(4-phenylpiperazin- 1 -yl)ethyl, 2-(N- methylamino)ethyl, 2-morpholinoethyl or 2-(N-methyl-N-benzylamino)ethyl; ii) when -X-Y-Z- is -CH=CH-S-, R2-(CR'R3)n- cannot be amino or l-methyl-5-phenyl-2-oxo- 2,3-dihydro-lH-benzo(E)(l,4)diazepin-3-yl; iii) when -X-Y-Z- is -CH=C(SO2ΝH2)-S-, R2-(CR1R3)n- cannot be methyl or isobutyl; and iv) when -X-Y-Z- is as initially defined, n is 1, R1 is arylmethyl, substituted arylmethyl, (heterocyclic group)methyl and substituted (heterocyclic group)methyl and R3 is hydrogen then R2 is not a group -C(=O)-A or a group -CH(OH)-C(=O)-A in which A is NRdRd, - NRaCH2CH2ORa, or
Figure imgf000008_0001
each Ra and Rb is independently hydrogen or -d-C8alkyl; each Rd is independently hydrogen, d-C8alkyl, d-C8alkoxy, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; each Rc is independently hydrogen, -C(=O)ORa -OR\ -SRa, or -NRaRa; and each n is independently 1-3, and X1 is NRβ, -CH2-, O or S. hi another aspect the present invention provides a compound of formula (I):
Figure imgf000009_0001
(I) wherein:
-X-Y-Z- is selected from -S-CR4=CR5-, -CR4=CR5-S-, -O-CR4=CR5-, -CR4=CR5-O-, -N=CR4-S-, -S-CR4=N-, -NR6-CR4=CR5- and -CR4=CR5-NR6-; wherein R4 and R5 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(d.6alkyl)2amino, d_6alkanoylamino, N-(d.6alkyl)carbamoyl, NN-(C1-6alkyl)2carbamoyl, C1.6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, Cι-6alkoxycarbonylamino, N-(Cι-6alkyl)sulphamoyl, NN-(C1_6alkyl)2sulphamoyl, d-βalkylsulphonylamino and d.6alkylsulphonyl-N-(d_6alkyl)amino;
R6 is hydrogen or C1-6alkyl;
R1 is selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, d-6alkanoyloxy, N-(d-6alkyl)amino, NN-(C1-6alkyl)2amino, d-6alkanoylamino, N-(C1-6alkyl)carbamoyl, NN-(C1.4alkyl)2carbamoyl, d_6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, C1-6alkoxycarbonylamino, N- d-ealky sulphamoyl, NN-(C1-6alkyl)2sulphamoyl, d-βalkylsulphonylamino, C1-6alkylsulphonyl-N-(C1-6alkyl)amino, C3-8cycloalkyl, C3_8cycloalkyld_6alkyl, aryl, arylC1-6alkyl, heterocyclic group and (heterocyclic group)C1-6alkyl; wherein R1 may be optionally substituted on carbon by one or more groups selected from P and wherein if said heterocyclic group contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R;
R2 is selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2-6alkenyl, d^alkynyl, C1-6alkoxy, C1-6alkanoyl, Cι-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1.6alkyl)2amino, C1-6alkanoylamino,
Figure imgf000010_0001
NN-(C1. alkyl)2carbamoyl, N-(C1-6alkyl)-N-(C1-6alkoxy)carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, d-6alkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, NN-(C1.6alkyl)2Sulphamoyl, sulphamoylamino, N-(C1-6alkyl)sulphamoylamino, NN-(C1-6alkyl)2sulphamoylamino, C1-6alkylsulphonylamino, Ci-βalkylsulphonylaminocarbonyl, C1-6alkylsulphonyl-N-(d-6alkyl)amino and a group -E-F-G-H; wherein E and G are independently selected from a direct bond, -O-, -S-, -SO-, -SO2-, -OC(O)-, -C(O)O-, -C(O)-, -ΝR\ -NRaC(O)-, -C(O)NRa-, -SO2NRa-, -NRaSO2-, -NRaC(O)NRb-, -OC(O)NRa-, -NRaC(O)O-, -NRaSO2NRb-, -SO2NRaC(O)- and
-C(O)NRaSO2-; wherein Ra and Rb are independently selected from hydrogen or C1-6alkyl; F is C1-6alkylene optionally substituted by one or more Q or a direct bond; H is selected from aryl, C3.8cycloalkyl and heterocyclic group; wherein H may be optionally substituted on carbon by one or more groups selected from S and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from T;
R3 is hydrogen or C1-6alkyl; n is selected from 0-4; wherein the values of R1 may be the same or different; and wherein the values of R3 may be the same or different; P, S and Q are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1.6alkyl)2amino, C1-6alkanoylamino, N-(d.6alkyl)carbamoyl, NN-(C1-6alkyl)2carbamoyl, N-(C1.6alkyl)-N-(C1.6alkoxy)carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, d-6alkoxycarbonylamino, N-(d.6alkyl)sulphamoyl,
NN-(d-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, C1.6alkylsulphonyl-N-(C1.6alkyl)amino, C3-8cycloalkyl, aryl and heterocyclic group; wherein P, S and Q may be optionally and independently substituted on carbon by one or more groups selected from V and wherein if said heterocyclic group contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from U;
V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl;
R, T and U are independently selected from C1-4alkyl, C1- alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N-(C1- alkyl)carbamoyl, NN-(C1- alkyl)carbamoyl, phenyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof; with the provisos :i)when -X-Y-Z- is -S-CH=CH-, R2-(CR1R3)n- cannot be amino, l-phenyl-5- methyl-lH-l,5-benzodiazepine-2,4(3H,5H)dion-3-yl, l-methyl-5-phenyl-2-oxo-2,3-dihydro- lH-benzo(E)(l,4)diazeρin-3-yl, 2-(4-ρhenyl-l,2,5,6-tetrahydropyrid-l-yl)ethyl, 3-(4- phenyl-l,2,5,6-tetrahydropyrid-l-yl)propyl, 2-(4-phenylpiperazin-l-yl)ethyl, 2-(N- methylamino)ethyl, 2-morpholinoethyl or 2-(N-methyl-N-benzylamino)ethyl; ii)when -X-Y-Z- is -CH=CH-S-, R2-(CR1R3)n- cannot be amino or l-methyl-5-phenyl-2-oxo- 2,3-dihydro-lH-benzo(E)(l,4)diazepin-3-yl; iii)when -X-Y-Z- is -CH=C(SO2ΝH2)-S-, R2- (CR!R3)n- cannot be methyl or isobutyl; and iv) when -X-Y-Z- is as initially defined, n is 1, R1 is arylmethyl, substituted arylmethyl, (heterocyclic group)methyl and substituted (heterocyclic group)mefhyl and R3 is hydrogen then R2 is not a group -C(=O)-A or a group - CH(OH)-C(=O)-A in which A is NRdRd, -NRaCH2CH2ORa, or
Figure imgf000011_0001
each Ra and Rb is independently hydrogen or -d-C8alkyl; each Rd is independently hydrogen, d-Csalkyl, Cj-C8alkoxy, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; each Rc is independently hydrogen, -C(=O)ORa -ORa, -SRa, or -NRaRa; and each n is independently 1-3, and X1 is NRa, -CH2-, O or S. In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. For example, "d.6alkyl" includes d_4alkyl, propyl, isopropyl and t-butyl. However, references to individual alkyl groups such as 'propyl' are specific for the straight chained version only and references to individual branched chain alkyl groups such as
'isopropyl' are specific for the branched chain version only. A similar convention applies to other radicals, for example "arylC1-6alkyl" includes arylC1-4alkyl, benzyl, 1-phenylethyl and 2-phenylethyl. The term "halo" refers to fluoro, chloro, bromo and iodo.
Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.
A "heterocyclic group" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)-and a ring sulphur atom may be optionally oxidised to form the S-oxide(s). Examples and suitable values of the term "heterocyclic group" are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, imidazolyl, thiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, 1,3-dioxolanyl, thiadiazolyl, piperazinyl, isothiazolidinyl, 1,3,4-triazolyl, tetrazolyl, pyrrolidinyl, 2-oxazolidinonyl, 5-isoxazolonyl, benz-3-azepinyl, 1,4-benzodioxanyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, 3-pyrazolin-5-onyl, tetrahydropyranyl, benzimidazolyl, benzthiazolyl, imidazo[l,2-a]pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone 2,3-dihydro-l,5-benzothiazepin-4(5H)-one. Preferably a "heterocyclic group" is pyridyl, imidazolyl, thiazolyl, quinolyl, thienyl, 1,3-benzodioxolyl, 1,3-dioxolanyl, isothiazolidinyl, 1,3,4-triazolyl, tetrazolyl, 2-oxazolidinonyl, 5-isoxazolonyl, benz-3-azepinyl, hydantoinyl, 1,4-benzodioxanyl, thiomorpholino, 3-pyrazolin-5-onyl, benzimidazolyl, benzthiazolyl, imidazo[l,2-a]pyridyl, pyrimidyl, pyrazinyl, and 2,3-dihydro-l,5-benzothiazepin-4(5H)-one "Aryl" is a partially saturated or unsaturated, mono or bicyclic ring containing 4-12 carbon atoms, wherein a -CH2- group can optionally be replaced by a -C(O)-. Preferably aryl is phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl (tetralinyl) or indanyl. More preferably aryl is phenyl, naphthyl or 1,2,3,4-tetrahydronaphthyl. Most preferably aryl is phenyl, or naphthyl. An example of "C1-6alkanoyloxy" is acetoxy. Examples of "C1-6alkoxycarbonyl" include C1-4alkoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl. Examples of "C1-6alkoxycarbonylamino" include methoxycarbonylamino, ethoxycarbonylamino, n- and t-butoxycarbonylamino. Examples of "C1-6alkoxy" include methoxy, ethoxy and propoxy. Examples of "C1-6alkanoylamino" include formamido, acetamido and propionylamino. Examples of "C1.6alkylS(O)a wherein a is 0 to 2" include C1-4alkylsulphonyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of "C1-6alkylsulphonylamino" include methylsulphonylamino, ethylsulphonylamino and propylsulphonylamino. Examples of "C1-6alkylsulphonyl-N-(C1-6alkyl)amino" include methylsulphonyl-N-methylamino, ethylsulphonyl-N-methylamino and propylsulphonyl-N-ethylamino. Examples of "C1-6alkanoyl" include C1-4alkanoyl, propionyl and acetyl. Examples of "N-(Cι-6alkyl)amino" include methylamino and ethylamino. Examples of "NN-(C1.6alkyl)2amino" include di-N-methylamino, di-(N-ethyl)amino and N-ethyl-N-methylamino. Examples of "C2_6alkenyl" are vinyl, allyl and 1-propenyl. Examples of "C2.6alkynyl" are ethynyl, 1-propynyl and 2-propynyl. Examples of "N-(Ci.6alkyl)sulphamoyl" are N-(methyl)sulphamoyl and N-(ethyl)sulphamoyl. Examples of "N-(C1-6alkyl)2sulphamoyl" are N,N-(dimethyl)sulphamoyl and N-(methyl)-N-(ethyl)sulphamoyl. Examples of "N-(d..6alkyl)carbamoyl" are N-(C1-4alkyl)carbamoyl, methylaminocarbonyl and ethylaminocarbonyl. Examples of "NN-(d_6aιkyl)2carbamoyl" are NN-(C1-4alkyl)carbamoyl, dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of "C3-8cycloalkyl ring" are cyclopropyl and cyclohexyl. Examples of "(heterocyclic group)d.6alkyl" include pyridylmethyl, 3-morpholinopropyl and 2-pyrimid-2-ylethyl. Examples of "C3_8cycloarkyld-6cycloalkyr' include cyclopropylmethyl and 2-cyclohexylpropyl. ''N-td-ealky^sulphamoylamdno'' are N-(methyl)sulphamoylamino and N-(ethyl)sulphamoylamino. Examples of "N-(C1-6alkyl)2sulphamoylamino" are
N,N-(dimethyl)sulphamoylamino and N-(methyl)-N-(ethyl)sulphamoylamino. Examples of "C1-6alkylsulphonylaminocarbonyl" include methylsulphonylaminocarbonyl, ethylsulphonylaminocarbonyl and propylsulphonylaminocarbonyl.
A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
An in vivo hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically acceptable esters for carboxy include C1-6alkoxymethyl esters for example methoxymethyl, C1-6alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters,
C3-8cycIoalkoxycarbonyloxyd_6alkyl esters for example 1-cyclohexylcarbonyloxyethyl; l,3-dioxolen-2-onylmethyl esters for example 5-methyl-l,3-dioxolen-2-onylmethyl; and d_6alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention. An in vivo hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and α-acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group. Examples of α-acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of in vivo hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl. Examples of substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl ring. Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess glycogen phosphorylase inhibitory activity.
The invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess glycogen phosphorylase inhibitory activity.
It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess glycogen phosphorylase inhibitory activity.
Preferred values of R1, R2, R3, -X-Y-Z-and n are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
Preferably -X-Y-Z- is selected from -S-CR4=CR5-, -CR4=CR5-S-, -O-CR4=CR5- and -N=CR4-S-.
More preferably -X-Y-Z- is selected from -S-CR4=CR5- and -CR4=CR5-S-.
In one aspect of the invention preferably -X-Y-Z- is selected from -S-CR4=CR5-. In another aspect of the invention preferably -X-Y-Z- is selected from -CR4=CR5-S-.
Preferably R4 and R5 are independently selected from hydrogen, halo or d-6alkyl.
More preferably R4 and R5 are independently selected from hydrogen, chloro, bromo or methyl.
Particularly R4 and R5 are independently selected from hydrogen or chloro. More particularly R4 and R5 are both chloro.
Preferably -X-Y-Z- is selected from -S-C(C1)=C(C1)-, -S-C(C1)=CH-, -S-CH=C(C1)-, -S-C(Br)=CH-, -S-CH=CH-, -CH=CH-S-, -O-CH=CH- , -N=C(Me)-S- and -S-CH=CCl-.More preferably -X-Y-Z- is selected from -S-C(C1)=C(C1)-, -S-C(C1)=CH-, -S-CH=C(C1)-, -S-C(Br)=CH-, -S-CH=CH-, -CH=CH-S-, -O-CH=CH- and -N=C(Me)-S-. Most preferably -X-Y-Z- is selected from -S-C(C1)=C(C1)-, -S-C(C1)=CH- and
-S-CH=C(C1)-.
Particularly -X-Y-Z- is selected from -S-C(C1)=C(C1)-.
In one aspect of the invention, preferably R6 is hydrogen.
In another aspect of the invention, preferably R6 is C1-6alkyl. Preferably R1 is selected from hydrogen, hydroxy, d_6alkyl, d-6alkoxycarbonyl, arylCj-ealkyl and (heterocyclic group)C].6alkyl; wherein R1 may be optionally substituted on carbon by one or more groups selected from P; and
P is selected from hydroxy and C1.6alkylsulphonyl-N-(C1.6alkyl)amino.
More preferably R1 is selected from hydrogen, hydroxy, methyl, methoxycarbonyl, benzyl and imidazol-4-ylmethyl; wherein R1 may be optionally substituted on carbon by one or more groups selected from P; and
P is selected from hydroxy and mesyl-N-(methyl)amino. Particularly R1 is selected from hydrogen, hydroxy, methyl, methoxycarbonyl, mesyl-N-(methyl)aminomethyl, benzyl, hydroxymethyl and imidazol-4-ylmethyl.
More particularly R1 is selected from hydrogen, mesyl-N-(methyl)aminomethyl or benzyl. Preferably R2 is selected from N,N-(C1.4alkyl)2carbamoyl,
N,N-(C1-6alkyl)2sulphamoylamino, C1-6alkylsulphonylaminocarbonyl and a group -E-F-G-H; wherein E and G are independently selected from a direct bond, -O-, -S-, -C(O)-, -ΝRa-, -C(O)NRa-, -NRaSO2- and -NRaC(O)O-; wherein Ra is hydrogen;
F is C1-6alkylene optionally substituted by one or more Q or a direct bond; H is selected from aryl, C3-8cycloalkyl and heterocyclic group; wherein H may be optionally substituted on carbon by one or more groups selected from S and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from T;
S is selected from halo, hydroxy, trifluoromethyl, sulphamoyl, ureido, C1-6alkyl, C1-6alkoxy, NN-(C1.6alkyl)2amino, C1.6alkanoylamino and aryl; wherein S may be optionally substituted on carbon by one or more groups selected from V;
Q is hydroxy;
N is carbamoyl; and
T is independently selected from C1- alkyl or phenyl. More preferably R2 is selected from NN-dimethylcarbamoyl,
N,N-dimethylsulphamoylamino, mesylaminocarbonyl and a group -E-F-G-H; wherein E and G are independently selected from a direct bond, -O-, -S-, -C(O)-, -ΝRa-, -C(O)NRa-, -NRaSO2- and -NRaC(O)O-; wherein Ra is hydrogen;
F is methylene optionally substituted by one or more Q or a direct bond; H is selected from phenyl, naphthyl, cyclopropyl, thiomorpholino, pyridyl, thiazolyl, isothiazolyl, morpholinyl, 2,3-dihydro-l,5-benzothiazepin-4(5H)-onyl, 5-oxo-3-pyrazolinyl, 2-oxazolidinonyl, 5-hydroxy-l,3,4,5-tetrahydro-benzo[b]azepin-2-onyl, 5-oxo-2-isoxazolinyl, imidazo[l,2-a]pyridinyl, benzothiazolyl, 2,5-dioxoimidazolidinyl, pyrazinyl, pyridazinyl, imidazolyl, benzimidazolyl, tetrazolyl, quinolyl, 1,3-dioxolanyl and thienyl; wherein H may be optionally substituted on carbon by one or more groups selected from S and wherein if a heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from T; S is selected from fluoro, chloro, hydroxy, trifluoromethyl, sulphamoyl, ureido, methyl, ethyl, methoxy, NN-dimethylamino, acetamido and phenyl; wherein S may be optionally substituted on carbon by one or more groups selected from V; Q is hydroxy; N is carbamoyl; and
T is independently selected from methyl or phenyl.
Particularly R is selected from NN-dimethylcarbamoyl, NN-dimethylsulphamoyl- amino, mesylaminocarbonyl, 2-methoxyphenyl, phenoxy, 2-phenylcyclopropyl, thien-2-yl, 4- fluorophenyl, benzoyl, thiomorpholino, anilinocarbonyl, pyrid-2-ylamino, thiazol-2-yl, benzylsulphonylamino, 2,3-dihydro-l,5-benzothiazepin-4(5H)-one-3-yl, l-phenyl-2,3- dimethyl-5-oxo-3-pyrazolin-4-yl, 3-phenyl-2-oxazolidinon-5-yl, 5-hydroxy-l,3,4,5-tetrahydro- benzo[b]azepin-2-onyl, 3-phenyl-5-oxo-2-isoxazolin-4-yl, imidazofl ,2-a]pyridin-2-yl, benzothiazol-2-yl, 2,5-dioxoimidazolidin-3-yl, naphth-2-ylaminocarbonyl, phenyl, 4- sulphamoylphenethyl, 4-(NN-dimethylamino)phenyl, 4-sulphamoylphenyl, anilino, 4- hydroxyphenyl, quinolin-3-yl, 4-chlorophenyl, 2-methoxypyrid-5-yl, 3-methylisothiazol-5-yl, 3-trifluoromethylpyrid-2-yl, tetrazol-5-yl, benzyloxycarbonylamino, benzimidazol-2-yl, 2- trifluoromethylpyrid-5-yl, pyridazin-2-yl, pyridazin-3-yloxy, pyrid-2-yl, imidazol-5-yl, 4- acetamidophenoxy, 2-ureidothiazol-4-yl, benzylthio, 2-phenyl-l,3-dioxolan-2-yl, 4- carbamoylmethylphenoxy, (N-benzylcarbamoylmethyl), phenethyl, 3-phenylpropyl, [2-(2- hydroxyphenyl)ethyl], -(α, -dimethylphenethyl), (l-phenylcyclobutyl)methyl), (β-methylphenethyl), (l,2,3,4-tetrahydronaphth-2-yl), benzyl, (N-benzyl-N- methylcarbamoylmethyl), (N-methyl-N-phenylcarbamoylmethyl), [N-(2-cyanoethyl)-N- phenylcarbamoylmethyl] , [Ν-(4-methoxyphenyl)carbamoylmethyl] , [N-(4- fluorophenyl)carbamoylmethyl] , [N-(4-nitrophenyl)carbamoylmethyl] , [N-(2,6- dimethylphenyl)carbamoylmethyl], [N-methyl-N-(4-methylphenyl)carbamoylmethyl], [N- methyl-N-(3-methylphenyl)carbamoylmethyl], [N-(3-chlorophenyl) N-methylcarbamoyl- methyl] , [N-(2-hydroxyethyl)-N-phenylcarbamoylmethyl] , [N-( 1 , 1 -dimethyl-2- hydroxyethyl)carbamoylmethyl] , [N-(2-hydroxyethyl)-N-methylcarbamoyl-methyl] , [N-(2- hydroxyethyl)carbamoylmethyl] , [N-(3-hydroxypropyl)carbamoylmethyl], [N-(4- hydroxybutyl)carbamoylmethyl] , {N-[bis(hydroxymethyl)methyl]carbamoylmethyl } ,
[N-(2,3-dihydroxypropyl)carbamoylmethyl] , [Ν-(4-hydroxymethylphenyl)-carbamoylmethyl] , [N-(5-isoquinolyl)carbamoylmethyl], [N-(3-hydroxymethy)lphenyl]-carbamoylmethyl], {N-[4- (2-hydroxyethyl)phenyl]carbamoyl-methyl } , [N-(2,4-difluorophenyl)-N-methyl- carbamoylmethyl] , [( 1 ,2,3 ,4-tetrahydro- 1 -quinolyl)carbonyl-methyl] , [N-(2-cyanoethyl)-N- methylcarbamoylmethyl] , [N-(4-hydroxypiperidino)-carbamoylmethyl] , (N- cyclopentylcarbamoylmethyl), (N-isopropyl-carbamoylmethyl), (N-isopropyl-N- methylcarbamoylmethyl), (thiomorpholin-carbonylmethyl), (morpholino-carbonylmethyl), [(1,1 -dioxothiomorpholino)carbonyl-methyl] , [( 1 -oxothiomorpholino)-carbonylmethyl] , (2- indanyl), (benz[l,2]oxazol-3-ylmethyl), {2-[2-(hydroxymethyl)phenyl]-ethyl}, (4- phenylisoxazol-3-ylmethyl), {2-[2-(2-morpholino-ethoxy)phenyl]ethyl}, {2-[2- (methoxycarbonyl-methoxy)phenyl]ethyl}, {2-[2-(carboxy-methoxy)phenyl]ethyl}, [2-(3- methoxyphenyl)ethyl], (2-oxo-l,2,3,4-tetrahydroquinol-3-yl), {2-[2-(2- methoxyethoxy)phenyl] ethyl } , { 2-[2-(carbamoylmethoxy)phenyl]ethyl } , { 2-[2-(Ν- methylcarbamoylmethoxy)phenyl]ethyl } , { 2- [2-(N,N-dimethylcarbamoyl- methoxy)phenyl]ethyl } , 2-[2-(morpholinocarbonylmethoxy)-phenyl]ethyl, 2-[2-(N- benzylcarbamoylmethoxy)phenyl]ethyl, 2-[2-(4-hydroxypiperidinocarbonylmethoxy)- phenyl]ethyl, [ 1 -(5-ethoxycarbonyl- 1 ,3 ,4-oxadiazo-2-yl)-2-phenylethyl] , [ 1 -(4- methoxycarbonyl-oxazo-5-yl)-2-phenylethyl], [2-phenylethyl-l-(pyrid-3-yl)], [2-phenylethyl - l-(3-phenyl-l,2,4-oxadiazo-5-yl) ], (l-hydroxyindan-2-yl), [(lS,2S)-2-indan-l-ol], [(1R,2R)- 2-indan-l-ol], (3-indanyl), (l-hydroxy-l,2,3,4-tetrahydronaphth-2-yl) , (6-fluoro-l- hydroxyindan-2-yl), (7-methoxy- 1 -oxo- 1 ,2,3 ,4-tetrahydronaphth-2-yl), -(3-methylisoxazol-5- yl)methyl], (4-hydroxy-l,l-dioxotetrahydrothiophen-3-yl), -{N-methyl-N-[(l-oxo-l,2,3,4- tetrahydronaphth-2-yl)methyl]carbamoylmethyl } , (3-methylisoxazol-5-yl)methyl] , (4- hydroxy- 1 , 1 -dioxotetrahydrothiophen-3-yl), {N-methyl-N-[( 1-oxo- 1 ,2,3,4-tetrahydronaphth-2- yl)methyl]carbamoylmethyl}, (2-oxo-l,2,3,4-tetrahydroquinol-3-yl), (1,2,3,4- tetrahydroquinol-3-yl), (l-methyl-2-oxo-l,2,3,4-tetrahydroquinol-3-yl), (3-oxo-2,3,4,5- tetrahydro-lH-benz[2]azepin-4-yl), (l-methoxyindan-2-yl), { 1-[N-(1,1- dimethylethoxy)carbonylamino]indan-2-yl } , ( 1 -aminoindan-2-yl)] , ( l-acetamidoindan-2-yl), [l-(methanesulphonamido)indan-2-yl], [l-(methylamino)indan-2-yl], or [1-(N- methylacetamido)indan-2-yl] .
More particularly R2 is selected from NN-dimethylcarbamoyl, NN-dimethylsulphamoylamino, mesylaminocarbonyl, 2-methoxyphenyl, phenoxy, 2- phenylcyclopropyl, thien-2-yl, 4-fluorophenyl, benzoyl, thiomorpholino, anilinocarbonyl, pyrid-2-ylamino, thiazol-2-yl, benzylsulphonylamino, 2,3-dihydro-l,5-benzothiazepin-4(5Η)- one-3-yl, l-phenyl-2,3-dimethyl-5-oxo-3-pyrazolin-4-yl, 3-phenyl-2-oxazolidinon-5-yl, 5- hydroxy- 1 ,3,4,5-tetrahydro-benzo[b]azepin-2-onyl, 3-phenyl-5-oxo-2-isoxazolin-4-yl, imidazo[l,2-a]pyridin-2-yl, benzothiazol-2-yl, 2,5-dioxoimidazolidin-3-yl, naphth-2- ylaminocarbonyl, phenyl, 4-sulphamoylphenethyl, 4-(NN-dimethylamino)phenyl, 4- sulphamoylphenyl, anilino, 4-hydroxyphenyl, quinolin-3-yl, 4-chlorophenyl, 2-methoxypyrid- 5-yl, 3-methylisothiazol-5-yl, 3-trifluoromethylpyrid-2-yl, tetrazol-5-yl, benzyloxycarbonylamino, benzimidazol-2-yl, 2-trifluoromethylpyrid-5-yl, pyridazin-2-yl, pyridazin-3-yloxy, pyrid-2-yl, imidazol-5-yl, 4-acetamidophenoxy, 2-ureidothiazol-4-yl, benzylthio, 2-phenyl-l,3-dioxolan-2-yl and 4-carbamoylmethylphenoxy. Most particularly R2 is selected from NN-dimethylcarbamoyl, phenoxy, 2- phenylcyclopropyl, thien-2-yl, 4-fluorophenyl, benzoyl, thiomorpholino, anilinocarbonyl, pyrid-2-ylamino or thiazol-2-yl.
Preferably R3 is hydrogen.
Preferably n is selected from 0-3; wherein the values of R1 may be the same or different; and wherein the values of R3 may be the same or different.
More preferably n is selected from 0-2; wherein the values of R1 may be the same or different; and wherein the values of R3 may be the same or different.
In one aspect of the invention preferably n is 2; wherein the values of R1 may be the same or different; and wherein the values of R3 may be the same or different. In one aspect of the invention preferably n is i.
In one aspect of the invention preferably n is 0.
In another aspect of the invention, preferred compounds of the invention are any one of the Examples or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
In another aspect the present invention provides a compound of formula (I) (as depicted above) wherein:
-X-Y-Z- is selected from -S-CR4=CR5-, -CR4=CR5-S-, -O-CR4=CR5- and -Ν=CR4-S-;
R4 and R5 are independently selected from hydrogen, halo or C1-6alkyl;
R1 is selected from hydrogen, hydroxy, C1-6alkyl, C1-6alkoxycarbonyl, aryld-6alkyl and (heterocyclic group)C1-6alkyl; wherein R1 may be optionally substituted on carbon by one or more groups selected from P; and
P is selected from hydroxy and C1-6alkylsulphonyl-N-(C1.6alkyl)amino;
R2 is selected from NN-(C1-4alkyl)2carbamoyl, NN-(C1.6alkyl)2sulphamoylamino, Ci-6alkylsulphonylaminocarbonyl and a group -E-F-G-H; wherein E and G are independently selected from a direct bond, -O-, -S-, -C(O)-, -NRa-, -C(O)NRa-, -NRaSO2- and -NRaC(O)O-; wherein Ra is hydrogen;
F is Cι-6alkylene optionally substituted by one or more Q or a direct bond; H is selected from aryl, C -8cycloalkyl and heterocyclic group; wherein H may be optionally substituted on carbon by one or more groups selected from S and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from T;
S is selected from halo, hydroxy, trifluoromethyl, sulphamoyl, ureido, d-ealkyl, d_ alkoxy, N)N-(C1_6alkyl)2amino, C1-6alkanoylamino and aryl; wherein S may be optionally substituted on carbon by one or more groups selected from N; Q is hydroxy; V is carbamoyl; and
T is independently selected from d-4alkyl or phenyl; R3 is hydrogen; n is selected from 0-3; wherein the values of R1 may be the same or different; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof; with the provisos: i) when -X-Y-Z- is -S-CH=CH-, R -(CR1R3)n- cannot be l-phenyl-5-methyl-lH-l,5- benzodiazepine-2,4(3H,5H)dion-3-yl, l-methyl-5-phenyl-2-oxo-2,3-dihydro-lH- benzo(E)(l,4)diazeρin-3-yl, 2-(4-phenyl-l,2,5,6-tetrahydropyrid-l-yl)ethyl, 3-(4- phenyl-l,2,5,6-tetrahydropyrid-l-yl)propyl, 2-(4-phenylpiperazin-l-yl)ethyl or 2- morpholinoethyl ; ii) when -X-Y-Z- is -CH=CH-S-, R2-(CR1R3)n- cannot be l-methyl-5-phenyl-2-oxo-2,3- dihydro- lH-benzo(E)( 1 ,4)diazepin-3-yl;and iii) when -X-Y-Z- is as initially defined, n is 1, R1 is arylmethyl, substituted arylmethyl,
(heterocyclic group)mefhyl and substituted (heterocyclic group)methyl and R3 is hydrogen then R2 is not a group -C(=O)-A or a group -CH(OH)-C(=O)-A in which A is ΝRdRd, - NRaCH2CH2ORa, or
Figure imgf000021_0001
each Ra and Rb is independently hydrogen or -d-C8alkyl; each Rd is independently hydrogen, d-C8alkyl, d-C8alkoxy, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; each R° is independently hydrogen, -C(=O)ORa -ORa, -SRa, or -NR Ra; and each n is independently 1-3, and
X1 is NRa, -CH2-, O or S.
In yet another aspect the present invention provides a compound of formula (I) (as depicted above) wherein:
-X-Y-Z- is selected from -S-C(C1)=C(C1)-, -S-C(C1)=CH-, -S-CH=C(C1)-, -S-C(Br)=CH-, -S-CH=CH-, -CH=CH-S-, -O-CH=CH- and -N=C(Me)-S-;
R1 is selected from hydrogen, hydroxy, methyl, methoxycarbonyl, mesyl-N-(methyl)aminomethyl and hydroxymethyl ;
R2 is selected from NN-dimethylcarbamoyl, NN-dimethylsulphamoylamino, mesylaminocarbonyl, 2-methoxyphenyl, phenoxy, 2-phenylcyclopropyl, thien-2-yl, 4- fluorophenyl, benzoyl, thiomorpholino, anilinocarbonyl, pyrid-2-ylamino, thiazol-2-yl, benzylsulphonylamino, 2,3-dihydro- 1 ,5-benzothiazepin-4(5H)-one-3-yl, 1 -phenyl-2,3- dimethyl-5-oxo-3-pyrazolin-4-yl, 3-phenyl-2-oxazolidinon-5-yl, 5-hydroxy-l ,3, 4,5-tetrahydro- benzo[B]azepin-2-onyl, 3-phenyl-5-oxo-2-isoxazolin-4-yl, imidazo[l,2-a]pyridin-2-yl, benzothiazol-2-yl, 2,5-dioxoimidazolidin-3-yl, naphth-2-ylaminocarbonyl, phenyl, 4- sulphamoylphenethyl, 4-(NN-dimethylamino)phenyl, 4-sulphamoylphenyl, anilino, 4- hydroxyphenyl, quinolin-3-yl, 4-chlorophenyl, 2-methoxypyrid-5-yl, 3-methylisothiazol-5-yl, 3-trifluoromethylpyrid-2-yl, tetrazol-5-yl, benzyloxycarbonylamino, benzimidazol-2-yl, 2- trifluoromethylpyrid-5-yl, pyridazin-2-yl, pyridazin-3-yloxy, pyrid-2-yl, imidazol-5-yl, 4- acetamidophenoxy, 2-ureidothiazol-4-yl, benzylthio, 2-phenyl-l,3-dioxolan-2-yl and 4- carbamoylmethylphenoxy;
R3 is hydrogen; and n is selected from 0-3; wherein the values of R1 may be the same or different; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof. In a first preferred aspect the present invention provides a compound of formula (I) (as depicted above) wherein:
-X-Y-Z- is selected from -S-CR4=CR5- or -CR4=CR5-S-; wherein R4 and R5 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, Cι-6alkyl, C2_6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1-6alkyl)2amino, d.6alkanoylamino, N-(C1-6alkyl)carbamoyl, NN-(C1.6alkyl)2carbamoyl, d_6alkylS(O)a wherein a is 0 to 2, C!-6alkoxycarbonyl, C1-6alkoxycarbonylamino, N-(d..6alkyl)sulphamoyl, NN-(C1_6alkyl)2sulphamoyl, d-6alkylsulphonylamino and C1-6alkylsulphonyl-N-(C1.6alkyl)amino; n is 0;
R2 is a group -E-F-G-H; wherein E, F and G are each a direct bond; H is a C3_12cycloalkyl which is optionally fused to a benz ring wherein H may be optionally substituted on carbon by one or more groups S which are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, d^alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1-6alkyl)2amino, Cι-6alkanoylamino, N-(C1-6alkyl)carbamoyl, NN-(C1-6alkyl)2carbamoyl, N-(Cι.6alkyl)-N-(C1-6alkoxy)carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, d_6alkoxycarbonyl, C1-6alkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, NN-(C1-6alkyl)2sulphamoyl, d-βalkylsulphonylamino, C1_6alkylsulphonyl-N-(C1.6alkyl)amino, C3-8cycloalkyl, aryl and heterocyclic groups; wherein S may be optionally substituted on carbon by one or more groups selected from V;
N is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl, N-methyl-N-ethylsulphamoyl, morpholino , morpholinocarbonyl , N- benzylcarbamoyl, and 4- hydroxypiperidinocarbonyl ; or a pharmaceutically acceptable salt thereof.
Preferred values of R2, R4, and R5 are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
In this first preferred aspect preferably R4 and R5 are independently selected from hydrogen, halo or d-βalkyl.
- In this first preferred aspect preferably H is indanyl, 1,2,3,4-tetrahydronaphthyl or cyclopropyl. More preferably H is indanyl or 1,2,3,4-tetrahydronaphthyl. Most preferably H is indanyl.
In this first preferred aspect preferably S is independently selected from from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, d-6alkyl, d_6alkoxy, C1-6alkanoyl, d_6alkanoyloxy, N-(d-6alkyl)amino, NN-(C1.6alkyl)2amino, d-6alkanoylamino, N-(C1-6alkyl)carbamoyl, NN-(C1.6alkyl)2carbamoyl, N-(C1.6alkyl)-N-(C1-6alkoxy)carbamoyl, Cι.6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, d.6alkoxycarbonylamino, C3-8cycloalkyl and aryl. More preferably S is selected from hydroxy, amino, C1-6alkoxy and C ϊ _6alkoxycarbonylamino .
In a second preferred aspect the present invention provides a compound of formula (I) (as depicted above) wherein:
-X-Y-Z- is selected from -S-CR4=CR5- or -CR4=CR5-S-; wherein R and R are independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, d_6alkyl, C2-6alkenyl, C2.6alkynyl, C1-6alkoxy, Cι-6alkanoyl, C1-6alkanoyloxy, N-(Cι-6alkyl)amino, NN-(d-6alkyl)2amino, d-6alkanoylamino, N-(Cι-6alkyl)carbamoyl, NN-(C1.6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, d-ealkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, NN-(C1.6alkyl)2sulphamoyl, d-ealkylsulphonylamino and d_6alkylsulphonyl-N- (d-ealky^amino; n is 0;
R2 is a group -E-F-G-H; wherein E, F and G are each a direct bond; and
H is a cyclic amide of formula
Figure imgf000024_0001
in which k is 0, 1, 2 or 3 and 1 is 0, 1, 2 or 3 such that the sum of k and 1 is 2 or 3 and wherein one of the carbon atoms governed by k or 1 may be replaced by sulphur and wherein H is optionally substituted on carbon by one or more groups selected from S and may be independently optionally substituted on nitrogen by a group selected from T;
S is selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, d_6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1.6alkanoyloxy, N^d-όalk amino, NN-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, NN-(C1.6alkyl)2carbamoyl, N-(C1-6alkyl)-N-(C1-6alkoxy)carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, d-6alkoxycarbonyl, d_6alkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, NN-(d_6alkyl)2sulphamoyl, d_6alkylsulphonylamino, Ci.6alkylsulphonyl-N-(Cι.6alkyl)amino, C3.8cycloalkyl, aryl and heterocyclic group; wherein S may be optionally and independently substituted on carbon by one or more groups selected from V and wherein if said heterocyclic group contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from U;
T and U are independently selected from C1-4alkyl, C1-4alkanoyl, Cι_4alkylsulphonyl, C1- alkoxycarbonyl, carbamoyl, N-(C1.4alkyl)carbamoyl, NN-(C1.4alkyl)carbamoyl, phenyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl wherein T and U may be optionally and independently substituted on carbon by one or more groups selected from V;
V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl,
NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl, N-methyl-N-ethylsulphamoyl, morpholino, morpholinocarbonyl, N- benzylcarbamoyl and 4- hydroxypiperidinocarbonyl ; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
Preferred values of R4, R5 and H are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
In this second preferred aspect preferably R4 and R5 are independently selected from hydrogen, halo or C1-6alkyl.
In this second preferred aspect preferably H is 1,2,3,4-tetrahydroquinolyl, 2-oxo- 1,2,3,4-tetrahydroquinolyl, 4-oxo-2,3,4,5-tetrahydrobenz[l,5]thiazepin-3-yl, 2-oxo-2,3,4,5- tetrahydro-lH-benz[t>]azepinyl, 2,3,4,5-tetrahydro-lH-benz[6]azepinyl or 3-oxo-2,3,4,5- tetrahydro-lH-benz[c]azepinyl each optionally substituted on carbon by one or more groups selected from S wherein S is selected from hydroxy, d_6aιkyl or d-6alkoxy, and each independently optionally substituted on nitrogen by a group selected from T wherein T is selected from d-4alkyl or C1-4alkanoyl.
More preferably H is 2-oxo-l,2,3,4-tetrahydroquinol-3-yl, l-methyl-2-oxo-l,2,3,4- tetrahydroquinol-3-yl, 4-oxo-2,3,4,5-tetrahydrobenz[l,5]thiazepin-3-yl, 5-hydroxy-2-oxo- 2,3,4,5-tetrahydro-lH-benz[Z>]azepin-4-yl, 2-oxo-2,3,4,5-tetrahydro-lH-benz[δ]azepin-3-yl or 3-oxo-2,3 ,4,5-tetrahydro- lH-benz[c]azepin-4-yl. In a third preferred aspect the present invention provides a compound of formula (I)
(as depicted above) wherein:
-X-Y-Z- is selected from -S-CR4=CR5- or -CR4=CR5-S-; wherein R4 and R5 are independently selected from hydrogen, halo or C1-6alkyl. n is 1; R1 is hydrogen or arylC1-6alkyl;
R is selected from a group -E-F-G-H; wherein E, F and G are each a direct bond;
H is an unsaturated five membered heterocyclic group containing at least one nitrogen atom and one or two ring atoms selected from oxygen and sulphur and wherein H may be optionally substituted on carbon by one or more groups S which are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, Cι-6alkanoyl, C1-6alkanoyloxy, N-(d_6alkyl)amino, NN-(C1.6alkyl)2amino, Cι-6alkanoylamino, N-(C1.6alkyl)carbamoyl, NN-(C1-6alkyl)2carbamoyl, N-(C1-6alkyl)-N-(Cι-6alkoxy)carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, d-ealkoxycarbonyl, C1-6alkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, NN-(C1.6alkyl)2sulphamoyl, Cι_6alkylsulphonylamino, C1.6alkylsulphonyl-N-(C1-6alkyl)amino, C3-8cycloalkyl and aryl groups;
R3 is hydrogen or C1-6alkyl; or a pharmaceutically acceptable salt thereof.
Preferred values of R1, R3 and H are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
In this third preferred aspect preferably R1 is selected from hydrogen or benzyl and more preferably benzyl.
In this third preferred aspect preferably R is hydrogen.
In this third preferred aspect preferably H is 1,3,4-oxadiazolyl, isoxazolyl, oxazolyl or 1,2,4-oxadiazolyl. More preferably H is 5-ethoxycarbonyl-l,3,4-oxadiazol-2-yl, 4- phenylisoxazol-3-yl, 3-phenyl-l,2,4-oxadiazol-5-yl, 4-methoxycarbonyloxazol-5-yl or 3- methylisoxazol-5-yl.
In this third preferred aspect preferably H may be optionally substituted on carbon by one or more groups S which are independently selected from halo, carboxy, C1-6alkyl, d-βalkoxy, d-βalkanoyloxy, N-(d.6alkyl)amino, NN-(C1.6alkyl)2amino, C1-6alkanoylamino, d-6alkoxycarbonyl, C3_8cycloalkyl and aryl groups. Preferably S is C1-6alkoxy, d-όaikoxycarbonyl or phenyl.
In a fourth preferred aspect the present invention provides a compound of formula (I) (as depicted above) wherein: -X-Y-Z- is selected from -S-CR4=CR5- or -CR4=CR5-S-; wherein R4 and R5 are independently selected from hydrogen, halo or C1-6alkyl. n is O;
R2 is a group -E-F-G-H; wherein E is a direct bond; F is methylene; wherein G is -C(O)ΝRa-, wherein Ra is selected from hydrogen or Cι_6alkyl which is optionally substituted by a group V ; H is aryl which may be optionally substituted on carbon by one or more groups selected from S;
S is selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, Cι-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(Cι-6alkyl)2amino, d_6alkanoylamino, N^d-ealky carbamoyl, NN-(Cι.6alkyl)2carbamoyl, N-(C1-6alkyl)-N-(C1.6alkoxy)carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, d_6alkoxycarbonylamino, N-(C].6alkyl)sulphamoyl, NN-(Cι.6alkyl)2sulphamoyl, Ci_6alkylsulphonylamino, C1.6alkylsulphonyl-N-(C1-6alkyl)amino, C3.8cycloalkyl, aryl and heterocyclic group; wherein S may be optionally and independently substituted on carbon by one or more groups selected from V ;
V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl,
NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl, N-methyl-N-ethylsulphamoyl, morpholino, morpholinocarbonyl, N- benzylcarbamoyl , and 4- hydroxypiperidinocarbonyl; or a pharmaceutically acceptable salt thereof.
Preferred values of R1, R2, R3, -X-Y-Z-and n are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter. In this fourth preferred aspect preferably H is aryl.
In this fourth preferred aspect preferably V is cyano or hydroxy. Specific compounds of the present invention are: 2 ,3 -dichloro-5- [N-(2-phenoxyethyl)carbamoyl] -4H-thieno [3 ,2-b] pyrrole ; 2,3-dichloro-5-{N-[2-(2-thienyl)ethyl]carbamoyl}-4H-thieno[3,2-b]pyrrole; 2,3-dichloro-5-{N-[2-(2-methoxyphenyl)ethyl]carbamoyl}-4H-thieno[3,2-t3]pyrrole; 2,3-dichloro-5-[N-(2-phenyl-l-cyclopropyl)carbamoyl]-4H-thieno[3,2-t)]pyrrole; 2,3-dichloro-5-{N-[2-(4-fluorophenyl)ethyl]carbamoyl}-4H-thieno[3,2-t ]pyrrole; 2,3-dichloro-5-[N-(N-phenylcarbamoylmethyl)carbamoyl]-4H-thieno[3,2-t3]pyrrole; 2,3-dichloro-5-(N-{2-[(2-pyridyl)amino]ethyl}carbamoyl)-4H-thieno[3,2-t>]pyrrole;
2,3-dichloro-5-{N-[2-(N-methylmethanesulphonamido)-l-(thiazol-2-yl)ethyl]carbamoyl}-4H- thieno[3,2-Z>]pyrrole;
2,3-dichloro-5-{N-[2-(thiomorpholino)ethyl]carbamoyl}-4H-thieno[3,2-t>]pyrrole; 5-[N-(benzoylmethyl)carbamoyl]-2,3-dichloro-4H-thieno[3,2-b]pyrrole;
3-chloro-5-[N-(N-phenylcarbamoylmethyl)carbamoyl]-4H-thieno[3,2-t>]pyrrole;
3-chloro-5-{N-[2-(thiomorpholino)ethyl]carbamoyl}-4H-thieno[3,2-tj]pyrrole;
3-chloro-5-{N-[2-(N-methylmethanesulphonamido)-l-(thiazol-2-yl)ethyl]carbamoyl}-4H- thieno [3 ,2-b] pyrrole; 3-chloro-5-[N-(benzoylmethyl)carbamoyl]-4H-thieno[3,2-έ]pyrrole;
3-chloro-5-{N-[2-(2-methoxyphenyl)ethyl]carbamoyl}-4H-thieno[3,2-t>]pyrrole;
3-chloro-5-{N-[2-(2-thienyl)ethyl]carbamoyl}-4H-thieno[3,2-t3]pyrrole;
3-chloro-5-[N-(2-phenyl-l-cyclopropyl)carbamoyl]-4H-thieno[3,2-t]pyrrole;
3-chloro-5-{N-[2-(4-fluorophenyl)ethyl]carbamoyl}-4H-thieno[3,2-έ]pyrrole; 3-chloro-5-[N-(2-phenoxyethyl)carbamoyl]-4H-thieno[3,2-δ]pyrrole;
3-chloro-5- {N-[2-( 1 -phenylmethanesulphonamido)ethyl]carbamoyl } -4H-thieno[3,2-t3]pyrrole;
3-chloro-5-[N-(4-oxo-2,3,4,5-tetrahydrobenz[l,5]thiazepin-3-yl)carbamoyl]-4H-thieno[3,2- bjpyrrole;
2-chloro-5-[N-(benzoylmethyl)carbamoyl]-4H-thieno[3,2-t)]pyrrole; 2-chloro-5-[N-(2-phenyl-l-cyclopropyl)carbamoyl]-4H-thieno[3,2-Z>]pyrrole;
2-chloro-5-[N-(N-phenylcarbamoylmethyl)carbamoyl]-4H-thieno[3,2-ό]pyrrole;
2-chloro-5-(N-{2-[(2-pyridyl)amino]ethyl}carbamoyl)-4H-thieno[3,2-/>]pyrrole;
2-chloro-5-{N-[2-(2-methoxyphenyl)ethyl]carbamoyl}-4H-thieno[3,2-t3]pyrrole;
2-chloro-5-[N-(2-phenoxyethyl)carbamoyl]-4H-thieno[3,2-έ]pyrrole; 2-chloro-5-{N-[2-(2-thienyl)ethyl]carbamoyl}-4H-thieno[3,2-b]pyrrole;
2-chloro-5-{N-[2-(4-fluorophenyl)ethyl]carbamoyl}-4H-thieno[3,2-t>]pyrrole;
2-chloro-5-{N-[2-(N-methylmethanesulphonamido)-l-(thiazol-2-yl)ethyl]carbamoyl}-4H- thieno [3 ,2-t3]pyrrole ;
2-chloro-5-{N-[2-(thiomorpholino)ethyl]carbamoyl}-4H-thieno[3,2-ό]pyrrole; 2,3-dichloro-5-[N-(2,3-dimethyl-5-oxo-l-phenyl-2,5-dihydro-lH-pyrazol-4-yl)carbamoyl]-
4H-thieno [3 ,2-ό jpyrrole ;
2,3-dichloro-5-[N-(4-sulphamoylphenylmethyl)carbamoyl]-4H-thieno[3,2-t)]pyrrole;
2,3-dichloro-5-[N-(2-hydroxy-l-phenethyl)carbamoyl]-4H-thieno[3,2-t3]pyrrole; 2,3-dichloro-5-{N-(2-[(3-trifluoromethylpyrid-2-yl)amino]ethyl)carbamoyl}-4H-thieno[3,2- δjpyrrole;
2,3-dichloro-5-{N-[3-(5-tetrazolyl)propyl]carbamoyl}-4H-thieno[3,2-δ]pyrrole;
2,3-dichloro-5-[N-(5-oxo-3-phenyl-4,5-dihydroisoxazol-4-yl)carbamoyl]-4H-thieno[3,2- όjpyrrole;
2,3-dichloro-5-[N-(5-hydroxy-2-oxo-2,3,4,5-tetrahydro-lΗ-benz[Z)]azepin-4-yl)carbamoyl]-
4H-thieno[3 ,2-Z>]pyrrole ;
2-chloro-5-{N-[3-(benzyloxycarbonylamino)propyl]carbamoyl}-4H-thieno[3,2-t>]pyrrole;
2,3-dichloro-5-{N-[(4-dimethylaminophenyl)methyl]carbamoyl}-4H-thieno[3,2-_j]pyrrole; 5- [N-( 1 -benzyl-2-hydroxyethyl)carbamoyl] -2 ,3-dichloro-4H-thieno [3 ,2-b] pyrrole ;
2,3-dichloro-5-{N-[2-(phenylamino)ethyl]carbamoyl}-4H-thieno[3,2-t>]pyrrole;
2,3-dichloro-5-[N-(β-( ? -hydroxy- -methylphenethyl)carbamoyl]-4H-thieno[3,2-b]pyrrole;
2,3-dichloro-5-[N-(β-hydroxyphenethyl)carbamoyl)-4H-thieno[3,2-t3]pyrrole;
2,3-dichloro-5-{N-[2-(4-hydroxyphenyl)ethyl]carbamoyl}4H-thieno[3,2-t>]pyrrole; 2,3-dichloro-5-{N-[(benzimidazol-2-yl)methyl]carbamoyl}-4H-thieno[3,2-ό]pyrrole;
2,3-dichloro-5-{N-[2-(4-chlorophenyl)-2-hydroxy-l-(methoxycarbonyl)ethyl]carbamoyl}-4H- thieno [3 ,2-Z>]pyrrole ;
2,3-dichloro-5-{N-(imidazo[l,2-a]pyrid-2-yl)carbamoyl}-4H-thieno[3,2-t>]pyrrole;
5-{N-[(benzthiazol-2-yl)methyl]carbamoyl}-2,3-dichloro-4H-thieno[3,2-t ]pyrrole; 2,3-dichloro-5-{N-[(6-trifluoromethylpyrid-3-yl)methyl]carbamoyl}-4H-thieno[3,2-Z)]pyrrole;
2,3-dichloro-5-{N-(2-[(2-pyridazinyl)methyl]carbamoyl}-4H-thieno[3,2-t>]pyrrole;
2,3-dichloro-5-{N-[ N-(2-hydroxy-3-phenoxypropyl)carbamoylmethyl] carbamoyl }-4H- thieno [3 ,2-Z>]pyrrole ;
2,3-dichloro-5- {N-[N-(3-methylisothiazol-5-yl)carbamoylmethyl]carbamoyl } -4H-thieno[3 ,2- 5]pyrrole;
2,3-dichloro-5-{N-[2-(pyridazin-3-yloxy)ethyl]carbamoyl}-4H-thieno[3,2-Z)]pyrrole;
2-chloro-5-(N-{2-[(3-trifluoromethylpyrid-2-yl)amino]ethyl}carbamoyl)-4H-thieno[3,2- bjpyrrole;
2,3-dichloro-5-{N-[2-(4-sulphamoylphenyl)ethyl]carbamoyl}-4H-thieno[3,2-tJ]pyrrole; 2,3-dichloro-5-{N-[2-(2-pyridyl)ethyl]carbamoyl}-4H-thieno[3,2-&]pyrrole;
2,3-dichloro-5-{N-(2-[l-hydroxymethyl-2-(4-imidazolyl)ethyl]carbamoyl}-4H-thieno[3,2- bjpyrrole; 2,3-dichloro-5-{N-(2-[(3-quinolyl)methyl]carbamoyl}-4H-thieno[3,2-5]pyrrole;
5-{N-[3-(4-acetamidophenoxy)-2-hydroxypropyl]carbamoyl}-2,3-dichloro-4H-thieno[3,2- ό]pyrrole;
2,3-dichloro-5-{N-[3-(N-methylsulphonylcarbamoyl)propyl]carbamoyl}-4H-thieno[3,2- ό]pyrrole;
2,3-dichloro-5-[N-(2-{ [2-(guanidino)thiazol-4-yl]methylthio}ethyl)carbamoyl]-4H-thieno[3,2- t>]pyrrole;
2,3-dichloro-5-{N-[2-(2,4-dioxoimidazolidin-l-yl)ethyl]carbamoyl}-4H-thieno[3,2-t>]pyrrole;
5-{N-[2-benzylthio-l-(hydroxymethyl)ethyl]carbamoyl}-2,3-dichloro-4H-thieno[3,2- έjpyrrole;
2,3-dichloro-5-{N-[2-(dimethyaminosulphonylamino)ethyl]carbamoyl}-4H-thieno[3,2- t>]pyrrole;
2,3-dichloro-5-{N-[(6-methoxypyrid-3-yl)methyl]carbamoyl}-4H-thieno[3,2-έ]pyrrole;
(S)-2,3-dichloro-5-{N-[(2-oxo-3-phenyl-2,3,4,5-tetrahydrooxazol-5-yl)methyl]carbamoyl}- 4H-thieno[3,2-Z>]pyrrole;
2,3-dichloro-5-(N-{2-[3-(carbamoylmethyl)phenoxy]ethyl}carbamoyl)-4H-thieno[3,2- ό]pyrrole;
5-(N-{ [6-(benzo[l,3]dioxol-5-yl)-4-methylmorpholin-2-yl]methyl}carbamoyl)-2,3-dichloro-
4H-thieno[3,2-b]pyrrole; 5-(N-benzylcarbamoyl)- 2,3-dichloro-4H-thieno[3,2-t3]pyrrole;
2,3-dichloro-5-(N-phenethylcarbamoyl)-4H-thieno[3,2-/J>]pyrrole;
2,3-dichloro-5- [N-(3-phenylpropyl)carbamoyl] -4H-thieno [3 ,2-Z> ]pyrrole;
2,3-dichloro-5-{N-[2-(2-hydroxyphenyl)ethyl]carbamoyl}-4H-thieno[3,2-ό]pyrrole;
2,3-dichloro-5-[N-(α,α-dimethylphenethyl)carbamoyl]-4H-thieno[3,2-δ]pyrrole; 2,3-dichloro-5-[N-(l-phenylcyclobutyl)methyl)carbamoyl]-4H-thieno[3,2-Z)]pyrrole;
2,3-dichloro-5-[N-(β-methylphenethyl)carbamoyl]-4H-thieno[3,2-t>]pyrrole;
2,3-dichloro-5-[N-(l,2,3,4-tetrahydronaphth-2-yl)carbamoyl]-4H-thieno[3,2-ό]pyrrole;
5-[N-(N-benzylcarbamoylmethyl)carbamoyl]- 2,3-dichloro-4H-thieno[3,2-Z>]pyrrole;
5-[N-(N-benzyl-N-methylcarbamoylmethyl)carbamoyl]-2,3-dichloro-4H-thieno[3,2-&]pyrrole; 2,3-dichloro-5-[N-(N-methyl-N-phenylcarbamoylmethyl)carbamoyl]-4H-thieno[3,2-t)]pyrrole;
2,3-dichloro-5-{N-[N-(2-cyanoethyl)-N-phenylcarbamoylmethyl]carbamoyl}-4H-thieno[3,2- t3]pyrrole; 2,3-dichloro-5-{N-[N-(4-methoxyphenyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2- δ]pyrrole;
2,3-dichloro-5-{N-[N-(4-fluorophenyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2-/3]pyrrole;
2,3-dichloro-5-{N-[N-(4-nitrophenyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2-b]pyrrole; 2,3-dichloro-5-{N-[N-(2,6-dimethylphenyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2-
_>]pyrrole;
2,3-dichloro-5-{N-[N-methyl-N-(4-methylphenyl)carbamoylmethyl]carbamoyl}-4H- thieno [3 ,2-/J>]pyrrole;
2,3-dichloro-5-{N-[N-methyl-N-(3-methylphenyl)carbamoylmethyl]carbamoyl}-4H- thieno[3,2-_j]pyrrole;
2,3-dichloro-5-{N-[N-(3-chlorophenyl) N-methylcarbamoylmethyl]carbamoyl}-4H- thieno [3 ,2-ό]pyrrole;
2,3-dichloro-5-{N-[N-(2-hydroxyethyl)-N-phenylcaι-bamoylmethyl]carbamoyl}-4H- thieno [3 ,2-έ]pyrrole ; 2,3-dichloro-5-{N-[N-(l,l-dimethyl-2-hydroxyethyl)carbamoylmethyl]carbamoyl}-4H- thieno [3 ,2-b] pyrrole ;
2,3-dichloro-5-{N-[N-(2-hydroxyethyl)-N-methylcarbamoylmethyl]carbamoyl}-4H- thieno[3,2-έ]pyrrole;
2,3-dichloro-5-{N-[N-(2-hydroxyethyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2- t>]pyrrole;
2,3-dichloro-5- {N-[N-(3-hydroxypropyl)carbamoylmethyl]carbamoyl } -4H-thieno[3 ,2-
_>]pyrrole;
2,3-dichloro-5-{N-[N-(4-hydroxybutyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2-
_>]pyrrole; 2,3-dichloro-5-(N-{N-[bis(hydroxymethyl)methyl]carbamoylmethyl}carbamoyl)-4H- thieno[3,2-t>]pyrrole;
2,3-dichloro-5-{N-[N-(2,3-dihydroxypropyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2-
/3]pyrrole;
2,3-dichloro-5-{N-[N-(4-hydroxymethylphenyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2- t>]pyrrole;
2,3-dichloro-5-{N-[N-(5-isoquinolyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2-b]pyrrole;
2,3-dichloro-5-{N-[N-(3-hydroxymethy)lphenyl]carbamoylmethyl]carbamoyl}-4H-thieno[3,2- έ]pyrrole; 2,3-dichloro-5-(N-{N-[4-(2-hydroxyethyl)phenyl]carbamoylmethyl}carbamoyl)-4H- thieno [3 ,2-έ]pyrrole;
2,3-dichloro-5- {N-[N-(2,4-difluorophenyl)-N-methyl-carbamoylmethyl]carbamoyl } -4H- thieno[3,2-ό]pyrrole; 2,3-dichloro-5-{N-[(l,2,3,4-tetrahydro-l-quinolyl)carbonylmethyl]carbamoyl}-4H-thieno[3,2- δ]pyrrole;
2,3-dichloro-5-{N-[N-(2-cyanoethyl)-N-methylcarbamoylmethyl]carbamoyl}-4H-thieno[3,2- ό]pyrrole;
2,3-dichloro-5-{N-[N-(4-hydroxypiperidino)carbamoylmethyl]carbamoyl}-4H-thieno[3,2- δ]pyrrole;
2,3-dichloro-5-[N-(N- cyclopentylcarbamoylmethyl)carbamoyl]-4H-thieno[3,2-t>]pyrrole;
2,3-dichloro-5-[N-(N-isopropylcarbamoylmethyl)carbamoyl]-4H-thieno[3,2-ό]pyrrole;
2,3-dichloro-5-[N-(N-isopropyl-N-methylcarbamoylmethyl)carbamoyl]-4H-thieno[3,2-
_>]pyrrole; 2,3-dichloro-5-[N-(thiomorpholinocarbonylmethyl)carbamoyl]-4H-thieno[3,2-ό]pyrrole;
2,3-dichloro-5-[N-(morpholinocarbonylmethyl)carbamoyl]-4H-thieno[3,2-/ ]pyrrole;
2,3-dichloro-5-{N-[(l,l-dioxothiomorpholino)carbonylmethyl]carbamoyl}-4H-thieno[3,2/)]- pyrrole;
2,3-dichloro-5-{N-[(l-oxothiomorpholino)carbonylmethyl]carbamoyl}-4H-thieno[3,2- έjpyrrole;
2-chloro-5-[N-(2-indanyl)carbamoyl]-6H-thieno[2,3-b]pyrrole;
5-[N-(benz[l,2]oxazol-3-ylmethyl)carbamoyl]-2,3-dichloro-4H-thieno[3,2-_7]pyrrole;
2,3-dichloro-5-(N-{2-[2-(hydroxymethyl)phenyl]ethyl}carbamoyl)-4H-thieno[3,2-b]pyrrole;
2,3-dichloro-5-[N-(4-phenylisoxazol-3-ylmethyl)carbamoyl]-4H-thieno[3,2-ό]pyrrole; 2,3-dichloro-5-(N-{2-[2-(2-morpholinoethoxy)phenyl]ethyl}carbamoyl)-4H-thieno[3,2-
Zj]pyrrole;
2,3-dichloro-5-(N-{2-[2-(methoxycarbonylmethoxy)phenyl]ethyl}carbamoyl)-4H-thieno[3,2- >]pyrrole;
5-(N-{2-[2-(carboxymethoxy)phenyl]ethyl}carbamoyl)-2,3-dichloro-4H-thieno[3,2-ό]pyrrole; 2,3-dichloro-5-{N-[2-(3-methoxyphenyl)ethyl]carbamoyl}-4H-thieno[3,2-t3]pyrrole;
2,3-dichloro-5-[N-(2-oxo-l,2,3,4-tetrahydroquinol-3-yl)carbamoyl]-4H-thieno[3,2-b]pyrrole;
2,3-dichloro-5-(N-{2-[2-(2-methoxyethoxy)phenyl]ethyl}carbamoyl)-4H-thieno[3,2-
_?]pyrrole; 5-(N-{2-[2-(carbamoylmethoxy)phenyl]ethyl}carbamoyl)-2,3-dichloro-4H-thieno[3,2- b]pyrrole;
2,3-dichloro-5-(N-{2-[2-(N-methylcarbamoylmethoxy)phenyl]ethyl}carbamoyl)-4H- thieno [3 ,2-3]pyrrole ; 2,3-dichloro-5-(N-{2-[2-(N,N-dimethylcarbamoylmethoxy)phenyl]ethyl}carbamoyl)-4H- thieno[3,2-t>]pyrrole;
2,3-dichloro-5-(N- { 2-[2-(morpholinocarbonylmethoxy)phenyl]ethyl } carbamoyl)-4H- thieno[3 ,2-/>]pyrrole;
5-(N- { 2-[2-(N-benzylcarbamoylmethoxy)phenyl]ethyl } carbamoyl)-2,3-dichloro-4H- thieno[3,2-_j]pyrrole;
2,3-dichloro-5-(N-{2-[2-(4-hydroxypiperidinocarbonylmethoxy)phenyl]ethyl}carbamoyl)-4H- thieno [3 ,2-b] pyrrole ;
(S)-2-chloro-5-{N-[ -(5-ethoxycarbonyl-l,3,4-oxadiazol-2-yl)phenethyl]carbamoyl}-6H- thieno[2,3-/3]pyrrole; (S)-2-chloro-5-{N-[ -(4-methoxycarbonyloxazol-5-yl)phenethyl]carbamoyl}-6H-thieno[2,3- b] pyrrole;
2-chloro-5-{N-[ -(3-pyridyl)phenethyl]carbamoyl}-6H-thieno[2,3-δ]pyrrole;
2,3-dichloro-5-{N-[ -(3-pyridyl)phenethyl)]carbamoyl}-4H-thieno[3,2-δ]pyrrole;
(S)-2-chloro-5-{N-[α-(3-phenyl-l,2,4-oxadiazol-5-yl)phenethyl]carbamoyl}-6H-thieno[2,3- bjpyrrole;
2,3-dichloro-5-[N-(l-hydroxyindan-2-yl)carbamoyl]-4H-thieno[3,2-t>]pyrrole;
2,3-dichloro-5-[N-((7S,2S)-l-hydroxyindan-2-yl)carbamoyl]-4H-thieno[3,2-t>]pyrrole;
2,3-dichloiO-5-[N-((ii?,2i?)-l-hydroxyindan-2-yl)carbamoyl]-4H-thieno[3,2-t>]pyrrole;
2-chloro-5-[N-(l-hydroxyindan-2-yl)carbamoyl]-6H-thieno[2,3-έ]pyrrole; 2,3-dichloro-5-[N-(l-hydroxy-l,2,3,4-tetrahydronaρhth-2-yl)carbamoyl]-4H-thieno[3,2- bjpyrrole;
2,3-dichloro-5-[N-(6-fluoro-l-hydroxyindan-2-yl)carbamoyl]-4H-thieno[3,2-6]pyrrole;
2,3-dichloro-5-[N-(7-methoxy- 1 -oxo- 1 ,2,3 ,4-tetrahydronaphth-2-yl)carbamoyl] -4H- thieno[3,2-b]pyrrole; 2,3-dichloro-5-[N-(2-indanyl)carbamoyl]-4H-thieno[3,2-ό]ρyrrole;
2,3-dichloro-5-[N-(3-methylisoxazol-5-yl)methyl]carbamoyl]-4H-thieno[3,2- )]pyrrole; 2,3-dichloro-5-[N-(4-hydroxy-l,l-dioxotetrahydrothiophen-3-yl)carbamoyl]-4H-thieno[3,2- b]pyrrole;
2,3-dichloro-5-(N-{N-methyl-N-[(l-oxo-l,2,3,4-tetrahydronaphth-2- yl)methyl]carbamoylmethyl } carbamoyl)-4H-thieno [3 ,2-/j]pyrrole; 2-chloro-5-[N-(2-oxo-l,2,3,4-tetrahydroquinol-3-yl)carbamoyl]-6H-thieno[2,3-Zj]pyrrole;
2-chloro-5-[N-(l,2,3,4-tetrahydroquinol-3-yl)carbamoyl]-6H-thieno[2,3-b]pyrrole;
2-chloro-5-[N-(l-methyl-2-oxo-l,2,3,4-tetrahydroquinol-3-yl)carbamoyl]-6H-thieno[2,3-
Z?]pyrrole;
2-chloro-5-[N-(3-oxo-2,3,4,5-tetrahydro-lH-benz[2]azepin-4-yl)carbamoyl]-6H-thieno[2,3- bjpyrrole;
2,3-dichloro-5-[N-(l-methoxyindan-2-yl)carbamoyl]-4H-thieno[3,2-t]pyrrole;
2 , 3 -dichloro-5-(N- { 1 - [N-( 1 , 1 -dimethylethoxy)carbonylamino] indan-2-yl } carbamoyl)-4H- thieno [3 ,2-έ]pyrrole;
5- [N-( 1 -aminoindan-2-yl)carbamoyl] -2 , 3 -dichloro-4H-thieno [3 ,2-b] pyrrole ; 5-[N-(l-acetamidoindan-2-yl)carbamoyl]-2,3-dichloro-4H-thieno[3,2-t)]pyrrole;
2,3-dichloro-5-{N-[l-(methanesulphonamido)indan-2-yl]carbamoyl}-4H-thieno[3,2- δjpyrrole;
2,3-dichloro-5-{N-[l-(methylamino)indan-2-yl]carbamoyl}-4H-thieno[3,2-&]pyrrole; and
2 ,3 -dichloro-5 - { N- [ 1 -(N-methylacetamido)indan-2-yl]carbamoyl } -4H-thieno [3 ,2-t ]pyrrole. Preferred aspects of the invention are those which relate to the compound of formula
(I) or a pharmaceutically acceptable salt thereof.
Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof which process (wherein R1, R2, R3, -X-Y-Z-and n are, unless otherwise specified, as defined in formula (I)) comprises of: a) reacting an acid of the formula (II):
Figure imgf000034_0001
(II) or an activated derivative thereof; with an amine of formula (III):
Figure imgf000035_0001
(HI) and thereafter if necessary: i) converting a compound of the formula (I) into another compound of the formula (I); ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt or in vivo hydrolysable ester. Specific reaction conditions for the above reaction are as follows. Process a) Acids of formula (II) and amines of formula (III) may be coupled together in the presence of a suitable coupling reagent. Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, or for example carbonyldiimidazole, l-ethyl-3-(3-dimethylaminopropyl)carbodi-imide hydrochloride and dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as 1- hydroxybenzotriazole, dimethylaminopyridine or 4-pynOlidinopyridine, optionally in the presence of a base for example triethylamine, di-isopropylethylamine, pyridine, or 2,6-di-α/£y/-pyridines such as 2,6-lutidine or 2,6-di-tert-butylpyridine. Suitable solvents include dimethylacetamide, dichloromethane, benzene, tetrahydrofuran and dimethylformamide. The coupling reaction may conveniently be performed at a temperature in the range of -40 to 40°C.
Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters. The reaction of these types of compounds with amines is well known in the art, for example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those described above. The reaction may conveniently be performed at a temperature in the range of -40 to 40°C. The acids of formula (II) may be prepared according to Scheme 1:
Figure imgf000035_0002
Scheme 1 Compounds of formula (Ila) and amines of formula (III) are commercially available or they are known compounds or they are prepared by processes known in the art.
It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl. It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.
A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylrnethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art. As stated hereinbefore the compounds defined in the present invention possesses glycogen phosphorylase inhibitory activity. This property may be assessed, for example, using the procedure set out below.
Assay
The activity of the compounds is determined by measuring the inhibitory effect of the compounds in the direction of glycogen synthesis, the conversion of glucose- 1 -phosphate into glycogen with the release of inorganic phosphate, as described in EP 0 846464 A2. The reactions were in 96well microplate format in a volume of lOOμl. The change in optical density due to inorganic phosphate formation was measured at 620nM in a Labsystems iEMS Reader MF by the general method of (Nordlie R.C and Arion W.J, Methods of Enzymology, 1966, 619-625). The reaction is in 50mM HEPES, 2.5mM MgCl2, 2.25mM ethylene glycol- bis(b-aminoethyl ether) NNN',N'-tetraacetic acid, lOOmM KC1, 2mM D-(+)-glucose pH7.2, containing 0.5mM dithiothreitol, the assay buffer solution, with 0. lmg type HI glycogen,
0.15ug glycogen phosphorylase a (GPα) from rabbit muscle and 0.5mM glucose- 1 -phosphate. GP is pre-incubated in the assay buffer solution with the type HI glycogen at 2.5 mg ml"1 for 30 minutes. 40μl of the enzyme solution is added to 25μl assay buffer solution and the reaction started with the addition of 25 μl 2mM glucose- 1 -phosphate. Compounds to be tested are prepared in lOμl 10% DMSO in assay buffer solution, with final concentration of 1% DMSO in the assay. The non-inhibited activity of GPα is measured in the presence of lOμl 10% DMSO in assay buffer solution and maximum inhibition measured in the presence of 30μM CP320626 (Hoover et al (1998) J Med Chem 41, 2934-8; Martin et al (1998) PΝAS 95, 1776-81). The reaction is stopped after 30min with the addition of 50μl acidic ammonium molybdate solution, 12ug ml"1 in 3.48% H2SO4 with 1% sodium lauryl sulphate and lOug ml"1 ascorbic acid. After 30 minutes at room temperature the absorbency at 620nm is measured.
The assay is performed at a test concentration of inhibitor of lOμM or lOOμM. Compounds demonstrating significant inhibition at one or both of these concentrations may be further evaluated using a range of test concentrations of inhibitor to determine an IC50, a concentration predicted to inhibit the enzyme reaction by 50%. Activity is calculated as follows:- % inhibition = (1 - (compound OD620 - fully inhibited OD620)/ (non-inhibited rate OD620 - fully inhibited OD620)) * 100. OD620 = optical density at 620nM. Typical IC50 values for compounds of the invention when tested in the above assay are in the range lOOμM to InM.
The activity of the compounds is alternatively determined by measuring the inhibitory effect of the compounds on glycogen degradation, the production of glucose- 1 -phosphate from glycogen is monitored by the multienzyme coupled assay, as described in EP 0 846464 A2, general method of Pesce et al ( Pesce, M A, Bodourian, S H, Harris, R C, and Nicholson, J F (1977) Clinical Chemistry 23, 1171 - 1717). The reactions were in 384well microplate format in a volume of 50μl. The change in fluorescence due to the conversion of the co-factor NAD to NADH is measured at 340nM excitation, 465nm emission in a Tecan Ultra Multifunctional Microplate Reader. The reaction is in 50mM HEPES, 3.5mM KH2PO4, 2.5mM MgCl2, 2.5mM ethylene glycol-bis(b-aminoethyl ether) NNN'N-tetraacetic acid, lOOmM KC1, 8mM D-(+)-glucose pH7.2, containing 0.5mM dithiothreitol, the assay buffer solution. Human recombinant liver glycogen phosphorylase a (hrl GPα) 20nM is pre-incubated in assay buffer solution with 6.25mM NAD, 1.25mg type HI glycogen at 1.25 mg ml"1 the reagent buffer, for 30 minutes. The coupling enzymes, phosphoglucomutase and glucose-6-phosphate dehydrogenase ( Sigma) are prepared in reagent buffer, final concentration 0.25Units per well. 20μl of the hrl GPa solution is added to lOμl compound solution and the reaction started with the addition of 20ul coupling enzyme solution. Compounds to be tested are prepared in lOμl 5% DMSO in assay buffer solution, with final concentration of 1% DMSO in the assay. The non-inhibited activity of GPα is measured in the presence of lOμl 5% DMSO in assay buffer solution and maximum inhibition measured in the presence of 5mgs ml"1 N- ethylmaleimide. After 6 hours at 30°C Relative Fluoresence Units (RFUs) are measured at 340nM excitation, 465nm emission .
The assay is performed at a test concentration of inhibitor of lOμM or lOOμM. Compounds demonstrating significant inhibition at one or both of these concentrations may be further evaluated using a range of test concentrations of inhibitor to determine an IC50, a concentration predicted to inhibit the enzyme reaction by 50%. Activity is calculated as follows :-
% inhibition = (1 - (compound RFUs - fully inhibited RFUs)/ (non-inhibited rate RFUs - fully inhibited RFUs)) * 100.
Typical IC50 values for compounds of the invention when tested in the above assay are in the range lOOμM to InM. The inhibitory activity of compounds was further tested in rat primary hepatocytes.
Rat hepatocytes were isolated by the collagenase perfusion technique, general method of Seglen (P.O. Seglen, Methods Cell Biology (1976) 13 29-83). Cells were cultured on Nunclon six well culture plates in DMEM with high level of glucose containing 10% foetal calf serum, NEAA, Glutamine, penicillin /streptomycin ((100units/100ug)/ml) for 4 to 6 hours. The hepatocytes were then cultured in the DMEM solution without foetal calf serum and with lOnM insulin and lOnM dexamethasone. Experiments were initiated after 18-20 hours culture by washing the cells and adding Krebs-Henseleit bicarbonate buffer containing 2.5mM CaCl2 and 1% gelatin. The test compound was added and 5 minutes later the cells were challenged with 25nM glucagon. The Krebs-Henseleit solution was removed after 60 min incubation at 37°C , 95%O2/5%CO2 and the glucose concentration of the Krebs-Henseleit solution measured. According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.
The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
In general the above compositions may be prepared in a conventional manner using conventional excipients. The compound of formula (I) will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.1-100 mg/kg, and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient. Preferably a daily dose in the range of 1-50 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
According to a further aspect of the present invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore, for use in a method of treatment of a warm-blooded animal such as man by therapy.
According to an additional aspect of the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore, for use as a medicament. According to an another aspect of the invention there is provided the use of a compound of the formula (I'):
Figure imgf000041_0001
(I') wherein:
-X-Y-Z- is selected from -S-CR4=CR5-, -CR4=CR5-S-, -O-CR4=CR5-, -CR4=CR5-O-, -N=CR4-S-, -S-CR4=N-, -NR6-CR4=CR5- and -CR4=CR5-NR6-; wherein R4 and R5 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2.6alkenyl, C2.6alkynyl, C1-6alkoxy, d_6alkanoyl, d_6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1_6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, NN-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, d-ealkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, NN-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino and Cι_6alkylsulphonyl-N-(C1-6alkyl)amino; R6 is hydrogen or C1-6alkyl; R1 is selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2-6alkenyl, C2_6alkynyl, C1-6alkoxy, d_6alkanoyl, C1-6alkanoyloxy, N-(d.6alkyl)amino, NN-(C1-6alkyl)2amino, d.6alkanoylamino, N-(Cj.6alkyl)carbamoyl, NN-(C1.4alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C^ealkoxycarbonyl, C1-6alkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, NN-(C1_6alkyl)2sulphamoyl, d.6alkylsulphonylamino, C1.6alkylsulphonyl-N-(C1-6alkyl)amino, C3.8cycloalkyl, C3-8cycloalkylC1-6alkyl, aryl, arylC1-6alkyl, heterocyclic group and (heterocyclic group)C1.6alkyl; wherein R1 may be optionally substituted on carbon by one or more groups selected from P and wherein if said heterocyclic group contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R; R2 is selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, d.6alkoxy, C1-6alkanoyl, d_6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1.6alkyl)2amino, C1-6alkanoylamino, N-(C1_6alkyl)carbamoyl, NN-(C1- alkyl)2carbamoyl, N-(C1-6alkyl)-N-(C1-6alkoxy)carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, d_6alkoxycarbonyl, Cι.6alkoxycarbonylamino, N-(Cι.6alkyl)sulphamoyl, NN-(C1-6alkyl)2Sulphamoyl, sulphamoylamino, N-(d-6alkyl)sulphamoylamino, NN-(d_6alkyl)2Sulphamoylamino, Cι_6alkylsulphonylamino, C1-6alkylsulphonylaminocarbonyl, C1-6alkylsulphonyl-N-(C1.6alkyl) amino and a group -E-F-G-H; wherein E and G are independently selected from a direct bond, -O-, -S-, -SO-, -SO2-, -OC(O)-, -C(O)O-, -C(O)-, -ΝRa-, -NRaC(O)-, -C(O)NRa-, -SO2NRa-, -NRaSO2-, -NRaC(O)NRb-, -OC(O)NRa-, -NRaC(O)O-, -NRaSO2NRb-, -SO2NRaC(O)- and -C(O)NRaSO2-; wherein Ra and Rb are independently selected from hydrogen or C1-6alkyl which is optionally substituted by a group V ;
F is d-6alkylene optionally substituted by one or more Q or a direct bond;
H is selected from aryl, C3.8cycloalkyl and heterocyclic group; wherein H may be optionally substituted on carbon by one or more groups selected from S and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from T;
R3 is hydrogen or C1-6alkyl; n is selected from 0-4; wherein the values of R1 may be the same or different; and wherein the values of R3 may be the same or different;
P, S and Q are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2.6alkenyl, C2-6alkynyl, d_6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(d_6alkyl)2amino, d.6alkanoylamino, N-(Cι_6alkyl)carbamoyl, NN-(C1-6alkyl)2carbamoyl, N-(C1_6alkyl)-N-(C1-6alkoxy)carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, d-δalkoxycarbonylamino, N-(d.6alkyl)sulphamoyl, NN-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, C1.6alkylsulphonyl-N-(C1.6alkyl)amino, C3_8cycloalkyl, aryl and heterocyclic group; wherein P, S and Q may be optionally and independently substituted on carbon by one or more groups selected from V and wherein if said heterocyclic group contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from U; V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl, N-methyl-N-ethylsulphamoyl, morpholino, morpholinocarbonyl, N- benzylcarbamoyl, and 4- hydroxypiperidinocarbonyl ;
R, T and U are independently selected from C1- alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl, NN-(C1_ alkyl)carbamoyl, phenyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof; with the proviso that when -X-Y-Z- is as initially defined, n is 1, R1 is arylmethyl, substituted arylmethyl, (heterocyclic group)methyl and substituted (heterocyclic group)mefhyl and R3 is hydrogen then R2 is not a group -C(=O)-A or a group -CH(OH)-C(=O)-A in which A is ΝRdRd, - NRaCH2CH2ORa, or
Figure imgf000043_0001
each Ra and Rb is independently hydrogen or -d-C8alkyl; each Rd is independently hydrogen, Ci-Cgalkyl, d-C8alkoxy, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; each Rc is independently hydrogen, -C(=O)ORa -ORa, -SRa, or -NRaRa; and each n is independently 1-3, and
X1 is NRa, -CH2-, O or S; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of a glycogen phosphorylase inhibitory effect in a warm-blooded animal such as man.
According to this another aspect of the invention there is provided the use of a compound of the formula (I'), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal such as man. According to this another aspect of the invention there is provided the use of a compound of the formula (I'), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of type 2 diabetes in a warm-blooded animal such as man.
According to a further feature of this aspect of the invention there is provided a method of producing a glycogen phosphorylase inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I').
According to this further feature of this aspect of the invention there is provided a method of treating type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I').
According to this further feature of this aspect of the invention there is provided a method of treating type 2 diabetes in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (V).
As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular cell-proliferation disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. A unit dose in the range, for example, 1-100 mg/kg, preferably 1-50 mg/kg is envisaged. In addition to their use in therapeutic medicine, the compounds of formula (I) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents. In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply. Examples
The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:
(i) temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C and under an atmosphere of an inert gas such as argon;
(ii) organic solutions were dried over anhydrous magnesium sulphate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mmHg) with a bath temperature of up to 60°C; (iii) chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates; where a Bond Elut column is referred to, this means a column containing 10 g or 20 g or 50 g of silica of 40 micron particle size, the silica being contained in a 60 ml disposable syringe and supported by a porous disc, obtained from Varian, Harbor City, California, USA under the name "Mega Bond Elut SI"; "Mega Bond Elut" is a trademark; where a Biotage cartridge is referred to this means a cartridge containing KP-SIL™ silica, 60 angstroms, particle size 32-63mM, supplied by Biotage, a division of Dyax Corp., 1500 Avon Street Extended, Charlottesville, VA 22902, USA; (iv) in general, the course of reactions was followed by TLC and reaction times are given for illustration only; (v) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required; (vi) where given, NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using perdeuterio dimethyl sulphoxide (DMSO-δ6) as solvent unless otherwise indicated, other solvents (where indicated in the text) include deuterated chloroform CDC13;
(vii) chemical symbols have their usual meanings; SI units and symbols are used; (viii) reduced pressures are given as absolute pressures in Pascals (Pa); elevated pressures are given as gauge pressures in bars; (ix) solvent ratios are given in volume : volume (v/v) terms;
(x) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (CI) mode using a direct exposure probe; where indicated ionisation was effected by electron impact (El), fast atom bombardment (FAB) or electrospray (ESP); values for m/z are given; generally, only ions which indicate the parent mass are reported and unless otherwise stated the value quoted is (M-H)"; (xi) The following abbreviations are used:
SM starting material;
EtOAc ethyl acetate;
MeOH methanol;
DCM dichloromethane
HOBT 1 -hydroxybenzotriazole
DIAD diisopropyl azodicarboxylate
HATU O-(7-azabenzotriazol-l-yl)-N, N N', N', tetramethyluronium hexafluorophosphate
TFA trifluoroacetic acid
DIPEA di-isopropylethylamine; and
EDAC l-ethyl-3-(3-dimethylaminopropyl)carbodi-imide hydrochloride
Example #1
2,3-Dichloro-5-IN-(2-phei noxvethvl)carbamovll-4H-thienor3,2-61pvrrole
Figure imgf000046_0001
5-Carboxy-2,3-dichloro-4H-thieno[3,2-&]pyrrole (Method #9; 47 mg, 0.2 mmol) was dissolved in DCM (10 ml) containing 2-phenoxyethylamine (27 mg, 0.2 mmol), ΗOBT (27 mg, 0.2 mmol) and DIPEA (70 ml, 0.4 mmol). The mixture was stirred for 1 minute before the addition of EDAC (50 mg, 0.26 mmol). The mixture was stirred at ambient temperature for approximately 18 hours before being washed with water. The organic fraction was concentrated and was purified on a Bond Elut column (eluent 1:1 EtOAc/isohexane) to afford the title compound as an off white solid (32 mg). ΝMR: 12.4 (1Η, br), 8.4 (1Η, t), 7.3 (1Η, d), 7.1 (1Η, s), 6.9 (2Η, m), 3.5 (2H, m), 3.0 (2H, t); m/z 353.2.
Examples #2 - #9 The following compounds were made by the process of Example #1 using 5-carboxy-
2,3-dichloro-4H-thieno[3,2-t>]pyrrole (Method #9) and the appropriate amine:
Example #2: 2,3-Dichloro-5-(N-r2-(2-thienyl)ethyllcarbamoyll-4H-thienor3.2-blpyrrole
Example #3: 2,3-Dichloro-5-IN-r2-(2-methoxyphenyl)ethvncarbamoyll-4H-thienor3.2- /jlpyrrole
Example #4: 2,3-Dichloro-5-rN-(2-phenyl-l-cvclopropyl)carbamoyl1-4H-thienor3,2- bl pyrrole
Example #5: 2.3-Dichloro-5-{N-r2-(4-fluorophenyl)ethyllcarbamoyl|-4H-thienor3.2- fclpyrrole Example #6: 2.3-dichloro-5-rN-(N-phenylcarbamoylmethyl)carbamoyll-4H-thienor3.2-
/jlpyrrole
Example #7: 2,3-Dichloro-5-(N-(2-r(2-pyridyl)amino1ethvncarbamoyl)-4H-thienor3.2- b\ pyrrole
Example #8: 2,3-Dichloro-5-{N-r2-(N-methylmethanesulphonamido)-l-(thiazol-2- yDethyll carbamoyl } -4H-thienor3 ,2-t31pyrrole
Example #9: 2 3-Dichloro-5-{N-r2-(thiomorpholino)ethyllcarbamoylj-4H-thienor3.2- b] pyrrole
Figure imgf000047_0001
Figure imgf000047_0002
Figure imgf000048_0002
1 Water was added and the title compound precipitated as a yellow solid which was filtered off, washed with water, dried under reduced pressure and was not purified further.
2 Amine: Eur J Med Chem, 1987, 22, 91.
3 Amine: Method #15
Example #10
5-rN-(Benzoylmethyl)carbamoyn-2.3-dichloro-4H-thienor3,2-/jlpyrrole
Figure imgf000048_0001
2,3-Dichloro-5-{N-[(2-phenyl-l,3-dioxolan-2-yl)methyl]carbamoyl}-4H-thieno[3,2- έjpyrrole (Method #17; 80 mg, 0.2 mmol) was dissolved in acetone (15 ml) containing aqueous hydrochloric acid (2.0 M, 1 ml). The mixture was heated under reflux for 90 minutes. The white precipitate formed was filtered off and washed with acetone. The filtrate was concentrated and the residue was triturated with water. The solid formed was filtered off and dried under reduced pressure to afford the title compound as a white solid (20 mg). NMR: 12.4 (IH, s), 8.6 (IH, t), 7.6-8.0 (5H, m), 7.2 (IH, s), 4.8 (2H, d); m/z 351.1.
Example #11
3-Chloro-5-rN-(N-phenylcarbamoylmethyl)carbamoyl1-4H-thienor3,2-tJ1pyrrole
Figure imgf000049_0001
5-Carboxy-3-chloro-4H-thieno[3,2-έ]pyrrole (Method #7; 100 mg, 0.5 mmol) was dissolved in DCM (6 ml) containing ΗOBT (68 mg, 0.5 mmol), DIPEA (176 ml, 1.0 mmol) and N-glycylaniline (75 mg, 0.5 mmol). The mixture was allowed to stand for one minute before the addition of EDAC (150 mg, 0.7 mmol). The solution was allowed to stand for approximately 18 hours before being washed with water. The organic phase was dried, filtered and concentrated under reduced pressure to afford the title compound (112 mg, 67%). ΝMR (CDC13) 9.7 (1Η, br), 8.6 (1Η, br), 7.0-8.0 (8Η, m), 4.3 (2H, d); m/z 332.1.
Examples #12 - #21
The following compounds were made by the process of Example #11 using 5-carboxy- 3-chloro-4H-thieno[3,2-_7]pyrrole (Method #7) and the appropriate amine: Example #12: 3-Chloro-5-{N-r2-(thiomorpholino)ethvncarbamoyll-4H-thieno[3,2-&lpyrrole Example #13: 3-Chloro-5-{N-r2-(N-methylmethanesulphonamido)-l-(thiazol-2- vDethyllcarbamoyl I -4H-thieno F3 ,2-fclpyrrole
Example #14: 3-Chloro-5-rN-(benzoylmethyl)carbamoyll-4H-thienor3,2-&lpyrrole Example #15: 3-Chloro-5-{N-r2-(2-methoxyphenyl)ethyllcarbamoyli-4H-thienor3.2- bl pyrrole Example #16: 3-Chloro-5-{N-r2-(2-thienyl)ethyllcarbamoyl)-4H-thienor3,2-tjlpyrrole
Example #17: 3-Chloro-5-rN-(2-phenyl-l-cvclopropyl)carbamoyll-4H-thienor3.2-t>1pyrrole Example #18: 3-Chloro-5-{N-r2-(4-fluorophenyl)ethyllcarbamoyl}-4H-thienor3.2-61pyrrole Example #19: 3-Chloro-5-rN-(2-phenoxyethyl)carbamoyll-4H-thienor3,2-b1pyrrole Example #20: 3-Chloro-5-(N-r2-(l-phenylmethanesulphonamido)ethyllcarbamoyll-4H- thieno \3,2-b pyrrole Example #21: 3-Chloro-5-rN-(4-oxo-2,3,4.5-tetrahydrobenzri,51thiazepin-3-yl)carbamoyll- 4H-thienor3.2-tJ1pyrrole
Figure imgf000050_0001
Figure imgf000050_0002
Figure imgf000051_0001
1 Amine: Method #15
Amine: J Med Chem, 1985, 28, 1517
Example #22
2-Chloro-5-rN-(benzoylmethyl)carbamoyn-4H-thienor3,2-t 1pyrrole
Η O
5-Carboxy-2-chloro-4H-thieno[3,2-t>]pyrrole (Method #8; 50 mg, 0.25 mmol) was dissolved in DCM (7 ml) containing ΗOBT (34 mg, 0.25 mmol), DIPEA (49 ml, 0.28 mmol) and 2-amino-l-phenylethanone (43 mg, 0.25 mmol). The mixture was stirred for one minute and EDAC (63 mg, 0.33 mmol) was added. The mixture was stirred at room temperature for approximately 18 hours. Water was added to the solution and a solid precipitated out. This solid was filtered off and was washed with water and DCM before being dried under reduced pressure to afford the title compound as a white solid (45 mg, 61%). ΝMR: 11.9 (1Η, s), 8.6 (1Η, t), 7.1-8.1 (7Η, m), 4.8 (2H, d); m/z 317.3.
Examples #23 - #25
The following compounds were made by the process of Example #22 using 5-carboxy- 2-chloro-4H-thieno[3,2-b]pyrrole (Method #8) and the appropriate amine: Example #23: 2-Chloro-5-rN-(2-phenyl-l-cvclopropyl)carbamoyll-4H-thienor3.2-/j1pyrrole Example #24: 2-Chloro-5-rN-(N-phenylcarbamoylmethyl)carbamovn-4H-thienor312- fclpyrrole
Example #25: 2-Chloro-5-(N- ( 2-r(2-pyridyl)amino1ethyl 1 carbamoyl)-4H-thienor3 ,2- άlpyrrole
Figure imgf000052_0001
Figure imgf000052_0003
1 Amine: Eur J Med Chem, 1987, 22, 91.
Example #26
2-Chloro-5-fN-r2-(2-methoxyphenyl)ethvncarbamoyl)-4H-thienor3.2-t31pyrrole
Figure imgf000052_0002
5-Carboxy-2-chloro-4H-thieno[3,2-t>]pyrrole (Method #8; 50 mg, 0.25 mmol) was dissolved in DCM (7 ml) containing ΗOBT (34 mg, 0.25 mmol), DIPEA (49 ml, 0.28 mmol) and 2-(2-methoxyphenyl)ethylamine (43 mg, 0.25 mmol). The mixture was stirred for one minute and EDAC (63 mg, 0.33 mmol) was added. The mixture was stirred at room temperature for approximately 18 hours. The reaction mixture was washed with water, the organic phase was dried, filtered and concentrated to afford the title compound as an off-white solid (84 mg, 100%). NMR (CDC13): 9.7 (IH, br), 6.9-7.2 (5H, m), 6.5 (IH, s), 6.3 (IH, br), 3.9 (3H, s), 3.7 (2H, m), 3.0 (2H, t); m z 333.4.
Examples #27 - #31
The following compounds were made by the process of Example #26 using 5-carboxy- 2-chloro-4H-thieno[3,2-t>]pyrrole (Method #8) and the appropriate amine.
Figure imgf000053_0001
Example #27: 2-Chloro-5-rN-(2-phenoxyethyl)carbamoyll-4H-thienor3.2-61pyrrole Example #28 : 2-Chloro-5- IN- r2-(2-thienyl)ethyllcarbamoyl 1 -4H-thieno \3 ,2-άlpyrrole Example #29: 2-Chloro-5-(N-r2-(4-fluorophenyl)ethyllcarbamoyll-4H-thienor3.2-t>lρyrrole Example #30: 2-Chloro-5-{N-r2-(N-methylmethanesulphonamido)-l-(thiazol-2- yl)ethyl1carbamoyl)-4H-thienor3,2-/j1pyrrole Example #31: 2-Chloro-5-{N-r2-(thiomorpholino)ethyllcarbamoyl|-4H-thienor3,2-61pyrrole
Figure imgf000053_0002
Figure imgf000054_0001
Amine: Method #15
Examples #32 - #69 The following compounds were made by the process of Example #1 using 5-carboxy-
2,3-dichloro-4H-thieno[3,2-t3]pyrrole (Method #9) or Example #22 using 5-carboxy-2-chloro-
4H-thieno[3,2-ό]pyrrole (Method #8) and the appropriate amine:
Example #32: 2.3-Dichloro-5-rN-(2,3-dimethyl-5-oxo-l-phenyl-2.5-dihvdro-lH-pyrazol-4- yl)carbamoyl1-4H-thieno[~3,2-t31pyrrole Example #33: 2,3-Dichloro-5-rN-(4-sulphamoylphenylmethyl)carbamovn-4H-thienor3,2- άlpyrrole
Example #34: 2.3-Dichloro-5-rN-(2-hydroxy-l-phenethyl)carbamoyll-4H-thienor3,2- tjlpyrrole
Example #35: 2,3-Dichloro-5-{N-(2-r(3-trifluoromethylpyrid-2-yl)aminolethyl)carbamoyl)- 4H-thieno [3.2-t31pyrrole
Example #36: 2,3-Dichloro-5-IN-r3-(5-tetrazolyl)propyllcarbamoyll-4H-thienor3,2- fclpyrrole
Example #37: 2,3-Dichloro-5-rN-(5-oxo-3-phenyl-4.5-dihvdroisoxazol-4-yl)carbamoyll-4H- thieno |"3 ,2-blpyrrole Example #38: 2.3-Dichloro-5-rN-(5-hvdroxy-2-oxo-2.3.4.5-tetrahvdro- !Η-benzr61azepin-4- yl)carbamoyl1-4H-thienor3.2-t>1pyrrole
Example #39: 2-Chloro-5-fN-r3-(benzyloxycarbonylamino)propyl1carbamoyl)-4H- thieno \3 ,2-/31pyrrole
Example #40: 2.3-Dichloro-5-IN-r(4-dimethylaminophenyl)methyllcarbamoyl|-4H- thienor3,2-t lpyrrole Example #41 : 5-|N-( l-Benzyl-2-hvdroxyethyl)carbamovn-2,3-dichloro-4H-thienor3,2- tjlpyrrole
Example #42: 2,3-Dichloro-5-|N-r2-(phenylamino)ethyllcarbamoyl|-4H-thienor3,2- b~\ pyrrole Example #43: 2,3-Dichloro-5-rN-(β-(K)-hydroxy- -methylphenethyl)carbamoyll-4H- thieno \3 ,2-blpyrrole
Example #44: 2,3-Dichloro-5-rN-(β-hvdroxyphenethyl)carbamoyl)-4H-thieno[3,2-t>1pyrrole
Example #45: 2,3-Dichloro-5-{N-r2-(4-hvdroxyphenyl)ethyllcarbamoyl }4H-thieno[3,2- t>l pyrrole Example #46: 2,3-Dichloro-5-{N-r(benzimidazol-2-yl)methyllcarbamoyl}-4H-thienor3,2- t>lpyrrole
Example #47: 2.3-Dichloro-5-(N-r2-(4-chlorophenyl)-2-hydroxy-l-
(methoxycarbonyl)ethyllcarbamoyl}-4H-thienor3,2-tJlpyrrole
Example #48: 2.3-Dichloro-5-(N-(imidazor 2-αlpyrid-2-yl)carbamoyll-4H-thienor3,2- dlpyrrole
Example #49: 5-{N-r(Benzthiazol-2-yl)methyllcarbamoyl|-2,3-dichloro-4H-thienor3,2- tjlpyrrole
Example #50: 2,3-Dichloro-5-{N-[(6-trifluoromethylpyrid-3-yl)methyllcarbamoyl)-4H- thieno \32-bλ pyrrole Example #51: 2.3-Dichloro-5-fN-(2-r(2-pyridazinyl)methyllcarbamoyl}-4H-thienor3.2- άlpyrrole
Example #52: 2.3-Dichloro-5-{N-r N-(2-hvdroxy-3-phenoxypropyl)carbamoylmethyll carbamoyl ) -4H-thieno \ ,2-t)1pyrrole
Example #53: 2,3-Dichloro-5-{N-rN-(3-methylisothiazol-5-yl)carbamoylmethvncarbamoyl}- 4H-thienor3.2-blpyrrole
Example #54: 2,3-Dichloro-5-{N-r2-(pyridazin-3-yloxy)ethyllcarbamoyl)-4H-thienor3,2- bλ pyrrole
Example #55: 2-Chloro-5-(N-{2-r(3-trifluoromethylpyrid-2-yl)aminolethyl}carbamoyl)-4H- thieno \ ,2-61 pyrrole Example #56: 2.3-Dichloro-5-{N-r2-(4-sulphamoylphenyl)ethyllcarbamoyl)-4H-thienor3.2- άlpyrrole
Example #57: 2.3-Dichloro-5-(N-r2-('2-pyridyl)ethyllcarbamoyll-4H-thienor3.2-t31pyrrole Example #58: 2.3-Dichloro-5- {N-(2-f 1 -hvdroxymethyl-2-(4-imidazolyl)ethyllcarbamoyl } -
4H-thienor3.2-blpyrrole
Example #59: 2.3-Dichloro-5-(N-(2-r(3-quinolyl)methyllcarbamoyll-4H-thienor3,2- fclpyrrole Example #60: 5-(N-r3-(4-Acetamidophenoxy)-2-hvdroxypropyl1carbamoyl)-2,3-dichloro-
4H-thienor3.2-blρyrrole
Example #61: 2.3-DichloiO-5-{N-r3-(N-methylsulphonylcarbamoyl)propyllcarbamoyll-4H- thieno 13.2-/ lpyrrole
Example #62: 2,3-Dichloro-5-|N-(2-( r2-(guanidino thiazol-4-yllmethylthiolethyl)- carbamovn-4H-thienor3,2-t31pyrrole
Example #63: 2,3-Dichloro-5-{N-r2-(2.4-dioxoimidazolidin-l-yl)ethyllcarbamoyll-4H- fhienor3,2-/ ipyrrole
Example #64: 5-{N-r2-Benzylthio-l-(hydroxymethyl)ethyllcarbamoyl}-2.3-dichloro-4H- thienor3.2-/31pyrrole Example #65: 2.3-Dichloro-5-{N-r2-(dimethvaminosulphonylamino)ethyllcarbamoyl)-4H- thienof3 ,2-_jlpyrrole
Example #66: 2,3-Dichloro-5-{N-r(6-methoxypyrid-3-yl)methyllcarbamoyl|-4H-thienor3.2- b\ pyrrole
Example #67: (S -2,3-Dichloro-5-(N-r(2-oxo-3-phenyl-2.3.4.5-tetrahvdrooxazol-5-yl)- methvncarbamoyl}-4H-thienor3.2-t)1pyrrole
Example #68: 2,3-Dichloro-5-(N-{2-r3-(carbamoylmethyl)phenoxylethyl}carbamoyl)-4H- thienor3,2-t>lpyrrole
Example #69: 5-(N-{ r6-(Benzor 31dioxol-5-yl)-4-methylmo holin-2-yllmethyl|- carbamoyl)-2,3-dichloro-4H-thienoF3,2-/j1pyrrole
Figure imgf000056_0001
Figure imgf000056_0002
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Example #70
5-(N-Benzylcarbamoyl)- 2,3-dichloro-4H-thienor3,2-blpyrrole
Figure imgf000061_0001
5-Carboxy-2,3-dichloro-4H-thieno[3,2- ?]pyrrole (Method # 9, 118mg, 0.5mmol) was dissolved in dichloromethane (10ml) containing benzylamine (55 mg, 0.5 mmol), 1-ΗOBT (68mg, 0.5mmol) and DIPEA (258μl, 2mmol). The mixture was stirred for one minute before the addition of EDAC (125mg, 0.65mmol). The mixture was stirred at ambient temperature for approximately lόhours before being washed with water. The organic fraction was concentrated and was purified using Bond-Elut silica column chromatography (eluent: dichloromethane-dichloromethane/methanol 5% gradient) to afford the title compound as a white solid (121mg, 75%).
ΝMR: 12.4 (IH, br), 8.8 (IH, t), 7.3 (5H, m), 7.1 (IH, s), 4.5 (2H, d); m/z 323.27
The following compounds were made by the process of Example #70 using 5-carboxy-
2,3-dichloro-4H-thieno[3,2-Z>]pyrrole (Method #9) and the appropriate amine:
Example #71 2,3-Dichloro-5-(N-phenethylcarbamoyl)-4H-thienor3,2-/31pyrrole
Example #72 2,3-Dichloro-5-rN-(3-phenylpropyl)carbamoyll-4H-thieno[3.2-t>lpyrrole
Example #73 : 2.3-Dichloro-5- {N-r2-(2-hvdroxyphenyl)ethyllcarbamoyl ) -4H-thieno[3.2- tjlpyrrole
Example #74: 2,3-Dichloro-5-rN-( ,«-dimethylphenethyl)caι-bamoyll-4H-thienor3,2-
Z>1pyrrole
Example #75: 2.3-Dichloro-5-rN-(l-phenylcvclobutyl)methyl)carbamoyll-4H-thienor3,2- b\ pyrrole Example #76: 2.3-Dichloro-5-rN-(β-methylphenethyl)carbamoyll-4H-thienor3.2-Z>lpyrrole
Example #77: 2.3-Dichloro-5-rN-(1.2.3.4-tetrahvdronaphth-2-yl)carbamoyll-4H-thienor3.2- t)lpyrrole
Example #78: 5-rN-(N-Benzylcarbamoylmethyl)carbamovH- 2,3-dichloro-4H-thienor3,2- t>lpyrrole Example #79: 5-rN-(N-Benzyl-N-methylcarbamoylmethyl)carbamoyll-2.3-dichloro-4H- thienor3,2-&lpyrrole
Example #80: 2,3-dichloro-5-[N-(N-methyl-N-phenylcarbamoylmethyl)carbamoyll-4H- fhieno|~3,2-/31pyrrole
Example #81 : 2,3-dichloro-5- (N-rN-(2-cvanoethyl)-N-phenylcarbamoylmethvncarbamoyl } -
4H-thienor3,2-61pyrrole
Figure imgf000062_0001
Figure imgf000062_0002
Figure imgf000063_0002
2 Amine: J. Med. Chem .; 1993, 36(22), 3300-3307
3 Amine: J. Am. Chem. Soc; 1960, 82, 2577
4 Amine: Method #6
5 Amine: Method #31
6 Amine: Method #30
7 Amine: Method #14
Example #82 2,3-dichloro-5-{N-rN-(4-methoxyphenyl)carbamoylmethyllcarbamoyll-4H-thienor3,2- t>lρyrrole
Figure imgf000063_0001
A solution of 5-(N-carboxymethylcarbamoyl)- 2,3-dichloro-4H-thieno[3,2-δ]pyrrole (Method #12, 150mg, 0.51mmol) and 4-methoxyaniline (69mg, 0.56mmol) in tetrahydrofuran (TΗF) (6ml) was stirred at ambient temperature for 30 minutes. 4-(4,6- dimethoxy-l,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) (142mg, 0.51 mmol) was added and the reaction mixture stirred at ambient temperature overnight, poured into water (15ml) and extracted with ethyl acetate (3x15ml). The organic extracts were combined and washed with IN citric acid solution (15ml), sodium bicarbonate solution (15ml), dried over magnesium sulphate, filtered and concentrated to give the title product as a white solid NMR: 12.4 (IH, s), 9.9 (IH, s), 8.6 (IH, t), 7.5 (2H, d), 7.2 (IH, s), 6.85 (2H, d), 4.0 (2H, d), 3.7 (3H, s); m/z 396.38
The following compounds were made by the process of Example #82 using 2,3- dichloro-5-[N-carboxymethylcarbamoyl]-4H-thieno[3,2-δ]pyrrole (Method #12) and the appropriate commercially available amine:
Example #83 : 2.3-dichloro-5- {N-rN-(4-fluorophenyl)carbamoylmethvncarbamoyl I -4H- thieno \3 ,2-tJlpyrrole
Example #84: 2,3-dichloro-5-{N-rN-(4-nitrophenyl)carbamoylmethyllcarbamoyll-4H- thienor3,2-61pyrrole
Example #85: 2,3-dichloro-5-{N-rN-(2.6-dimethylphenyl)carbamoylmethyllcarbamoyl)-4H- thienor3,2-/j1pyrrole
Example #86: 2,3-dichloro-5-(N-[N-methyl-N-(4-methylphenyl)carbamoylmethyll- carbamoyl } -4H-thienor3 ,2-_>1pyrrole Example #87: 2.3-dichloro-5-|N-[N-methyl-N-(3-methylphenyl)carbamoylmethyll- carbamoyl ) -4H-thieno \ ,2-fclpyrroιe
Example #88: 2,3-dichloro-5-(N-rN-(3-chlorophenyl) N-methylcarbamoylmethyll- carbamoyl)-4H-thienor3.2-t>1pyrrole
Example #89: 2,3-dichloro-5- (N-rN-(2-hvdroxyethyl)-N-phenylcarbamoylmethyll- carbamoyl }-4H-thienor3.2-61pyrrole
Example #90: 2,3-dichloro-5-IN-rN-(l,l-dimethyl-2-hvdroxyethyl)carbamoylmethyll- carbamoyl|-4H-thienor3.2-/jlpyrrole
Example #91 : 2.3-dichloro-5- |N-rN-(2-hvdroxyethyl)-N-methylcarbamoylmethyll- carbamoyl)-4H-thienor3.2-t)lpyrrole Example #92: 2,3-dichloro-5- {N-rN-(2-hvdroxyethyl)carbamoylmethyllcarbamoyl ) -4H- thienor3.2-t>lpyrrole Example #93: 2,3-dichloro-5-{N-rN-(3-hvdroxypropyl)carbamoylmethyllcarbamoyll-4H- thienor3,2-Z>lpyrrole
Example #94: 2,3-dichloro-5-{N-rN-(4-hvdroxybutyl)carbamoylmethyllcarbamoyll-4H- thieno f3 ,2-tJ>1pyrrole
Example #95: 2.3-dichloro-5-(N-{N-rbis(hvdroxymethyl)methyllcarbamoylmethyl}- carbamoyl)-4H-thienof3,2-blpyrrole
Example #96: 2.3-dichloro-5-{N-rN-(2.3-dihvdroxypropyl)carbamoylmethyllcarbamoyl)-
4H-thieno f3 ,2-t>l pyrrole
Figure imgf000065_0001
Figure imgf000065_0002
Figure imgf000066_0001
Example #97
2.3-dichloro-5-(N-rN-(4-hydroxymethylphenyl)carbamoylmethyllcarbamoyll-4H-thienor3,2- 61pyrrole
Figure imgf000067_0001
A solution of 5-(N-carboxymethylcarbamoyl)-2,3-dichloro-4H-thieno[3,2-ό]pyrrole (Method #12) (150mg, 0.51mmol), and 4-aminobenzyl alcohol (70.5mg, 0.56mmol) in TΗF (6ml) was stirred at ambient temperature for 30 minutes. 4-(4,6-dimethoxy-l,3,5-triazin-2- yl)-4-methylmorpholinium chloride (DMTMM) (142mg, 0.51mmol) was added and the reaction mixture stirred at ambient temperature overnight, then poured into water (15ml). The resultant precipitate was isolated by filtration, washed with water, ether and dried in vacuo to give the title product as a white solid (149mg, 73%)
ΝMR: 12.42 (1Η, br), 9.9 (1Η, s), 8.6 (1Η, t), 7.5 (2Η, d), 7.2 (2H, d), 7.1 (IH, s), 5.0 (IH, br), 4.4 (2H, s), 4.0 (2H, d); m/z 396.21
The following compounds were made by the process of Example #97 using 5-(N- carboxymethylcarbamoyl)-2,3-dichloro-4H-thieno[3,2-b]pyrrole (Method #12) and the appropriate commercially available amine: Example #98: 2.3-dichloro-5-{N-[N-(5-isoquinolyl)carbamoylmethyllcarbamoyl)-4H- thieno \32-bλ pyrrole
Example #99: 2,3-dichloro-5-{N-rN-(3-hvdroxymethy)lphenyllcarbamoylmethvn- carbamoyl } -4H-thieno \ ,2-t31pyrrole
Example #100: 2.3-dichloro-5-(N-(N-r4-(2- hydroxyethyl)phenyllcarbamoylmethyl)carbamoyl)-4H-thienor3,2-t31pyrrole
Example #101: 2.3-dichloro-5-{N-rN-(2.4-difluorophenyl)-N-methyl-carbamoylmethyll- carbamoyl } -4H-thieno \3 ,2-/31pyrrole
Example #102: 2.3-dichloro-5-{N-r(L2.3.4-tetrahydro-l-quinolyl)carbonylmethyl1- carbamoyl|-4H-thienor3,2-t)1pyrrole Example #103: 2.3-dichloro-5-{N-rN-(2-cvanoethyl)-N-methylcarbamoylmethyll- carbamoyl}-4H-thienoF3,2-&1pyrrole
Example #104: 2.3 -dichloro-5 - { N- rN-(4-hvdroxypiperidino carbamoylmethyll carbamoyl ) -
4H-thienor3,2-Z?1pyrrole Example #105: 2,3-dichloro-5-rN-(N- cvclopentylcarbamoylmethyl)carbamoyll-4H- thieno \3.2-t>lpyrrole
Example #106: 2,3-dichloro-5-rN-(N-isopropylcarbamoylmethyl)carbamoyn-4H-thienor3,2- /J>lpyrrole Example #107: 2.3-dichloro-5-rN-(N-isopropyl-N-methylcarbamoylmethyl)carbamoyll-4H- thieno \3.2-bl pyrrole
Example #108: 2,3-dichloro-5-rN-(thiomorpholinocarbonylmethyl)carbamoyll-4H- thieno[3.2-61pyrrole
Example #109: 2,3-dichloro-5-rN-(moφholinocarbonylmethyl)carbamoyll-4H-thienor3.2- Z yrrole
Figure imgf000068_0001
Figure imgf000068_0002
Figure imgf000069_0001
Example #110
2.3-dichloro-5-{N-r(l.l-dioxothiomorpholino)carbonylmethyllcarbamoyll-4H-thienor3.2t l- pyrrole and
Example #111
2 ,3 -dichloro-5- { N- \( 1 -oxothiomorpholino)carbonylmethyll carbamoyl ) -4H-thieno f3,2- όlpyrrole
Figure imgf000070_0001
A solution of -chloroperbenzoic acid (mCPBA) (14mg, 0.85mmol) in dichloromethane (5ml) was added dropwise to a suspension of 2,3-dichloro-5-[N- (thiomorpholinocarbonylmethyl)carbamoyl]-4H-thieno[3,2-t)]pyrrole (example # 108) in dichloromethane and the reaction mixture stirred at ambient temperature for one hour. 5% sodium metabisulfite solution (5ml) was added and the mixture stirred for several minutes. The aqueous layer was extracted with ethyl acetate (2 15ml) and the combined organic extracts washed with sodium bicarbonate solution (2x15ml) and concentrated. The two component mixture was separated using bond-elute silica column chromatography (eluent: dichloromethane-dichloromethane/methanol 5% gradient) to afford the less polar product (sulfone) as a white powder (57mg 33%) and the more polar product (sulfoxide) as a white solid (62mg, 37%).
ΝMR: (sulfone) 12.43 (1Η, br), 8.4 (1Η, t), 7.1 (1Η, s), 4.2 (2Η, d), 3.9 (4H, br), 3.3 (2H, br), 3.1 (2H, br); m/z 408.33 ΝMR: (sulfoxide) 12.42 (IH, br), 8.4 (IH, t), 7.1 (IH, s), 4.2 (3H, m), 3.9 (2H, d), 3.6 (IH, m), 2.9 (4H, m).
Example #112
2-Chloro-5-rN-(2-indanyl)carbamoyll-6H-thienor2,3-t31pyrrole
Figure imgf000070_0002
5-Carboxy-2-chloro-6H-thieno[2,3-t3]pyrrole (Method #10; lOlmg, 0.5mmol) was dissolved in dichloromethane (6ml) containing 2-aminoindane (68mg, 0.5mmol), 1- Ηydroxybenotriazole (ΗOBT) (68mg, 0.5mmol) and DIPEA (355μl, 2.0mmol). The mixture was stirred for one minute before the addition of EDAC (125mg, 0.65 mmol). The mixture was stirred at ambient temperature for approximately 16 hours before being washed with water. The organic fraction was concentrated and was purified using bon-elute silica column chromatography (eluent: dichloromethane-dichloromethane/methanol 2.5% gradient) to afford the title compound as a beige solid (96mg, 61%).
NMR: 11.80 (IH, br), 8.3 (IH, t), 7.2 (5H, m), 7.0 (IH, s), 4.6 (IH, m), 4.7 (IH, d), 3.2 (2H, m), 2.9 (2H, m); m z 315.46
Example #113
5-rN-(Benzri,21oxazol-3-ylmethyl)carbamoyll-2,3-dichloro-4H-thienor3,2-61pyrrole
Figure imgf000071_0001
5-Carboxy-2,3-dichloro-4H-thieno[3,2-6jpyrrole (Method #9; 118 mg, 0.5 mmol) was dissolved in DMF (5 ml) containing ΗOBT (83 mg, 0.55 mmol), DIPEA (52 ul, 0.30 mmol) and l,2-Benzisoxazole-3-methylamine (Eur.J.Med.Chem-Chimica Therapeutica, Jan.-Feb.-10, Νo.l p32) (89 mg, 0.6 mmol). The mixture was stirred for one minute and EDAC (106 mg, 0.55 mmol) was added. The mixture was stirred at room temperature for approximately 18 hours. Water was added to the solution and a solid precipitated out. This solid was filtered off and was washed with water before being dried under reduced pressure to afford the title compound as a white solid (174mg) 1Η ΝMR : 4.9(2Η,s), 7.1(lH,s), 7.4(lH,t), 7.6(lH,t), (7.8(lH,d), 8.0(lH,d), 9.2(lH,s), 12.5(lH,s); m/z 366 (M+H); HPLC Hichrome C18 column Acetonitrile/water/0.1%TFA 5-95% over 7.5 min Rt 4.9min m/z 366 (M+H)
The following compounds were made by the process of Example #113 using 5- carboxy-2,3-dichloro-4H-thieno[3,2-b]pyrrole (Method #9) and the appropriate amine: Example #114: 2.3-Dichloro-5-(N- ( 2-r2-(hydroxymethyl)phenyllethyl I carbamoyl)-4H- thieno [3 ,2-t>1pyrrole
Example #115: 2.3-Dichloro-5-rN-(4-phenylisoxazol-3-ylmethyl)carbamoyll-4H-thienor3.2- tjlpyrrole
Example #116: 2.3-Dichloro-5-('N-(2-r2-(2-morpholinoethoxy)phenyllethyllcarbamoyl)-4H- thieno \3 ,2-/31 pyrrole Example #117: 2,3-Dichloro-5-(N- { 2-r2-(methoxycarbonylmethoxy)phenyllethyl } - carbamoyl)-4H-thienoF3,2-/j1pyrrole
Figure imgf000072_0002
Figure imgf000072_0001
2 Amine: Method #33
3 Amine: Method #34
4 Amine: Method #35 Example #118
5-(N- { 2- r2-(Carboxymethoxy)phenyll ethyl } carbamoyl)-2,3-dichloro-4H-thieno[3.2-_7lpyrrole
Figure imgf000073_0001
2,3-Dichloro-5-(N- { 2-[2-(methoxycarbonylmethoxy)phenyl]ethyl } carbamoyl)-4H- thieno[3,2-t3]pyrrole (Example #117, 100mg,0.25mmol) dissolved in 2:1 TΗF : methanol (2ml), was treated with IN Lithium hydroxide solution (0.25ml, 0.25mmol), followed by the addition of water till the solution was just opalescent and then stirred for 2 hours at room 0 temperature. The organic solvents were removed by evaporation under reduced pressure, the solution filtered then acidified with 2Ν ΗC1 to give a thick white precipitate which was isolated by filtration, washed with water and dried under reduced pressure over phosphorous pentoxide to give the title compound (83mg) 1Η NMR : 2.9(2Η,q), 3.5(2H,q), 4.7(2H,s), 6.8(2H,m), 7.1(lH,s), 7.2(2H,m), 8.4(lH,m), 5 12.4(lH,s)
HPLC Hichrome C18 column Acetonitrile/water/0.1%TFA 5-95% over 7.5 min Rt 4.47min m/z 413 (M+H)
Example #119 0 2.3-Dichloro-5-(N-r2-(3-methoxyphenyl)ethvncarbamoyl|-4H-thienor3.2-/jlpyrrole
Figure imgf000073_0002
5-Carboxy-2,3-dichloro-4H-thieno[3,2- )]pyrrole (Method #9; lOOmg, 0.42mmol) was 5 suspended in DCM 10ml; 2M oxalyl chloride solution in DCM (750ul, 1.5mmol) was added dropwise followed by one drop of DMF and the resultant mixture stirred overnight at room temperature. The suspension was filtered, the residue washed with DCM and the filtrate evaporated to dryness under reduced pressure and then azeotroped with toluene to give a yellow solid which was dissolved in DCM (6.9ml) under nitrogen. Calcium carbonate (60mg, O.όmmol) was added followed by a solution of 3-methoxyphenethylamine; 90mg, 0.4mmol) and the mixture was stirred at room temperature overnight. The mixture was filtered, the residue washed with DCM followed by 0.1 M HCl then water to give the title compound as a white solid (98mg) IH NMR (CDC13) : 2.9(2H,t), 3.7(2H,t), 3.9(3H,s), 6.0(lH,m), 6.6(lH,s), 6.8(3H,m), 7.2(2H,m), 9.9(lH,s) m/z 369 (M+H)
Example #120
2,3-Dichloro-5-rN-(2-oxo- 2.3,4-tetrahydroquinol-3-yl)carbamovn-4H-thieno[3,2-t>1pyrrole
Figure imgf000074_0001
This was prepared following the procedure described in Example #97 using 3- aminohydrocarbostyril (Arch.Biochem&Biophys. 1963 109 48) was used in place of 4- aminobenzyl alcohol and 5-carboxy-2,3-dichloro-4H-thieno[3,2-δ]pyrrole (Method #9) was used in place of 5-(N-carboxymethylcarbamoyl)-2,3-dichloro-4H-thieno[3,2-έ]pyrrole to give the title compound: 1Η ΝMR : 3.0(2Η,d), 4.7(lH,q), 6.9(3H,m), 7.2(2H,m), 8.5(lH,d), 10.35(lH,s) HPLC Hichrome C18 column Acetonitrile/water/0.1%TFA 5-95% over 7.5 min Rt 4.44min m z 380 (M+H)
Example #121 2,3-Dichloro-5-(N-|2-r2-(2-methoxyethoxy)phenyllethyl)carbamoyl)-4H-thienor3.2-blpyrrole
Figure imgf000074_0002
2,3-Dichloro-5-{N-[2-(2-hydroxyphenyl)ethyl]carbamoyl}-4H-thieno[3,2-t)]pyrrole ( Example 73, 177.5mg, 0.5mmol) was dissolved in TΗF 3ml under nitrogen together with methoxyethanol (38μl, 0.5mmol) and triphenylphosphine (131mg, 0.5mmol), the resultant stirred solution was cooled to OC and treated with DIAD (98μl,0.5mmol) dropwise over 30 mins, then allowed to warm to room temperature overnight. After evaporation to dryness the mixture was purified by chromatography on a 20g Bond Elute silica column eluting with DCM. The product was taken up in diethyl ether 20ml, washed with 2Ν NaOΗ (3x5ml), water (5ml) and saturated brine (5ml) then dried over magnesium sulphate and evaporated under reduced pressure to give the title compound (45mg) 1Η NMR (CDC13) : 3.0(2Η,t), 3.5(3H,s), 3.7(2H,m), 3.9(2H,m), 4.2(2H,m), 6.6(lH,m), 6.8(lH,s), 6.9(2H,m), 7.2(2H,m), 9.9(lH,s) HPLC Hichrome C18 column Acetonitrile/water/0.1%TFA 5-95% over 7.5 min Rt 5.02min m/z 411 (M-H)
Example #122
5-(N-f2-r2-(Carbamoylmethoxy)phenynethyl)carbamoyl)-2,3-dichloro-4H-thieno[3,2- tjlpyrrole
Figure imgf000075_0001
5-(N-{2-[2-(Carboxymethoxy)phenyl]ethyl}carbamoyl)-2,3-dichloro-4H-thieno[3,2-t ]pyrrole (Example #118,124mg, 0.3 mmol) was dissolved in DMF (3 ml) containing ΗOBT (50 mg, 0.33 mmol), DIPEA (140 μl, 0.69 mmol) and ammonium chloride (18mg, 0.36 mmol). The mixture was stirred for one minute and EDAC (64mg, 0.33 mmol) was added. The mixture was stirred at room temperature for approximately 18 hours. Water was added to the solution and a solid precipitated out. This solid was filtered off and was washed with water before being dried under reduced pressure to afford the title compound as a white solid (11 lmg) 1Η ΝMR : 2.9(2Η,q), 3.5(2H,q), 4.5(2H,s), 6.8(2H,m), 7.0(lH,s), 7.2(2H,m), 7.5(lH,s), 7.6(lH,s), 8.4(lH,m), 12.4(lH,s) HPLC Hichrome C18 column Acetonitrile/water/0.1 %TFA 5-95% over 7.5 min Rt 4.37min m/z 412 (M+H)
The following compounds were made by the process of Example #122 using 5-(N-{2- [2-(Carboxymethoxy)phenyl]ethyl}carbamoyl)-2,3-dichloro-4H-thieno[3,2-έ]pyrrole
(Example #118) and the appropriate amine:
Example #123: 2.3-Dichloro-5-(N-(2-r2-(N-methylcarbamoylmethoxy)phenyllethyll- carbamoyl)-4H-thienor312-/jlpyrrole
Example #124: 2,3-Dichloro-5-(N-|2-r2-(NN-dimethylcarbamoylmethoxy)phenvn- ethyl}carbamoyl)-4H-thienor3,2-t1pyrrole
Example #125: 2.3-Dichloro-5-(N-{2-r2-(morpholinocarbonylmethoxy)phenyllethyl|- carbamoyl)-4H-thieno[3,2-t)1pyrrole
Example #126: 5-(N-{2-r2-(N-Benzylcarbamoylmethoxy)phenyllethyl}carbamoyl)-2.3- dichloro-4H-thieno[3,2-&lpyrrole Example #127: 2,3-Dichloro-5-(N-{ 2-r2-(4-hvdroxypiperidinocarbonylmethoxy)phenvn- ethyl)carbamoyl)-4H-thienor3,2-/J>lpyrrole
Figure imgf000076_0001
Figure imgf000076_0002
Figure imgf000077_0002
Example #128
(S)-2-Chloro-5- {N-r -(5-ethoxycarbonyl- 1.3 ,4-oxadiazol-2-yl)phenethyl]carbamoyl }-6H- thienor2,3-fc1pyrrole
Figure imgf000077_0001
5-Carboxy-2-chloro-6H-thieno[2,3-&]pyrrole (Method #10 172mg, 0.86mmol) was dissolved in DCM (10ml) containing ΗOBT (115mg, 0.86mmol), DIPEA (331mg,2.57mmol) and ethyl (S)-5-( -aminophenethyl)-l,3,4-oxadiazole-2-carboxylate trifluoroacetate (Method #16; 322mg, 0.86mmol). EDAC (205mg,1.07mmol) was added and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was filtered and the filtrate washed with dilute hydrochloric acid and water. After drying over magnesium sulphate and concentration the crude material was purified by bond elute silica column chromatography (eluent - DCM/Ethyl acetate gradient 0-20%) to give the title compound (104mg, 27%) NMR 1.3(3H, t); 3.3-3.5(2H, m); 4.4(2H,q); 5.5-5.6(lH,m); 7.05(lH,s); 7.15(lH,s); 7.2- 7.35(5H,m); 8.95(lH,d); 11.84(lH,s) m/z 444.9
Example #129
(S)-2-chloro-5-{N-r -(4-methoxycarbonyloxazol-5-yl)phenethyllcarbamoyl)-6H-thieno[2.3- tjlpyrrole
Figure imgf000078_0001
5-Carboxy-2-chloro-6H-thieno[2,3- yrrole (Method #10, lOOmg, 0.5mmol) was dissolved in DCM (10ml) containing ΗOBT (68mg, 0.5mmol), DIPEA (193mg, 1.5mmol) and methyl (S)-5-( -aminophenethyl)oxazole-4-carboxylate trifluoroacetate (Method #32, 230mg, 0.5mmol). EDAC (143mg, 0.75mmol) was added and the mixture stirred at ambient temperature for 4 hours. The reaction mixture was diluted with ethyl acetate (75ml) washed with dilute citric acid, water and brine, dried over magnesium sulphate and concentrated. The crude material was purified by bond elute silica column chromatography (eluent - DCM/Ethyl acetate gradient 0-50%) to give the title compound (147mg, 34%). ΝMR 3.05-3.15(lΗ,m); 3.2-3.25(lH,m); 3.8(3H,s); 5.85-5.95(lH,m); 7.1(lH,s); 7.15(lH,s); 7.15-7.25(5H,m); 7.75(lH,d) 8.4(lH,s); 11.74(lH,s); m/z 429
Example #130 2-Chloro-5-|N-rα-(3-pyridyl)phenethyllcarbamoyl|-6H-thienor2.3-t)1pyrrole
Figure imgf000079_0001
5-Carboxy-2-chloro-6H-thieno[2,3-έ] pyrrole (Method #10, lOOmg, 0.5mmol) was dissolved in DCM (10ml) containing ΗOBT (68mg, 0.5mmol), DIPEA (193mg,1.5mmol) and -(3-pyridyl)phenethylamine dihydrochloride (J. Am. Chem. Soc, 1950, 72, 1988; 135mg, 0.5mmol). EDAC (143mg,0.75mmol) was added and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was diluted with ethyl acetate (50ml), water (20ml) was added and the pΗ adjusted to 7 with dilute hydrochloric acid. The organic fraction was separated washed with water and brine, dried over magnesium sulphate and concentrated. The crude material was purified by bond elute silica column chromatography (eluent - Ethyl acetate ) to give the title compound as a solid (128mg, 67%).
NMR 3.0-3.2(2Η,m); 5.2-5.3(lH,m); 7.05(lH,s); 7.1-7.2(2H,m); 7.2-7.4(5H,m); 7.8(lH,d); 8.4(lH,d); 8.55-8.65(2H,m); 11.71(lH,s); m/z 381
Example #131 2,3-dichloro-5-{N-rα-(3-pyridyl)phenethyl)lcarbamoyl|-4H-thienor3,2--7lpyrrole
Figure imgf000079_0002
5-carboxy-2,3-dichloro-4H-thieno[3,2-δ]pyrrole (Method #9, 118mg, 0.5mmol) was dissolved in DCM (10ml) containing ΗOBT (68mg, 0.5mmol), DIPEA (193mg,1.5mmol), α- (3-pyridyl)phenethyl)amine dihydrochloride (J. Am. Chem. Soc, 1950, 72, 1988; 135mg, 0.5mmol). EDAC (143mg,0.75mmol) was added and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was diluted with ethyl acetate (100ml), water (20ml) was added and the pΗ adjusted to 7 with dilute hydrochloric acid. The organic fraction was separated washed with water and brine, dried over magnesium sulphate and concentrated. The crude material was purified by bond elute silica column chromatography (eluent - Ethyl acetate ) to give the title compound as a solid (72mg, 34%)
NMR 3.0-3.3(2H,m); 5.2-5.3(lH,m); 7.1-7.2(2H,m); 7.2-7.4(5H,m); 7.85(lH,dt); 8.4(lH,dd); 8.6(lH,s); 8.75(lH,d); 12.28(lH,s); m/z 417
Example #132
(S)-2-Chloro-5- (N-rα-(3-phenyl- 1 ,2.4-oxadiazol-5-yl)phenethvncarbamoyl } -6H-thienor2,3-
&1pyrrole
Figure imgf000080_0001
5-Carboxy-2-chloro-6H-thieno[2,3-ό] pyrrole (Method #10, 201mg, Immol) was dissolved in DCM (15ml) containing ΗOBT (148mg, 1. Immol), DIPEA (387mg,3mmol) and (S)-5 ( -aminophenethyl)-3-phenyl-l,2,4-oxadiazole trifluoroacetate (Method #18, 379mg, Immol). EDAC (238mg,1.25mmol) was added and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was filtered and the filtrate diluted with DCM (50ml) washed with dilute hydrochloric acid and water. After drying over magnesium sulphate and concentration the crude material was purified by bond elute silica column chromatography (eluent - DCM/Ethyl acetate gradient 0-20%) to give the title compound (120mg, 26%); ΝMR 3.3-3.6(2Η,m); 5.5-5.7(lH,m); 7.1(lH,s); 7.15-7.4(6H,m); 7.55-7.65(3H,m); 8.05(2H,d); 9.05(lH,d); 11.9(lH,s); m/z 449
Example #133 2.3-Dichloro-5-rN-(l-hydroxyindan-2-yl)carbamoyll-4H-thienor3.2-J)lpyrrole
Figure imgf000080_0002
5-Carboxy-2,3-dichloro-4H-thieno[3,2-t>]pyrrole (Method #9, 329 mg, 1.4 mmol) was dissolved in DCM (20 ml) containing ΗOBT (189 mg, 1.4 mmol), DIPEA (0.5 ml, 2.8 mmol) and 2-aminoindan-l-ol (Method #36, 250 mg, 1.4 mmol). The reaction mixture was stirred for one minute and EDAC (306 mg, 1.6 mmol) was added. The reaction mixture was stirred at room temperature for approximately 18 hours. The resulting solution was washed with water (20 ml) and the aqueous layer extracted with DCM (2 x 20 ml). The organic extracts were combined, dried over magnesium sulphate and concentrated under reduced pressure to give the title compound as a white solid (70 mg, 14%).
NMR: 2.8(lΗ,dd), 3.2(lH,dd), 4.4(lH,quin), 5.1(lH,d), 7.1(lH,s), 7.2-7.4(4H,m), 8.7(lH,d), 12.4(lH,s); m/z 366 (M-H)
Example #134 2.3-Dichloro-5-rN-((7S.2S)-l-hvdroxyindan-2-yl)carbamovn-4H-thienor3.2-t>lpyrrole
Figure imgf000081_0001
and
Example #135
2.3-Dichloro-5-rN-((7i-.2i-)-l-hvdroxyindan-2-yl)carbamoyll-4H-thienor3.2-jlpyrrole
Figure imgf000081_0002
2,3-Dichloro-5- [N-( 1 -hydroxyindan-2-yl)carbamoyl] -4H-thieno[3 ,2-t)]pyrrole (Example #133) was subject to preparative ΗPLC under the following conditions to give 2,3- dichloro-5-[N-((-/S,2S)-l-hydroxyindan-2-yl)carbamoyl]-4H-thieno[3,2-t3]pyrrole as a white solid (9 mg) and 2,3-dichloro-5-[N-((H-,2i-)-l-hydroxyindan-2-yl)carbamoyl]-4H- thieno[3,2-t)]pyrrole as a white solid (12 mg).
Figure imgf000081_0003
Figure imgf000082_0003
Example #136
2-Chloro-5-rN-(l-hydroxyindan-2-yl)carbamoyll-6H-thieno[2,3-61pyrrole
Figure imgf000082_0001
5-Carboxy-2-chloro-6H-thieno[2,3-t3]ρyrrole (Method #10; 280 mg, 1.4 mmol) was dissolved in DCM (20 ml) containing ΗOBT (189 mg, 1.4 mmol), DIPEA (0.5 ml, 2.8 mmol) and 2-aminoindan-l-ol (Method #36, 250 mg, 1.4 mmol). The reaction mixture was stirred for one minute and EDAC (306 mg, 1.6 mmol) was added. The reaction mixture was stirred at room temperature for approximately 18 hours. The resulting solution was washed with water (20 ml) and the aqueous layer extracted with DCM (2 x 20 ml). The organic extracts were combined, dried over magnesium sulphate and concentrated under reduced pressure to give the title compound as a white solid (78 mg, 17%).
ΝMR: 2.8(lΗ,dd), 3.2(lH,dd), 4.4(lH,quin), 5.1(lH,t), 5.6(lH,d), 7.1(lH,s), 7.2-7.4(5H,m), 8.4(lH,d), 11.8(lH,s); m/z 331 (M-H)
Example #137
2.3-Dichloro-5-rN-(l-hvdroxy-L2,3.4-tetrahydronaphth-2-yl)carbamoyll-4H-thienor3.2- tyipyrrole
Figure imgf000082_0002
5-Carboxy-2,3-dichloro-4H-thieno[3,2-t]pyrrole (Method #9; 216 mg, 0.9 mmol) was dissolved in DCM (15 ml) containing ΗOBT (122 mg, 0.9 mmol), DIPEA (0.3 ml, 1.8 mmol) and 2-amino-l,2,3,4-tetrahydronaphth-l-ol (Method #39, 150 mg, 0.9 mmol). The reaction mixture was stirred for one minute and EDAC (206 mg, 1.1 mmol) was added. The reaction mixture was stirred at room temperature for approximately 18 hours. The resulting solution was washed with water (20 ml) and the aqueous layer extracted with DCM (2x20 ml). The organic fractions were combined and concentrated under reduced pressure to give the title compound as a white solid (70 mg, 14%). NMR 1.8(lH,m), 2.0(lH,qd), 2.9(lH,m), 3.3(lH,qd), 4.4(lH,quin), 4.9(lH,m), 5.2(lH,s), 5.8(lH,brs), 6.8(lH,s), 7.0(lH,dd), 7.1(lH,d), 7.2(lH,s), 7.5(lH,d) 10.1(lH,brs). nα/Z 380 (M-H).
Example #138 2,3-Dichloro-5-rN-(6-fluoro-l-hvdroxyindan-2-yl)carbamoyll-4H-thienor3,2-jlpyrrole
Figure imgf000083_0001
5-Carboxy-2,3-dichloro-4H-thieno[3,2-/ ]pyrrole (Method #9; 141 mg, 0.6 mmol) was dissolved in DCM (10 ml) containing ΗOBT (81 mg, 0.6 mmol), DIPEA (0.2 ml, 1.2 mmol) and 2-amino-6-fluoro-l-indanol (Method #38, 100 mg, 0.6 mmol). The reaction mixture was stirred for one minute and EDAC (138 mg, 0.7 mmol) was added. The reaction mixture was stirred at room temperature for approximately 18 hours. The resulting solution was washed with water (20 ml) and the aqueous layer extracted with DCM (2x20 ml). The organic fractions were combined and concentrated under reduced pressure to give a white solid. Purification by flash column chromatography (Isohexane:ethyl acetate 1:1) gave the title compound as a white solid (70 mg, 14%). ΝMR 3.0(lΗ,dd), 3.3(lH,m), 4.6(lH,q), 4.9(lH,t), 5.5(lH,d), 4.9(lH,m), 6.9-7.2(4H,m), 8.1(lH,d), 12.4(lH,brs); m/Z 383 (M-H)
Example #139
2.3-Dichloro-5- [N-(7-methoxy- 1 -oxo- 1.2,3 ,4-tetrahydronaphth-2-yl)carbamoyll -4H- thienor3,2-/jlpyrrole
Figure imgf000084_0001
5-Carboxy-2,3-dichloro-4H-thieno[3,2-t)]pyrrole (Method #9; 216 mg, 0.9 mmol) was dissolved in DCM (20 ml) containing ΗOBT (122 mg, 0.9 mmol), DIPEA (0.3 ml, 1.8 mmol) and 2-amino-7-methoxy-l-oxo-l,2,3,4-tetrahydronaphthalene ((Farmaco, Ed. Sci. (1985), 40(6) , 422-428), 204 mg, 0.9 mmol). The reaction mixture was stirred for one minute and EDAC (206 mg, 1.0 mmol) was added. The reaction mixture was stirred at room temperature for approximately 18 hours. The resulting solution was washed with water (20 ml) and the aqueous layer extracted with DCM (2x20 ml). The organic fractions were combined and concentrated under reduced pressure to give the title compound as a brown solid (100 mg, 27%). NMR 3.0(lΗ,dd), 3.1(lH,dd), 3.3(2H,m), 4.8(lH,q), 5.8(lH,s), 6.9-7.2(4H,m), 8.6(lH,d), 12.2(lH,brs); m/z 408 (M-H).
Example #140
2,3-Dichloro-5-rN-(2-indanyl)carbamoyll-4H-thienor3.2-/jlpyrrole
Figure imgf000084_0002
5-Carboxy-2,3-dichloro-4H-thieno[3,2-δ]pyrrole (Method #9, 45 mg, 0.19 mmol) was dissolved in DMF (10 ml) with 2-aminoindan (28 mg, 0.21 mmol), di-isopropylethylamine (0.1 ml, 0.57 mmol) and ΗATU (80 mg, 0.21 mmol). The mixtures were stirred at ambient temperature for approximately 16 hours. The mixture was partitioned between water and ethyl acetate and was washed with water (x 5). The aqueous phase was dried, filtered and concentrated, and the residue purified by silica bond-elut chromatography using a gradient of ethyl acetate in iso-hexane (0-50%) as eluent to give the title compound, m/z 351.
Following a similar procedure to the process of Example #140 the following examples were prepared: Example #141 : 2,3-Dichloro-5-[N-(3-methylisoxazol-5-yl)methyllcarbamoyll-4H- thienor3.2-/jlpyrrole
Example #142: 2,3-Dichloro-5-rN-(4-hvdroxy-l,l-dioxotetrahvdrothiophen-3-yl)carbamoyll-
4H-thienor3,2-t lpyrrole
Example #143: 2.3-dichloro-5-(N-{N-methyl-N-r(l-oxo-1.2.3.4-tetrahvdronaphth-2- yl)methyllcarbamoylmethyllcarbamoyl)-4H-thieno[3,2-t)lpyrrole
Figure imgf000085_0001
Figure imgf000085_0003
1 Amine: Method #37
Example #144
2-Chloro-5-rN-(2-oxo-l,2.3,4-tetrahvdroquinol-3-yl)carbamoyll-6H-thienor2,3-t31pyrrole
Figure imgf000085_0002
5-Carboxy-2-chloro-6H-thieno[2,3-δ]pyrrole (Method #10; 101 mg, 0.5 mmol) was dissolved in DMF (2.5 ml) containing 3-amino-3,4-dihydro-2(lH)-quinolinone [J Med Chem (1986) 29 (12) 2427-32] (99 mg,0.5 mmol), ΗOBT (68 mg, 0.5 mmol) and Et3Ν (55 mg, 0.5 mmol). The mixture was stirred for 1 minute before the addition of EDAC (96 mg, 0.5 mmol). The mixture was stirred at ambient temperature for approximately 18 hours before being poured into water (50 ml), stirred vigorously and filtered. The recovered solid was washed with water, ether and dried to give the title compound as a amorphous solid.(161 mg). NMR (DMSOd6): 11.96 (IH, s), 10.36 (IH, s), 8.50 (IH, d), 7.20 (2H, m), 7.19 (IH, s), 7.09 (IH, s), 6.96 (IH, m), 6.91 (lH,m), 4.72 (IH, m), 3.08 (2H, m); MH+ 346.14.
Example #145
2-Chloro-5-fN-(l,2,3,4-tetrahvdroquinol-3-yl)carbamoyll-6H-thienor2,3-t31pyrrole
Figure imgf000086_0001
5-Carboxy-2-chloro-6H-thieno[2,3~ yrrole (Method #10; 157 mg, 0.78 mmol) was dissolved in DMF (4 ml) containing 3-amino-l,2,3,4-tetrahydroquinoline [J Med Chem (1982) 25 (1) 68-70] (115 mg, 0.78 mmol) and ΗOBT (105 mg, 0.78 mmol). The mixture was stirred for 1 minute before the addition of EDAC (149 mg, 0.78 mmol). The mixture was stirred at ambient temperature for approximately 64 hours before being partitioned between water and EtOAc. The organics were washed with water, saturated aqueous NaΗCO3, water, saturated brine and dried. The organics were filtered, concentrated and chromatographed on Fluorochem silica 40-63μ 60A (eluent 40:60 EtOAc/isohexane) to afford the title compound as an amorphous solid (44 mg). NMR (DMSOd6): 11.94 (IH, s), 8.04 (IH, d), 7.16 (IH, s), 7.06 (IH, s), 6.90 (2H, m), 6.48 (2H, m), 5.8 (IH, br), 4.18 (IH, m), 3.05 (IH, t), 2.85 (2H, m); MH+ 332.17.
Example #146
2-Chloro-5-rN-( 1 -methyl-2-oxo- 1 ,2.3 ,4-tetrahvdroquinol-3-yl)carbamoyl1-6H-fhienor2,3- /jlpyrrole
Figure imgf000086_0002
5-Carboxy-2-chloro-6H-thieno[2,3-t3]pyrrole (Method #10; 80 mg, 0.4 mmol) was dissolved in DMF (2 ml) containing 3-amino-3,4-dihydro-l-carbostyril [JCS 1965 1080-1087] (71 mg, 0.4 mmol) and ΗOBT (54 mg, 0.4 mmol). The mixture was stirred for 1 minute before the addition of EDAC (77 mg, 0.4 mmol). The mixture was stirred at ambient temperature for approximately 18 hours before being partitioned between water and EtOAc. The organics were washed with water, saturated aqueous NaΗCO , water, saturated brine and dried. The organics were filtered, concentrated and recrystalised from EtOAc to afford the title compound as an amorphous solid (66 mg). NMR 11.96 (IH, s), 8.54 (IH, d), 7.30 (2H, m), 7.17 (2H, m), 7.08 (2H, m), 4.68 (IH, m), 3.32 (3H, s), 3.14 (IH, m), 3.04 (IH, m); m/z (MH+) 360.14
Example #147
2-Chloro-5-rN-(3-oxo-2,3,4,5-tetrahvdro-lH-benzr21azepin-4-yl)carbamoyll-6H-thieno[2,3- tjlpyrrole
Figure imgf000087_0001
5-Carboxy-2-chloro-6H-thieno[2,3-tj]pyrrole (Method #10; 101 mg, 0.5 mmol) was dissolved in DMF (2.5 ml) containing 4-amino-l,2,4,5-tetrahydro-3Η-2-benzazepin-3-one hydrochloride [CAS Reg No 148842-85-7] (107 mg, 0.5 mmol), HOBT (68 mg, 0.5 mmol) and Et3N (101 mg, 1.0 mmol). The mixture was stirred for 1 minute before the addition of EDAC (96 mg, 0.5 mmol), then at ambient temperature for approximately 18 hours before being partitioned between water and EtOAc. The organics were washed with water, saturated aqueous NaHCO3, water, saturated brine and dried; filtered and evaporated to afford the title compound as an amorphous solid (26 mg). NMR: 11.92 (IH, s), 8.33 (IH, t), 8.29 (IH, d), 7.2 (6H, m), 5.30 (IH, m), 4.83 (IH, dd), 3.98 (IH, dd), 3.20 (2H, m); m/z (MH+) 360.19. Example #148
2,3-Dichloro-5-[N-(l-methoxyindan-2-yl)carbamoyl1-4H-thieno[3,2-/31pyrrole
Figure imgf000088_0001
5-Carboxy-2,3-dichloro-4H-thieno[3,2=δ]ρyrrole (Method #9, 145mg, 0.613mmol), trørø-2-amino-l-methoxyindan (Method #40, lOOmg, 0.163mmol), DIPEA (0.105ml, 0.613mmol), and ΗOBT (83mg, 0.613mmol) was stirred in dichloromethane (5ml) for one minute. EDAC (147mg, 0.766mmol) was added and the mixture stirred at room temperature for 20 hours. The reaction mixture was evaporated, ethyl acetate (25fnl) added and then washed with water. The organic solution was dried over magnesium sulphate and evaporated to give the title compound as a white powder (180mg, 77%). NMR2.8(1Η, dd), 3.3(1H, dd), 3.35(3H, s), 4.1-4.2QH, m), 5.35-5.45(lH, m), 7.1-7.3(4H, m), 7.15(1H, s), 8.7(1H, d); m/z 380.9/382.9 (M+H).
Example #149
2,3-Dichloro-5-(N- { 1 - [N-( 1 , 1 -dimethylethoxy)carbonylamino1indan-2-yl 1 carbamoyl)-4H- thieno [3 ,2--?1pyrrole
Figure imgf000088_0002
5-Carboxy-2,3-dichloro-4H;thieno[3,2-δ]pyrrole (Method #9, 1.18g, 5.0mmol), (IR, 2i-)-2-amino-l-[(l,l-dimethylethoxy)carbonylamino]indan (Method #43, 1.25g, 5.0mol), DIPEA (0.855ml, 5.0mmol), and ΗOBT (675mg, 5.0mmol) was stirred in dichloromethane (50ml) for one minute. EDAC (1.2g, 6.25mmol) was added and the mixture stirred at room temperature for 20 hours. The reaction mixture was diluted with dichloromethane (50ml), filtered and dried to give the title compound as a pale green powder (1.95g, 85% ). ΝMR1.4(9Η, s), 2.8(1H, dd), 3.2QH, dd), 4.5-4.7(lH, m), 5.1-5.2(1H, m), 7.05-7.3(5H, m), 7.4(1H, d), 8.6(1H, d), 12.4(1H, s). Example #150
5-[N-(l-Aιru.noindan-2-yl)carbamoyl1-2,3-dichloro-4H-thieno[3,2-tj]pyrrole
Figure imgf000089_0001
2,3-DichIoro-5-(N- { 1 -[( 1 , 1 -dimethylethoxy)carbonylamino]indan-2-yl Jcarbamoyl)- 4H-thieno[3,2-b]pyrrole (Example #149, l.Og, 2.15mmol) was dissolved in dichloromethane (20ml). Trifluoroacetic acid (2ml) was added and the mixture stirred at room temperature for 24 hours. The reaction was filtered and the isolated solid washed with dichloromethane to give the trifluoroacetic acid salt of the title compound as a pale green powder (800mg, 78%). ΝMR3.05(1Η, dd), 3.4(1H, dd), 4.6-4.85(2H, m), 7.2(1H, d), 7.3-7.45(3H, m), 7.55(1H, d), 8.6(3H, broad s), 8.8(1H, d), 12.5(1H, s)
Example #151
5-[N-(l-Acetamidoindan-2-yl)carbamoyn-2,3-dichloro-4H-thieno[3,2- )lpyιτole
Figure imgf000089_0002
Triethylamine (lOlmg, l.Ommol) was added to a suspension 5-[N-(l-aminoindan-2- yl)carbamoyl]-2,3-dichloro-4H-thieno[3,2-j]pyrrole trifluoroacetic acid salt (Example #150, 240mg, 0.5mmol) in dichloromethane (4ml), followed by acetyl chloride (47mg, 0.6mmol) dissolved in dichloromethane (1ml) and the reaction stirred at room temperature for 6 hours during which a white solid precipitated. The reaction was filtered and the crude material purified by silica chromatography with hexane : ethyl acetate to give the title compound as a white solid (50mg, 25%). ΝMR 1.87(3Η, s), 2.82(1H, dd), 3.22(1H, dd), 4.45-4.62(lH, m), 5.38-5.5(lH, m), 7.02-7.27(4H, m), 7.1(1H, s), 8.35(1H, d), 8.59(1H, d), 12.36(1H, broad s); m/z 406.13/408.8 (M-H).
Example #152 2,3-Dichloro-5-{N-[l-(methanesulphonamido)indan-2-yllcarbamoyl|-4H-thieno[3,2-b]pyrrole
Figure imgf000090_0001
5-Carboxy-2,3-dichloro-4H-thieno[3,2-t>]ρyrrole (Method #9, 236mg, l.Ommol), (li-,2i-)-2-amino-l-methanesulphonamidoindan (Method #42, 226mg, l.Omol), DIPEA (0.174ml, l.Ommol), and ΗOBT (135mg, l.Ommol) was stirred in dichloromethane (10ml) for one minute. EDAC (240mg, 1.25mmol) was added and the mixture stirred at room temperature for 20 hours. The mixture was diluted with ethyl acetate, washed with water (2 x 25ml), dried over magnesium sulphate and evaporated to give the title compound as a foam (400mg, 90%). ΝMR2.84(1Η, dd), 2.99(3H, s), 3.22(1H, dd), 4.44-4.64(lH, m), 4.89- 5.0(1H, m), 7.14(1H, s), 7.16-7.36(4H, m), 7.84(1H, d), 8.64(1H, d), 12.43QH, broad s); m z 442.2/444.0 (M-H).
Example #153 2,3-Dichloro-5-(N-[l-(methylamino)indan-2-yllcarbamoyl)-4H-thieno[3,2-t>]pyrrole
Figure imgf000090_0002
2,3-Dichloro-5-[N-(l-{N-[(l,l-dimethylethoxy)carbonyl]-N-methylamino}indan-2- yl)carbamoyl]-4H-thieno[3,2-t)]pyrrole (Method #44, 900mg, 1.87mmol) in dichloromethane (20ml) treated with trifluoroacetic acid (2ml) at room temperature for 1 hour. Evaporation followed by co-evaporation with chloroform and drying gave the trifluoroacetic acid salt of the title compound as a pale brown foam (850mg, 92%). ΝMR 2.75(3Η, s), 3.02(1H, dd), 3.5(1H, dd), 4.7-4.95(2H, m), 7.15(1H, s), 7.28-7.48(3H, m), 7.6(1H, d), 8.68(1H, d), 9.1(2H, broad s); m/z 380.4/382.4 (M+H).
Example #154 2,3-Dichloro-5-IN-ri-(N-methylacetamido)indan-2-yllcarbamoyl)-4H-thieno[3,2-t31pyrrole
Figure imgf000091_0001
2,3-Dichloro-5- {N-[ 1 -(methylamino)indan-2-yl]carbamoyl } -4H-thieno[3,2-ό]pyrrole trifluoroacetic acid salt (Example #153, 390mg, 0.79mmol) in dichloromethane (5ml) at 5°C was treated with triethylamine (0.33ml, 2.37mmol) and acetyl chloride (68mg, 0.86mmol). After stirring at 5°C for 15 minutes the reaction was allowed to warm to room temperature and stirred for a further 2 hours. The mixture was diluted with ethyl acetate (25ml) and washed with saturated sodium bicarbonate and water. Drying over magnesium sulphate followed by evaporation gave the title compound as a pale brown foam (270mg, 80%). ΝMR: Indicates an approximate 1:1 ratio of rotamers of the title compound; 2.05(1.5Η, s), 2.1(1.5H, s), 2.6(1.5H, s), 2.8(1.5H, s), 2.9-3.08(lH, m), 3.12-3.3(1H, m), 4.7-4.9(lH, m), 5.24(0.5H, d), 6.14(0.5H, d), 6.94-7.35(5H, m), 8.6(0.5H, d), 8.68(0.5H, d), 12.38(0.5H, broad s), 12.46(0.5H, broad s); m/z 421.9/423.9 (M+H)
Preparation of Starting Materials
The starting materials for the Examples above are either commercially available or are readily prepared by standard methods from known materials. For example the following reactions are illustrations but not limitations of the preparation of some of the starting materials used in the above reactions.
Method #1
3-Chloro-5-methoxycarbonyl-4H-thieno[3,2-J)]pyrrole
Figure imgf000091_0002
Methanolic sodium methoxide solution (28%) (5 ml, 25.9 mmol) was diluted with MeOΗ (5 ml) and was cooled to -25°C under nitrogen. A solution of 4-chloro-2- thiophenecarboxaldehyde (J Heterocyclic Chem, 1976, 13, 393; 1.1 g, 7.5 mmol) and methyl azidoacetate (3.0 g, 26.1 mmol) in MeOH (20 ml) was added dropwise, maintaining the temperature at -25°C. On completion of addition the solution was allowed to warm to 5°C over a period of approximately 16 hours. The solution was added to saturated aqueous ammonium chloride (250 ml) and the mixture was extracted using DCM. The combined organic layers were concentrated at 0°C. The residue was taken up in xylene (30 ml) and this solution was added dropwise to xylene (120 ml) under reflux. The solution was heated under reflux for 30 minutes before being cooled and concentrated. The title compound was purified by a mixture of crystallisation (EtOAc/isohexane) and chromatography on a Bond Elut column eluting with a graduated solvent of 5-50% EtOAc in isohexane (640 mg, 40%). NMR (CDC13) 9.1 (IH, br), 7.1 (2H, s), 3.9 (3H, s); m/z 214.3.
Methods #2 - #4
The following compounds were made by the process of Method #1 using the appropriate starting materials
Figure imgf000092_0002
1 Aldehyde: DE 2814798
2 Aldehyde: Aldehyde ref. Gronowitz et al. Tetrahedron Vol.32 1976 p.1403
Method #5
Figure imgf000092_0001
N-(tert-Butoxycarbonyl)glycine (875mg, 5mmol) was dissolved in DMF (7ml) containing DIPEA (3.5ml, 20mmol) and benzylamine (536mg, 5mmol). The mixture was allowed to stand for one minute before addition of 0-(7-Azabenzotriazol-l-yl)-NNN',N'- tetramethyluronium hexafluorophosphate (HATU) (2.09g, 5.5mmol). The solution was allowed to stand for approximately 18 hours before being partitioned between ethyl acetate (50ml) and water (50ml). The layers were separated and the organic phase dried using magnesium sulphate, filtered, concentrated and purified using bond-elute silica column chromatography (eluent: dichloromethane-dichloromethane/methanol 5% gradient) to afford the title compound as an oil (1.32g, quantitative). ΝMR: (CDC13): 7.2 (5H, m), 6.3(1H, br), 5.0(1H, br), 4.4(2H, d), 3.8(2H, d), 1.4(9H, s); m/z 265.4
Method #6
2-Amino-N-benzylacetamide
Figure imgf000093_0001
To a solution of N-benzyl-2-(tert-butoxycarbonylamino)acetamide (Method #5 , 1.18g, 4.47mmol) in dichloromethane (6ml) at 0°C was added dropwise, trifluoroacetic acid (2.4ml) and the resulting solution allowed to stir warming to room temperature overnight. The reaction mixture was neutralised by addition of saturated sodium bicarbonate solution and extracted with dichloromethane. The combined organic phases were dried over magnesium sulphate, filtered, concentrated and purified by bond-elute SCX column chromatography (eluent: methanol/dichloromethane (1:1) then methanol/dichloromethane (l:l)/ammonia5%) to afford the title compound as an oil (215mg, 29%). ΝMR: (CDC13): 7.2(6H, m), 4.4(1.4H,d), 4.3(0.6H,d), 3.4(2H, br); m/z 165.17
Method #7
5-Carboxy-3-chloro-4H-thieno[3.2-tj]pyrrole
Figure imgf000094_0001
3-Chloro-5-methoxycarbonyl-4H-thieno[3,2-t>]pyrrole_(Method #l; 0.61 g, 2.83 mmol) was taken up in MeOΗ (10 ml) and was heated under reflux. Aqueous lithium hydroxide (2.0 M, 3.0 ml, 6.0 mmol) was added portionwise over 45 minutes. The mixture was heated under reflux for 30 minutes before being cooled and concentrated. Water (20 ml) was added and the solution was neutralised using aqueous hydrochloric acid (2.0 M, 3.0 ml). The solution was extracted using EtOAc, and the combined organic layers were concentrated to afford the title compound as a yellow solid (0.57 g, 100%). NMR: 12.4 (1Η, br), 7.4 (1Η, s), 7.0 (1Η, s); m/z 200.3.
Methods #8 - #10
The following compounds were made by the process of Method #7 using the appropriate starting materials.
Figure imgf000094_0002
Method #11
2,3-Dichloro-5-rN-(ethoxycarbonylmethyl)carbamoyll-4H-thienor3,2-t]pyrrole
Figure imgf000095_0001
5-Carboxy-2,3-dichloro-4H-thieno[3,2-_j]pyrrole (Method #9, 4.0g 16.95mmol) was added to a solution of glycine ethyl ester hydrochloride (2.60g, 18.64mmol) and DIPEA in dichloromethane (200ml) followed by ΗOBT (2.29g, 16.95mmol). The solution was stirred under nitrogen for 15 minutes before the addition of EDAC (3.89g, 22.03mmol). The mixture was stirred at ambient temperature for approximately 16 hours. The resultant white precipitate was isolated by filtration, washed with water and ether and dried. (4.79g, 88%). NMR: 12.45 (lΗ,br), 8.75 (IH, t), 7.1 (IH, s), 4.1 (2H, q), 4.0 (2H, d), 1.2 (3H, t); m/z 321.2
Method #12
5-(N-Carboxymethylcarbamoyl)-2,3-dichloro-4H-thieno[3,2-t>1pyrrole
Figure imgf000095_0002
2Ν Sodium hydroxide solution (14.3ml, 28.7mmol) was added to a suspension of 2,3- dichloro-5-[N-(ethoxycarbonylmethyl)carbamoyl]-4H-thieno[3,2-ό]pyrrole (Method #11, 4.60g, 14.33mmol) in tetrahydrofuran (TΗF) (100ml). The resultant solution was stirred at room temperature for one hour. The reaction mixture was concentrated 'in vacuo', the residue diluted with water (250ml), the solution adjusted to pΗ=2 by addition of 2Ν Hydrochloric acid, and then extracted with ethyl acetate (3x150ml). The organic extracts were combined, dried over sodium sulphate then filtered and concentrated to give a white powder (3.34g, 80%); NMR: 12.6 (lH,br), 12.4 (IH, br), 8.6 (IH, t), 7.1 (IH, s), 3.9 (2H, d); m/z 291.17
Method #13
N-(2-Cvanoethyl)- N-phenyl-2-(tert-butoxycarbonylamino)acetamide
Figure imgf000096_0001
By a similar procedure to Method #5 the title compound was prepared using anilinopropionitrile to give a clear oil (598mg, 39%); NMR: (CDC13): 7.4(3H, m), 7.2(2H, m), 5.2(1H, br), 3.9(2H, t), 3.6(2H, d), 2.6(2H, t), 1.3(9H, s); m/z 304.51
Method #14
2-Amino-N-(2-cvanoethyl)-N-phenylacetamide
Figure imgf000096_0002
By a similar procedure to Method #6 the title compound was prepared using N-(2- cyanoethyl)- N-phenyl-2-(tert-butoxycarbonylamino)acetamide (Method #13) to give a clear oil (222mg, 60%); ΝMR: (CDC13): 7.4(3H, m), 7.2(1H, d), 7.1(1H, d), 3.9(2H, t), 3.1( 1.33H, s), 3.0(0.67H, s), 2.65(1.33H, t), (0.67H, t); m/z 204.31
Method #15 N-[(2-Amino-2-(2-thiazolyl)1ethyl-N-methylmethanesulphonamide
Figure imgf000096_0003
2-Bromothiazole (6.9 g, 42.0 mmol) was dissolved in dry diethyl ether (15 ml) and was added dropwise to butyl lithium (1.6 M, 29.7 ml, 47.5 mmol) in diethyl ether (40 ml) at -70°C. The mixture was stirred at -70°C for 30 minutes before the addition of a cold solution of ethyl 2-(N-methylmethanesulphonamido)acetate (Ger Offen, 1976, 27pρ; 7.6 g, 39.0 mmol) in dry THF (70 ml). The solution was stirred for a further 30 minutes at -70°C before being allowed to warm to ambient temperature. Aqueous ammonium chloride (10%, 200 ml) was added and the solution was extracted using diethyl ether. The aqueous layer was acidified and re-extracted using diethyl ether. The combined organic layers were dried, filtered and concentrated under reduced pressure. The residue (5.30 g, 22.6 mmol) was dissolved in ethanol (100 ml) containing pyridine (18 ml) and hydroxylamine hydrochloride (1.88 g, 27.1 mmol). The mixture was heated under reflux in an inert atmosphere for 2.5 hours before being cooled and concentrated under reduced pressure. The residue was suspended in water and cooled to 0°C. The mixture was acidified to pH 4 using aqueous hydrochloric acid (2.0 M). A solid precipitated out of solution and was filtered off and washed with water. The product was dried under reduced pressure in the presence of phosphorous pentoxide. The dry solid (4.34 g, 17.4 mmol) was dissolved in acetic acid and 5% rhodium on carbon (40% w/w, 1.7 g) was added. The solution was agitated under an atmosphere of hydrogen at 5 bar for 48 hours. The reaction vessel was flushed free of hydrogen using inert gas and the solution was filtered through celite. The filtrate was concentrated under reduced pressure. The residue was suspended in ethanol and cooled to 0 °C. Aqueous hydrochloric acid (5.0 M) and ethanol (50 ml, 1:1) was added and the mixture was stirred for 30 minutes. A white precipitate was filtered off to afford the title compound (3.16 g) as the hydrochloride salt.
Method #16
Ethyl (S)-5-( D -aminophenethyl)- 1 ,3 ,4-oxadiazole-2-carboxylate trifluoroacetate
Figure imgf000097_0001
Ethyl (S)-5-[D-[(tert-butoxycarbonylamino)phenethyl]-l,3,4-oxadiazole-2- carboxylate, (Borg et al. J. Org. Chem. 1995, 60, 3112; 350mg) was dissolved in trifluoroacetic acid (5ml. ) and allowed to stand at ambient temperature for 1 hour. The reaction mixture was concentrated and dried under vacuum to give a glassy solid (322mg) NMR 1.75(3H,t); 3.2-3.4(2H,m); 4.4(2H,q); 5.2(lH,t); 7.1-7.4(5H,m); 8.8-9.2(3H,bs) Method #17
2,3-Dichloro-5-(N-[(2-phenyl-l,3-dioxolan-2-yl)methyl1carbamoyl}-4H-thieno[3,2-Z7lpyrrole
Figure imgf000098_0001
2-Phenyl-l,3-dioxolan-2-ylmethylamine hydrochloride (65 mg, 0.3 mmol) and 5- carboxy-2,3-dichloro-4H-thieno[3,2-b]pyrrole (Method #9; 71 mg, 0.3 mmol) were dissolved in DCM (10 ml) containing DIPEA (175 ml, 1.0 mmol) and ΗOBT (40 mg, 0.3 mmol). The mixture was stirred for one minute before the addition of EDAC (75 mg, 0.39 mmol). The solution was stirred at room temperature for approximately 18 hours. The mixture was concentrated and chromatographed on a Bond Elut column eluting with 20% - 40% EtOAc in isohexane. The title compound was isolated as a white solid (100 mg). ΝMR: 12.4 (1Η, s), 8.2 (1Η, s), 7.2 (1Η, s), 4.0 (2Η, m), 3.7 (2H, m), 3.6 (2H, d); m/z 395.2.
Method #18
(S)-5-(D-Aminophenethyl)-3-phenyl-l,2,4-oxadiazole trifluoroacetate
Figure imgf000098_0002
BOC-Phenylalanine (614mg, 2.32mmol) was dissolved in DCM (20ml) cooled with ice/water and dicyclohexyl carbodiimide (239mg, l.lόmmol) added. After stirring at 0-5°C for 1 hour the reaction mixture was filtered and concentrated in vacuo. Phenylamidoxime
(104mg,0.77mmol) and pyridine (10ml) were added and the mixture heated to reflux for 2 hours. The reaction mixture was then evaporated to small volume, dissolved in ethyl acetate, washed with dilute citric acid, saturated sodium bicarbonate, water and brine, dried with magnesium sulphate and evaporated to give a crude product which was purified by chromatography on silica gel (eluted with Hexane/ ethyl acetate 4:1) to (S)-5-[D-(tert- butoxycarbonylamino)phenethyl] -3 -phenyl- 1 ,2,4-oxadiazole (274mg). NMR 1.2-1.4 (9H,s), 3.1-3.3 (2H,m); 5.1-5.2(lH,m); 7.2-7.3(5H,m); 7.5-7.6(3H,m); 7.8(lH,d); 7.95-8.05(2H,m); m/z 364
(S)-5-[D-(tert-Butoxycarbonylamino)phenethyl]-3-phenyl-l,2,4-oxadiazole (274mg) was dissolved in trifluoroacetic acid (5ml) and stirred at ambient temperature for 2 hours. After evaporation and drying under vacuum the title compound was obtained as a pale yellow solid (232mg). NMR 3.2-3.5(2H,m); 5.15(lH,t); 7.1-7.3(5H,m); 7.4-7.6(3H,m); 7.9(2H,d); 9.0(3H,s); m/z 266
Method #19
3-( lH-Tetrazol-5-yl)propylamine
Figure imgf000099_0001
4-{[(Phenylacetyl)oxy]amino}butanamide (J Biol. Chem., 1971, 246, 6683) (16 g) was dissolved in dry pyridine (150 ml) and the solution was cooled to -10°C. A solution of POCl3 (8.1 ml) in DCM (16.5 ml) was added dropwise over 30 minutes. The mixture was stirred at ambient temperature for 1 hour before being diluted with water until the pΗ reached 5. The solution was extracted using EtOAc. The combined organic layers were washed with dilute aqueous hydrochloric acid and water before being dried, filtered and concentrated. The resulting solid (9.2 g, 42.8 mmol) was dissolved in dry DMF (30 ml) and the solution was heated on a steam bath for 2 hours. Ammonium chloride (2.22 g, 41.5 mmol) was added to the hot solution along with sodium azide (2.68 g, 56.3 mmol). The mixture was cooled and left to stir for over 48 hours. The solution was filtered and basified to pΗ 8 using aqueous potassium bicarbonate. The aqueous layer was washed using EtOAc before being acidified using dilute aqueous hydrochloric acid. A white solid was filtered off. This solid (3.0 g, 11.5 mmol) was dissolved in acetic acid (50 ml) and water 5 ml. Palladium on charcoal (5%, 400 mg) was added and the solution was shaken under an atmosphere of hydrogen for 6.5 hours. The suspension was filtered and washed with acetic acid. The filtrate was concentrated and dried. The residue was treated with iso-propanol and the title compound was filtered off as a white solid (1.37 g, 94%). Method #20
2-Amino-N-(2-hvdroxy-3-phenoxypropyl)acetamide
Figure imgf000100_0001
N-Benzyloxycarbonylglycine (2.09 g) was dissolved in toluene (40 ml) and DMF (5 drops). Oxalyl chloride (1.3 ml) was added and the mixture was stirred at ambient temperature for 2 hours. The solution was diluted with diethyl ether (25 ml) and was added dropwise to a solution of l-amino-3-phenoxy-2-propanol (1.67 g) in diethyl ether (25 ml). Sodium hydroxide (0.4 g) was dissolved in water (1.5 ml) and was added to the mixture. The solution was stirred for greater than 48 hours before being filtered. The sticky solid isolated was added to saturated aqueous sodium bicarbonate (100 ml) and was stirred for 15 minutes before being filtered. The solid was recrystallized from an EtOAc/petrol mixture. This resulting compound (650 mg) was dissolved in MeOH (10 ml) and palladium on charcoal (5%, 50 mg) was added along with acetic acid (1 ml). The solution was stirred under an atmosphere of hydrogen for 4 hours before being filtered. The filtrate was concentrated to afford an oily residue. The residue was recrystallized from EtOH/diethyl ether mixture to afford the title compound (200 mg).
Method #21
2-Amino-N-(3-methylisothiazol-5-yl)acetamide
Figure imgf000100_0002
N-t-Butoxycarboylglycine (1.92 g, 1.1 mmol) was dissolved in dry EtOAc (20 ml) and the solution was cooled to -25°C. N-Methyl morpholine (1.1 g, 1.1 mmol) was added and the mixture was stirred for 2 minutes before the addition of ethyl chloroformate (1.08 g, 1.0 mmol). A white solid precipitated from solution. A suspension of 5-amino-3- methylisothiazole hydrochloride (1.5 g, 1.0 mmol) was added in triethylamine (1.01 g, 1.0 mmol) and dry EtOAc (10 ml). The mixture was stirred at ambient temperature for 17 hours before being filtered. The filtrate was concentrated and the residue was purified by flash column chromatography, using diethyl ether as eluent. The residue (271 mg, 0.1 mmol) was dissolved in EtOAc (3 ml). Ethanolic HCl (1 ml) was added and the mixture was stirred at ambient temperature for 2.5 hours. The title compound precipitated as a white solid and was isolated by filtration (220 mg, 92%).
Method #22
2-(Pyridazin-3-yloxy)ethylamine
Figure imgf000101_0001
Ethanolamine (6.0 ml) was suspended in dry xylene (100 ml) and the mixture was stirred at ambient temperature with sodium hydride (3 g). After 20 minutes the solution was cooled to 0°C. 3,6-Dichloropyridazine (15.0 g) was added. The solution was warmed to ambient temperature and was stirred for 15 hours before being extracted with chloroform. The chloroform was concentrated and the residue was taken up in EtOAc before being filtered. Ethanolic HCl was added and a white solid was filtered off. This compound (550 mg) was dissolved in MeOH (130 ml) and palladium on charcoal (5%, 200 mg) was added. The suspension was stirred under an atmosphere of hydrogen for 6 hours before being filtered. The filtrate was concentrated and the residue was triturated using diethyl ether. The title compound was isolated as a white solid (340 mg).
Method #23 1 -(2- Aminoethyl)imidazolidine-2 ,4-dione
Figure imgf000101_0002
Ethylene diamine (30 ml) was dissolved in DCM (130 ml) with di-t-Zmtyl dicarbonate (13.5 g). The mixture was stirred at ambient temperature for 30 minutes before the solvent was decanted off. The residue was washed with water and dried. The product (6.1 g) was dissolved in ethanol (15 ml). Chloroacetic acid (5.77 g) solution in aqueous sodium hydroxide (1 M, 61 ml) was added dropwise, followed by more aqueous sodium hydroxide (1 M, 31 ml). The mixture was stirred for 17 hours before being washed with diethyl ether. Benzyl chloroformate (5 g) was added to the aqueous phase and the mixture was stirred at ambient temperature for 4 hours. The solution was washed with diethyl ether and the aqueous layer was acidified using aqueous citric acid (30%). The solution was extracted using EtOAc. The combined organic layers were washed with brine, then water before being dried, filtered and concentrated. The residue was triturated using diethyl ether/petrol mixture and the required intermediate was isolated as a white solid. Following repeated procedure on a larger scale, this solid (28 g) was dissolved in ethanol (250 ml) containing palladium on charcoal (10%, 4.6 g). The suspension was stirred under an atmosphere of hydrogen until the reaction was complete. The mixture was filtered and the filtrate was concentrated. The residue (3 g, was treated with potassium cyanate (1.3 g) in water (30 ml) and the mixture was heated under reflux for 2 hours. An excess of concentrated hydrochloric acid was added and the mixture was heated for a short time before being concentrated. The residue was taken up in water (50 ml) and was loaded onto basic Amberlite® IRA resin. The resin was washed with water until the eluent was found to be neutral. Dilute aqueous hydrochloric acid was used to elute the crude product from the resin. The acidic fractions were concentrated and the residue was triturated with ethanol. The title compound was isolated as orange crystals (950 mg).
Method #24 N-(4-Aminobutyryl)methanesulphonamide
Figure imgf000102_0001
4-Phthalimidobutyryl chloride (J Am. Chem. Soc, 1981, 103, 6750) (1.27 g) was heated with methane sulphonamide (480 mg) at 100°C for 15 min under argon. The mixture was cooled and left to stand for 17 hours. The residue was triturated with ethanol to afford the required intermediate. The solid (4 g) was treated with potassium hydroxide (75 g) in water (100 ml) at ambient temperature for 2 hours. Concentrated hydrochloric acid was added until the pH of the solution reached 9. The solution was extracted using EtOAc. The combined organic layers were concentrated and the residue was triturated using diethyl ether/petrol mixture and filtered. The residue (5.7 g) was taken up in water (150 ml) and dilute hydrochloric acid (1 M) was added until the pH reached 1. The mixture was heated on a steam bath for 1 hour before being cooled and extracted using EtOAc. The aqueous phase was concentrated and the residue was triturated using EtOAc/ethanol mixture to afford the title compound (1.5 g). Method #25
2- [3 -(2- Aminoethoxy)phenyl] acetamide
Figure imgf000103_0001
3-Hydroxyphenylacetic acid (30.4 ml) was dissolved in MeOH (160 ml). Concentrated sulphuric acid (1.6 ml) was added and the mixture was heated under reflux for 6 hours. The mixture was concentrated to low bulk before the addition of toluene (120 ml). The mixture was washed with water, saturated aqueous sodium bicarbonate and brine. The combined organic layers were reduced in volume by one half before being stirred with ammonia solution (180 ml) for 16 hours. The mixture was concentrated and filtered. The solid was washed with water and was dried. The residue (24 g) was dissolved in MeOH (400 ml) with 1,2- dibromoethane (20 ml) and sodium hydroxide (6 g). The solution was heated under reflux for 36 hours before being concentrated. The residue was partitioned between water and EtOAc The organic phase was separated and concentrated. This residue was purified by medium pressure liquid chromatography, using 5% MeOH in DCM as eluent. The purified intermediate (7.5 g) was dissolved in ethanol (300 ml) with ammonia solution (500 ml). The reaction vessel was sealed and the mixture was stirred at ambient temperature for 6 hours before being allowed to stand for 2.5 days. The solution was concentrated and the residue was purified using medium pressure liquid chromatography, using 25% MeOH in DCM as eluent, to afford the title compound (4.1 g).
Method #26
(trans)-4- Amino-5-hydroxy- 1 ,3 ,4,5-tetrahydro-2H- 1 -benzazepin-2-one
Figure imgf000103_0002
Anhydrous toluene (33 ml) and ethanol (2.2 ml) were heated with potassium (0.3 g) until all the metal has dissolved. 3,4-Dihydro-lH-l-benzazepine-2,5-dione (J. Org. Chem., 1972, 37, 208) (11.6 g) was added and the mixture was heated under reflux for 2 minutes before being cooled to ambient temperature. Butyl nitrite (1.7 ml) was added and the mixture was stirred for 4 hours before being left to stand for 3 days. The solvent was decanted and the residue was passed down a Fluorisil® column, using 5% MeOH in chloroform as eluent. The product (1.0 g) was dissolved in water (40 ml) and MeOH (14 ml) containing palladium on charcoal (5%, 500 mg). The mixture was stirred under an atmosphere of hydrogen for 1 hour. The mixture was filtered and the filtrate was concentrated. The residue was recrystallized using ethanol to afford the title compound.
Method #27 (2/.,5S)- 2-Aminomethyl-5-( 1 ,3-benzodioxol-5-yl)- 4-methylmorpholine
Figure imgf000104_0001
A solution of l-(l,3-benzodioxol-5-yl)-2-(methylamino)ethanol (Synthesis, 1979, 423) (28.65 g) and oxirane-2-carboxamide (Bull. Chem. Soc. Jpn., 1989, 62, 3202) (14.0 g) in ethanol (500 ml) was heated under reflux for 1.5 hours. The solution was concentrated and the residue was triturated using diethyl ether. A white powder was filtered off. This product (3.0 g) was added portionwise to trifluoroacetic acid (30 ml) at ambient temperature. The solution was stirred for 45 minutes before being concentrated. The residue was basified using saturated aqueous sodium bicarbonate. The mixture was filtered and the filtrate was concentrated. The residual oil was purified by flash column chromatography, using a gradient of MeOH in EtOAc as eluent, to afford both cis- and trans- isomers of the required intermediate. The trans- isomer (1.6 g) was dissolved in dry diethyl ether (180 ml). The solution was heated under reflux using Soxhlet equipment with lithium aluminium hydride (2.0 g) for 16 hours. The solution was cooled and water (2 ml) was added with sodium hydroxide solution (3 M, 2 ml), followed by more water (6 ml). The metal residues were removed by filtration and the filtrate was extracted using DCM. The combined organic layers were dried, filtered and concentrated. The residue was triturated using ethanol to afford the title compound as a white solid.
Method #28 N-Methyl-N-phenyl-2-(tert-butoχvcarbonylamino)acetamide
Figure imgf000105_0001
By a similar procedure to Method #5 the title compound was prepared using N-methylaniline to give a pale orange oil (771mg, 58%); ΝMR: (CDC13): 7.4 (3H, m), 7.1(2H, m), 5.3(1H, br), 3.6(2H, br), 3.2(3H, s), 1.4(9H, s); m/z 265.42
Method #29
N-Benzyl-N-phenyl-2-ftert-butoxycarbonylamino)acetamide
Figure imgf000105_0002
By a similar procedure to Method #5 the title compound was prepared using N- benzylmethylamine to give a yellow oil (670mg, 48%); ΝMR: (CDC13): 7.2 (5H, m),
5.5(1H, br), 4.6 (1.33H, s), 4.4(0.67H, s), 3.9(2H, br), 2.9(1H, s), 2.8(2H, s), 1.4(9H, s); m/z 279.50
Method #30 2-Amino-N-methyl-N-phenylacetamide
Figure imgf000105_0003
By a similar procedure to Method #6 using N-methyl-N-phenyl-2-(tert- butoxycarbonylamino)acetamide (Method #28) the title compound was prepared to give the title compound as a clear oil (231mg, 56%); ΝMR: (CDC13): 7.3(3H, m), 7.1(2H, d), 3.2(3H, s), (2H, br); m/z 165.17
Method #31
2-Amino-N-methyl-N-benzylacetamide
Figure imgf000105_0004
By a similar procedure to Method #6 using N-benzyl-N-phenyl-2-(tert- butoxycarbonylamino)acetamide (Method #29) the title compound was prepared to give the title compound as a clear oil (256mg, 73%); ΝMR: (CDC13): 7.3(5H, m), 4.6(1.33H, s), 4.4(0.67H, s), 3.4(2H, br), 2.95(1.33H, s), 2.8(2.34H, s), (1.33H, s); m/z 179.23
Method #32
Methyl (S)-5-( D -aminophenethyl)oxazole-4-carboxylate trifluoroacetate
Figure imgf000106_0001
Methyl (S)-5-[ D -(tert-butoxycarbonylamino)phenethyl]-oxazole-4-carboxylate, (Tett. Lett., 1982, 23, 235; 417mg) was dissolved in trifluoroacetic acid (3ml) and stood at ambient temperature for 1 hour and concentrated to give an oil. Trituration with diethyl ether gave the title compound as a white solid. (281mg); ΝMR 3.1-3.25(lH,m); 3.3-3.4(lH,m); 3.7(3H,s); 5.2-5.3(lH,m); 7.05(2H,d); 7.2-7.3(3H,m); 8.7(lH,s); 8.75-8.85(3H,bs)
Method #33
3-Aminomethyl-4-phenylisoxazole
Figure imgf000106_0002
4-Phenylisoxazole-3-carboxylic acid ethyl ester (JOC 50 13 2372 1983; 404mg, 1.86mmol) dissolved in THF 10ml under nitrogen was treated with 2M lithium borohydride in THF (1.86ml, 3.72mmol). The resultant mixture was stirred at 0C for 5hours, then allowed to warm to room temperature overnight. 1M acetic acid was added dropwise till effervesence ceased, a further 20 ml of water was added and the resultant solution extracted with ethyl acetate (3x20 ml), the organic extracts were washed with saturated sodium bicarbonate solution (10ml) and saturated brine (10ml), dried with anhydrous magnesium sulphate and evaporated to dryness under reduced pressure to give 3-hydroxymethyl-4-phenylisoxazole (295mg); NMR (CDC13) : 4.9(2H,d), 7.3-7.5(5H,m), 8.5(lH,s) m/z 176 (M+H)
3-Hydroxymethyl-4-phenylisoxazole (295mg,1.68mmol) was dissolved in THF 5ml under nitrogen together with phthalimide (292mg, 1.68mmol) and triphenylphosphine (440mg, 1.68mmol), the resultant stirred solution was cooled to OC and treated with DIAD (330ul,1.68mmol) dropwise over 30 mins, then allowed to warm to room temperature overnight. After evaporation to dryness the mixture was purified by chromatography on a 20g Bond Elute silica column eluting with 1 : 1 DCM:hexane to give 4-phenyl-3- phthalimidomethylisoxazole (316mg): m/z 305 (M+H). This was dissolved in methanol 3ml, treated with hydrazine hydrate (114ul, 2.4mmol) and refluxed for 30 mins. The resultant suspension was filtered, the solid washed with ethanol (2x5ml) and the filtrate then evaporated to dryness, this residue was taken up in 2N HCl and any insoluble material again removed by filtration. The filtrate was basified with saturated sodium bicarbonate and extracted with ethyl acetate (3x10ml), the combined organic extracts were washed with water (5ml) and saturated brine (5ml), then dried over magnesium sulphate and evaporated under reduced pressure to give 3-aminomethyl-4-phenylisoxazole (130mg); NMR (CDC13) : 4.1(2H,s), 7.3-7.5(5H,m), 8.4(lH,s); m/z 175 (M+H)
Method #34
2-[2-(2-morpholinoethoxy)phenynethylamine
Figure imgf000107_0001
2-(2-Hydroxyphenyl)ethylamine (1.73g, lOmmol) dissolved in DCM 60ml was treated with a solution of sodium bicarbonate (1.68g, 20mmol) in water, the emulsion was stirred vigorously in an ice bath and benzyl chloroformate (1.785g, 10.5mmol) was added dropwise over 10 mins and the mixture was stirred overnght at room temperature. The DCM phase was removed and the aqueous phase extracted with DCM (2x20ml). The combined organics were then dried over magnesium sulphate and evaporated under reduced pressure, the product was purified by chromatography on 20g silica bond elute, eluting with DCM to give N-(benzyloxycarbonyl)-2-(2-hydroxyphenyl)ethylamine (1.4g); ΝMR (CDC13) : 2.8(2H,q), 3.4(2H,q), 5.1(3H,m), 6.4(lH,s), 6.8(2H,m), 7.1(2H,m), 7.3-7.4(5H,m)
N-(Benzyloxycarbonyl)-2-(2-hydroxyphenyl)ethylamine (542mg, 2mmol) dissolved in DMF 5ml was treated with potassium carbonate (325 mesh, 350mg, 2.5mmol) and 2- chloroethyl p-toluenesulphonate (484ul,2.6mmol) and the mixture was stirred at 60C overnight. After cooling, water 10ml was added and the mixture extracted with diethyl ether (3x20ml) dried over magnesium sulphate and evaporated under reduced pressure, the product was purified by chromatography on 20g silica bond elute, eluting with DCM to give N- (benzyloxycarbonyl)-2-[2-(2-chloroethoxy)phenyl]ethylamine(450mg); ΝMR (CDC13) : 2.9(2H,q), 3.5(2H,m), 3.8(2H,m), 4.2(2H,m), 4.9(lH,b), 5.1(2H,s), 6.8(lH,d), 6.9(lH,t), 7.1(2H,m), 7.3-7.4(5H,m) HPLC Hichrome C18 column Acetonitrile/water/0.1%TFA 5-95% over 7.5 min Rt 4.98min
N-(Benzyloxycarbonyl)-2-[2-(2-chloroethoxy)phenyl]ethylamine (HOmg, 0.33mmol) dissolved in ΝMP 3ml was heated with morpholine (174ul, 2mmol) at 80C overnight. Water (5ml) was added and the mixture extracted with ethyl acetate (30ml), the organic phase was washed with water (2x5ml) dried over magnesium sulphate and evaporated under reduced pressure to give N-(benzyloxycarbonyl)-2-[2-(2-morpholinoethoxy)phenyl]ethylamine (143mg); ΝMR (CDC13) : 2.5(4H,q), 2.8(4H,m), 3.4(2H,q), 3.7(4H,q), 4.1(2H,t), 5.0(2H,s), 5.3(lH,b), 6.8(2H,m), 7.1(lH,d), 7.2(lH,t), 7.3-7.4(5H,m) HPLC Hichrome C18 column Acetonitrile/water/0.1%TFA 5-95% over 7.5 min Rt 3.73min m/z 385 (M+H)
N-(Benzyloxycarbonyl)-2-[2-(2-morpholinoethoxy)phenyl]ethylamine (143mg) dissolved in methanol was treated with 10% palladium on carbon and hydrogenated for 2 hours. The solid was removed by filtration, washed with methanol (2x2ml), the filtrate evaporated under reduced pressure and azeotroped twice with toluene to give the title compound (83mg) m/z 251 (M+H), which was used directly in the next step. Method #35
Methyl 2-[2-(2-aminoethyl)phenoxy]acetate
Figure imgf000109_0001
N-(Benzyloxycarbonyl)-2-(2-hydroxyphenyl)ethylamine (see Method #34: 718mg,
2.65mmol) dissolved in DMF 6ml was treated with potassium carbonate (-325 mesh, 397mg, 4.0mmol) methyl bromoacetate (362ul, 3.7mmol) and the mixture was stirred overnight at room temperature. After cooling, water 10ml was added and the mixture extracted with diethyl ether (3x20ml) dried over magnesium sulphate and evaporated under reduced pressure to give methyl 2- {2-[2-(benzyloxycarbonyl(amino)ethyl)]phenoxy} acetate (847mg); ΝMR (CDC13) : 2.8(2H,q), 3.5(2H,m), 3.8(3H,s), 4.6(2H,s), 5.1(3H,m), 6.7(lH,d), 6.9(lH,t), 7.1- 7.4(7H,m)
Methyl 2-{2-[2-(benzyloxycarbonylamino)ethyl]phenoxy}acetate (343mg, Immol) dissolved in methanol together with p-toluenesulphonic acid (190mg, Immol) was treated with 10% palladium on carbon and hydrogenated for 2 hours. The solid was removed by filtration, washed with methanol (2x2ml), the filtrate evaporated under reduced pressure and azeotroped twice with toluene to give methyl 2-[2-(2-aminoethyl)phenoxy]acetate_(403mg), m/z 210 (M+H) which was used without further purification.
Method #36
2- Aminoindan- 1 -ol
Figure imgf000109_0002
Isoamyl nitrite (15 ml, 108 mmol) was added to a solution of indan-l,2-dione (12 g, 90 mmol) in methanol (380 ml) at 45°C followed by concentrated HCl (12 ml) dropwise over 5 minutes. The reaction mixture was stirred for 3 hours at room temperature. Excess isoamyl nitrite (1 ml) and concentrated HCl (1 ml) was added and the suspension stirred for a further 15 minutes. On cooling to room temperature a white precipitate formed. The precipitate was filtered off and washed with cold methanol (40 ml) followed by diethyl ether (40 ml) to afford indan-l,2-dione-2-oxime as a white solid (6.2 g, 43%). NMR: 3.8(2H,s), 7.4(lH,t), 7.6(lH,d), 7.7(2H,t); m/z 162 (M+H)
A solution of indan-l,2-dione-2-oxime (6.2 g, 39 mmol) in ethanol (470 ml) and 4MHCl/Dioxane (36 ml) was hydrogenated at room temperature and 40 psi. The reaction mixture was filtered through celite, washed with ethanol (30 ml) and concentrated under reduced pressure to give 10 g of an off-white solid which was recrystallised from ethanol to give the title compound as a white solid (5 g, 86%). NMR: 2.8(lH,dd), 3.2(lH,dd), 3.7(lH,q), 5.1(lH,t), 6.0(lH,d), 7.1-7.3(4H,m), 8.6(2H,s)
Method #37 2-Amino-N-methyl-N-( 1 -oxo- 1 ,2,3 ,4-tetrahydronaphth-2-yl)methylacetamide
Figure imgf000110_0001
Tetralone (1 eq, 100 mmol, 15 g) and methylamine hydrochloride (2.5 eq, 250 mmol, 15 g) and paraformaldehyde (1 eq, 100 mmol, 3 g) in ethanol (100 ml) were heated under reflux for 16 hours. The reaction mixture was cooled and filtered to afford 2- (methylaminomethyl)-3,4,dihydro-l-(2H)-naphthalenone as a solid (14 g).
2-(Methylaminomethyl)-3,4,dihydro-l-(2H)-naphthalenone (1 eq, 20 mmol, 4.5 g), ΗOBT (1 eq, 20 mmol, 2.7 g), N-benzyloxycarbonylglycine (1 eq, 20 mmol, 4.18 g), triethylamine (1.25 eq, 25 mmol, 3 ml) and dicyclohexylcarbodi-imide (1 eq, 20 mmol, 4.12 g) were dissolved in dichloromethane (130 ml) and were stirred at ambient temperature for 18 hours before being cooled to 0 °C and filtered. The filtrate was concentrated and the residue was taken up in ethyl acetate before being washed with aqueous sodium bicarbonate, dried, filtered and concentrated. The residue was left to stand in a solution of hydrogen bromide in acetic acid for 30 minutes. The mixture was triturated with diethyl ether and the solvent was decanted off. The residue was treated with ammonia solution and this was extracted with chloroform. The chloroform was concentrated and the residue was recrystallised from ethanol to afford the title compound.
Method #38
2- Amino-6-fluoro- 1 -indanol
Figure imgf000111_0001
To a solution of sodium carbonate (0.8 g, 7.2 mmol) in water (13 ml) was added 4- fluorophenylalanine (1.3 g, 7.2 mmol) followed by a solution of N- ethoxycarbonylphthalamide (1.6 g, 7.2 mmol) in ethyl acetate (10 ml). The two-phase reaction mixture was stirred for 24 hours at room temperature. The organic phase was separated and discarded and the aqueous phase was acidified with concentrated HCl to pH 2. The aqueous phase was then extracted with ethyl acetate (3 x 20 ml) and the combined extracts dried over magnesium sulphate then concentrated under reduced pressure to give 3- (4-fluorophenyl)-2-phthalimidopropanoic acid as a white solid (2g, 89%); ΝMR 3.3(lH,dd), 3.5(lH,dd), 5.1(lH,dd), 6.3(lH,brs), 7.0(2H,t), 7.1(2H,dd), 7.8(4H,s).
To a solution of 3-(4-fluorophenyl)-2-phthalimidopropanoic acid (2.0 g, 6.4 mmol) in DCM (20 ml) was added thionylchloride (0.6 ml, 6.4 mmol) and 1 drop of DMF. The reaction mixture was stirred at room temperature for 1 hour. Aluminium chloride (2.6 g, 19.2 mmol) was added and the reaction mixture stirred for 3 hours at room temperature. The resulting mixture was poured into ice and concentrated HCl (20 ml) and stirred for 10 minutes. This mixture was extracted with DCM (3 x 20 ml) and the combined organic extracts were washed with water (2 x 20 ml), saturated sodium hydrogen carbonate (1 x 20 ml) and water (1 x 20 ml). The organic phase was then dried over magnesium sulphate and concentrated under reduced pressure to give 6-fluoro-2-phthalamido-indan-l-one as a white solid (lg, 53%). ΝMR 3.3(lH,dd), 3.5(lH,dd), 5.1(lH,dd), 6.8(lH,t), 7.0(lH,dd), 7.7- 8.0(5H,m); m/z 296 (M+H)
Sodium borohydride (512 mg, 14 mmol) was added to a solution 6-fluoro-2- phthalamido-indan-1-one (800 mg, 2.7 mmol) in isopropanol/water (6: 1, 10.5 ml) and the - I ll - solution stirred at room temperature for 24 hours. Excess acetic acid was then added to the reaction mixture and the resulting solution heated at 60°C for 6 hours. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure to give a white solid which was purified by ion-exchange chromatography using Dowex 50wx2 (wateπmefhanol 1:1 containing 3% ammonia) to give the title compound as a white solid (141 mg, 31 %); NMR 3.3(lH,dd), 3.5(lH,dd), 4.8(lH,m), 4.9(lH,d), 6.8-7.4(3H,m); m/Z 168 (M+H)
Method #39
2- Amino- 1 ,2,3 ,4-tetrahydronaphth- 1 -ol
Figure imgf000112_0001
To a solution of sodium carbonate (0.8 g, 7.2 mmol) in water (13 ml) was added homophenylalanine (1.3 g, 7.2 mmol) followed by a solution of N-ethoxycarbonylphthalamide (1.6 g, 7.2 mmol) in ethyl acetate (10 ml). The two-phase reaction mixture was stirred for 24 hours at room temperature. The organic phase was separated and discarded and the aqueous phase was acidified with concentrated HCl to pH 2. The aqueous phase was then extracted with ethyl acetate (3 x 20 ml) and the combined extracts dried over magnesium sulphate then concentrated under reduced pressure to give 4-phenyl-2-phthalimidobutanoic acid as a white solid (1.5 g, 67%); m/z 308 (M-H).
To a solution of 4-phenyl-2-phthalimidobutanoic acid (1.5 g, 4.9 mmol) in DCM (20 ml) was added thionylchloride (0.4 ml, 4.9 mmol) and 1 drop of DMF. The reaction mixture was stirred at room temperature for 1 hour. Aluminium chloride (2.0 g, 14.7 mmol) was added and the reaction mixture stirred for 3 hours at room temperature. The resulting mixture was poured into ice and concentrated HCl (20 ml) and stirred for 10 minutes. This mixture was extracted with DCM (3 x 20 ml) and the combined organic extracts were washed with water (2 x 20 ml), saturated sodium hydrogen carbonate (1 x 20 ml) and water (1 x 20 ml). The organic phase was then dried over magnesium sulphate and concentrated under reduced pressure to give 2-phthalamido-3,4-dihydro-(2H)-naphthalen-l-one as a white solid (880 mg, 62%). NMR 2.3(lH,m), 2.7(lH,m), 3.1(lH,dt), 3.3(lH,m), 5.2(lH,dd), 7.3-8.0(8H,m); m/z 292 (M+H)
To a solution of 2-phthalamido-3,4-dihydro-(2H)-naphthalen-l-one (880 mg, 3 mmol) in isopropanol/water (6:1, 11.5 ml) was added sodium borohydride (567 mg, 15 mmol) and the solution stirred at room temperature for 24 hours. Excess acetic acid was then added to the reaction mixture and the resulting solution heated at 60°C for 6 hours. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure to give a white solid which was purified by ion-exchange chromatography using Dowex 50wx2 (water.methanol 1:1 containing 3% ammonia) to give the title compound as a white solid (150 mg, 30 %). NMR 2.8(lΗ,dd), 3.0(lH,dd), 3.3(lH,m), 3.5(lH,m), 4.5(lH,m), 4.8(lH,d), 7.1- 7.4(4H,m); m/z 164 (M+H)
Method #40 (+/-) T'rαrø-2-Amino- 1 -methoxyindan
Figure imgf000113_0001
A solution of (+/-) trα7M-2-bromo~l-hydroxyindan (21.0g, O.lmol) and potassium phthalimide (42.0g, 0.22 mol ) in dry DMF (120ml) was heated at 100°C for 5 hours. The reaction mixture was cooled and evaporated to an oil which was triturated with ethyl acetate and filtered. The filtrates were evaporated and purified by chromatography on silica with 2: 1 iso- hexane:ethyl acetate as eluent to give (+l-)-trans -l-hydroxy-2-phthalimido indan as a pale yellow amorphous powder (17.7g, 63%). NMR 2.8QH, dd), 3.15(lHdd), 4.8-5.0(lH, m), 5.4(1H, d), 5.45(1H, d), 7.0-7.3(4H, m), 7.75-8.95(4H, m).
To a solution of (+/-) trαrø-l-hydroxy-2-phthalimidoindan (1.4g, 5.0mmol) in dry tetrahydrofuran (20ml) was added 60% sodium hydride (300mg, 7.5mmol). The mixture was stirred at room temperature for 2 hours and then methyl iodide (0.62ml, lO.Ommol) added. The mixture was stirred for a further 2 hours and then 5% water in tetrahydrofuran (10ml) and ethyl acetate (75ml) added. The solution was washed with water, dried over magnesium sulphate and evaporated to give (+/-)-trαrø-l-methoxy-2-phthalimidoindan as a white solid (1.2g, 82%). NMR 2.85(1H, dd), 3.25(3H, s), 3.5(1H, dd), 4.5-4.65(lH, m), 5.55(1H, d), 7.05-7.3(4H, m), 7.85(4H, s).
A mixture of (+/-)~trατ7s-l-methoxy-2-phthalimidoindan (850mg, 2.9mmol) and hydrazine hydrate (5ml) in ethanol was stirred at room temperature for 24 hours. The mixture was evaporated and purified by ion exchange chromatography (Dowex 50W X2 H+ form) and the title compound eluted with 50% aqueous methanol containing 3% ammonium hydroxide to give the title compound a pale yellow solid (400mg, 85%). NMR 2.8(1H, dd), 3.35(3H, s), 3.38(1H, dd),4.05-4.15(lH, m), 4.5-4.6(lH, m), 7.2-7.35(3H, m), 7.45-7.55(lH, m); m/z 164 (M+H).
Method #41
(1R.2S)- !-[(!, l-dimethylethoxy)carbonylamino1-2 hydroxyindan
Figure imgf000114_0001
(l/-Λ2S)-l-Amino-2-hydroxyindan (lO.Og, 67. Immol) was dissolved in dichloromethane (550ml) and triethylamine (18.7ml, 134.2mmol). Di-tert-butyl dicarbonate (18.3g, 83,9mmol) in dichloromethane (50ml) was added and the mixture stined at room temperature for 20 hours then evaporated. Ethyl acetate (200ml) was added, the solution washed with water, dried over magnesium sulphate and evaporated. The crade product was purified by chromatography on silica with 4: 1 wø-hexane: ethyl acetate as eluent to give the title compound as a white solid (16.1g, 96%); NMR 1.42(9H, s), 2.78(1H, dd), 3.0(1H, dd), 4.3-4.42(lH, m), 4.78-4.9(lH, m), 4.9-5.0(lH, m), 6.3(1H, d), 7.0-7.25(4H, m).
Method #42
( li?, 2i?)-2-Amino- 1 -methanesulphonamidoindan
Figure imgf000115_0001
(li?,2S)-l-Amino-2-hydroxyindan (3.0g, 20mmol) was dissolved in dry tetrahydrofuran (40ml) and triethylamine (8.4ml, 60.0mmol) at 10°C. Methane sulphonyl chloride (5.0g, 44.0mmol) dissolved in tetrahydrofuran (10ml) was added at such a rate that the internal temperature remained below 15°C. Following the addition the mixture was stirred at room temperature for 20hours and then evaporated. To the residue was added ethyl acetate (100ml) and the mixture washed with saturated aqueous sodium bicarbonate and then water. The organic solution was dried over magnesium sulphate and evaporated to give (1R,2S)-1- methanesulphonamido-2-methylsulphonyloxyindan as a pale yellow solid (5.7g, 93%). NMR: 3.0-3.35(2H, m), 3.1(3H, s), 3.25(3H, s), 5.05-5.2QH, m), 5.3-5.4(1H, m), 7.2-7.4(4H, m), 7.85-8.0QH, m). m/z 304.2 (M-H).
(li?,2S)-l-Methanesulphonamido-2-methylsulphonyloxyindan (2.0g, 6.56mmol) was dissolved in dry dimethyl acetamide (20ml). Sodium azide (1.7g, 26.2mmol) was added and the mixture heated to 90°C for 1 hour. The reaction was cooled, diluted with ethyl acetate (100ml), washed with water (6 x 50ml), dried over magnesium sulphate and filtered. 10% Palladium on activated carbon was added and the mixture stined under a hydrogen atmosphere for 3 hours. Filtration through celite followed by evaporation gave the title compound as a pale green solid (1.25g, 83%). NMR (CDC13): 1.68(2H, broad s), 2.67(1H, dd), 3.2(3H, s), 3.23(1H, dd), 4.5-4.6(lH, m), 4.6-4.8(lH, m), 7.15-7.35(4H, m); m/z 227.4 (M+H).
Method #43 ( li?, 2i?)-2- Amino- !-[(!,! -dimethylethoxylcarbonylaminolindan
Figure imgf000116_0001
(li?,2S)-l-[(l,l-Dimethylethoxy)carbonylamino]-2-hydroxyindan (Method #41, 7.5g, 30. Immol) was dissolved in dry tetrahydrofuran (90ml) and triethylamine (6.3ml, 45.0mmol). Methanesulfonyl chloride (3.78g, 33.0mmol) dissolved in dry tetrahydrofuran (10ml) was added and the mixture stirred at room temperature for 20 hours. The mixture was evaporated and ethyl acetate (250ml) added. After washing with water and drying over magnesium sulphate the organic solution was evaporated to (li?,2S)-l-[(l,l- dimethylethoxy)carbonylamino]-2-methanesulphonyloxyindan as white solid (9.7g, 98%). NMR1.45(9H, s), 3.05-3.35(2H, m), 3.18(3H, s), 5.15-5.25QH, m), 5.28-5.38(lH, m), 7.15- 7.22(4H, m), 7.45(1H, d).
( li?, 2S)- 1 - [( 1 , 1 -Dimethylethoxy)carbonylamino]-2-methanesulphonyloxyindan (3.5g, 10.7mmol) was dissolved in dry dimethyl acetamide (50ml). Sodium azide (3.5g, 53.9mmol) was added and the mixture heated to 90°C for 3 hours. The reaction was cooled, diluted with ethyl acetate (150ml), washed with water (6 x 50ml) and dried over magnesium sulphate. 10% Palladium on activated carbon was added and the mixture stined under a hydrogen atmosphere for 4 hours. Filtration through celite followed by evaporation gave the title compound as a white solid (2.6g, 98%). NMR: 1.45(9H, s), 2.5(1H, dd), 3.0(1H, dd), 3.2- 3.45(3H, m), 4.5-4.6(lH, m), 7.0-7.25(5H, m).
Method #44
2.3-Dichloro-5-rN-( 1 - f N-[( 1 , 1 -dimethylethoxy)carbonvH-N-methylamino }indan-2- yl)carbamoyl]-4H-thieno[3,2- )1pyrrole
Figure imgf000116_0002
To a solution of (li?,2S)-l-[(l,l-dimethylethoxy)carbonylamino]-2-hydroxyindan (Method #41, 7.0g, 28. Immol) in dichloromethane (50ml) was added 3,4-dihydro-2H-pyran (4.7g, 56.2mmol) and pyridinium toluene-4-sulphonate (lOOmg). The mixture was stirred for 4 hours, diluted with ethyl acetate (200ml), washed with water (2 x 50ml), dried over magnesium sulphate and evaporated to give ( li?, 25)- 1 -[( 1 , 1 -dimethylethoxy)carbonylamino]- 2-[(tetrahydropyran-2-yl)oxy]indan as a white solid (8.9g, 96%). NMR1.25-1.85(6Η, m), 1.45(9H, d), 2.85-3.1(2H, m), 3.35-3.5(lH, m), 3.68-3.9(lH, m), 4.35-5.1(3H, m), 6.8(1H, dd), 7.1-7.3(4H, m).
( li?, 2S)- 1 -[( 1 , 1 -Dimethylethoxy)carbonylamino]-2-[(tetrahydropyran-2-yl)oxy]indan
(4.0g, 12.0mmol) was dissolved in dry DMA (25ml) at 10°C and 60% sodium hydride (575mg, 14.4mmol) added. The mixture was stirred at room temperature for 30 minutes and then methyl iodide (2.0g, 14.4mmol) added after which the reaction was stirred for a further 3 hours at room temperature. The mixture was diluted with ethyl acetate (50ml), washed with water (6 x 50ml), dried over magnesium sulphate and evaporated to give (li?,2S)-l-{N-[(l,l- dimethylethoxy)]carbonyl-N-methyl-amino}-2-(tetrahydropyran-2-yl)oxyindan as an oil (4.1g, 98%). ΝMR 1.4-1.9(6H, m), 1.5(9H, d), 2.7(3H, dd), 2.85-3.3(2H, m), 3.47-3.6(lH, m), 3.72-4.0(lH, m), 4.7-5.0(2H, m), 5.5-5.84(lH, m), 7.15-7.35(4H, m); m/z 348.6 (M+H).
To a solution of (li?,2S)-l-{N-[(l,l-dimethylethoxy)carbonyl]-N-methylamino}-2-
(tetrahydropyran-2-yl)oxyindan (4.0g, 11.5mmol) in methanol (50ml) was added toluene-4- sulphonic acid (lOOmg) and the mixture stirred at room temperature for 2 hours. Saturated aqueous sodium bicarbonate (50ml) and water (10ml) was added and the mixture extracted with ethyl acetate. The organic extract was washed with water, dried over magnesium sulphate and evaporated to give (li?,2S)-l-{N-[(l,l-dimethylethoxy)carbonyl]-N-methylamino}-2- hydroxyindan as an oil (3.0g, 100%). ΝMR 1.45(9H, s), 2.6(3H, s), 2.75(1H, .dd), 3.05(1H, dd), 4.4-4.57(lH,m), 5.0-5.12(1H, m), 5.34(1H, dd), 7.03-7.33(4H, m).
To a solution give (li?)2S)-l-{N-[(l,l-dimethylethoxy)carbonyl]-N-methylamino}-2- hydroxyindan (3.0g, 11.4mmol) in dry tetrahydrofuran (40mmol) was added triethylamine (2.4ml, 17. Immol) and methane sulphonyl chloride (1.44g, 12.55mmol). The mixture was stirred at room temperature for 1 hour, evaporated and diluted with ethyl acetate (100ml). The organic solution was washed with saturated aqueous sodium bicarbonate and then water, dried over magnesium sulphate and evaporated to give a pale yellow syrup. The crude material was purified by silica chromatography with 4:1 wo-hexane:ethyl acetate as eluent to (li?,2S)-l-{N- [(l,l-dimethylethoxy)carbonyl]-N-methyl-amino}-2-methanesulphonyloxyindan as a clear colourless syrup (3.1g, 80%). ΝMR (CDC13): 1.54(9H, s), 2.7(3H, d), 3.0(3H, s), 3.16- 3.42(2H, m), 5.35-5.51(lH, m), 5.78(1H, dd), 7.2-7.35(4H, m); m/z 342.5 (M+H).
( li?, 2S)- 1 - { N- [( 1 , 1 -Dimethylethoxy)carbonyl] -N-methyl-amino } -2- methanesulphonyloxyindan (3.0g, 8.8mmol) was dissolved in dry DMA (30ml) and sodium azide (2.3g, 35.2mmol) added. The mixture was heated to 90°C for 6 hours, cooled and diluted with ethyl acetate (100ml). The solution was washed with water (6 x 50ml), dried over magnesium sulphate and filtered. 10% Palladium on activated carbon was added and the mixture stirred under a hydrogen atmosphere for 4 hours. The mixture was filtered, evaporated and purified by silica chromatography with 10% methanol in dichloromethane to give (li?,2S)-2-amino-l-{N-[(l,l-dimethylethoxy)]carbonyl-N-methyl-amino}indan as an oil (1.2g, 55%). ΝMR 1.36-1.56(9H, m), 2.6(3H, s), 2.7-2.87(lH, m), 3.2-3.35(lH, m), 4.37- 4.54(1H, m), 5.4-5.7(lH, m), 6.93-7.1(lH, m), 7.12-7.5(4H, m); m/z 263.48 (M+H).
5-Carboxy-2,3-Dichloro-4H-thieno[3,2-t ]ρyrrole (Method #9, 472mg, 2.0 mmol), ( 1 R, 2S)-2-amino- 1 - { N- [( 1 , 1 -dimethylethoxy)] carbonyl-N-methyl-amino } indan (524mg, 2.0mmol), DIPEA (0.348ml, 2.0mmol) and ΗOBT (270mg, 2.0mmol) was stirred in dichloromethane (10ml) at room temperature for 2 minutes. EDAC (480mg, 2.5mmol) was added and the mixture stirred at room temperature for 20 hours. The reaction was evaporated, ethyl acetate (50ml) added and washed with water. The organic phase was dried over magnesium sulphate and evaporated to give the title compound as a pale brown foam (900mg, 94%). ΝMR 1.2-1.45(9Η, m), 2.77(3H, s), 2.9-3.26(2H, m), 4.7-4.94(lH, m), 5.5-5.8(lH, m), 6.9-7.34(5H, m), 8.55-8.73(lH, m), 12.25(1H, broad s); m/z 480.3/482.1 (M+H). Example 155
The following illustrate representative pharmaceutical dosage forms containing the compound of formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof (hereafter compound X), for therapeutic or prophylactic use in humans:-
Figure imgf000119_0001
Figure imgf000120_0001
Note
The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

Claims

Claims
A compound of formula (I):
Figure imgf000121_0001
(I) wherein:
-X-Y-Z- is selected from -S-CR4=CR5-, -CR4=CR5-S-, -O-CR4=CR5-, -CR4=CR5-O-, -N=CR4-S-, -S-CR4=N-, -NR6-CR =CR5- and -CR4=CR5-NR6-; wherein R and R5 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, d.6alkyl, C2-6aIkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, d„6alkanoyloxy, N-(d-6alkyl)amino, NN-(C1-6alkyl)2amino, d_6alkanoylamino, N-(Cι_6alkyl)carbamoyl, N,N-(Cι-6alkyl)2carbamoyl, C1.6alkylS(O)a wherein a is 0 to 2, d-6alkoxycarbonyl, C1-6alkoxycarbonylamino, N- d-όalky sulphamoyl, NN-(C1.6alkyl)2sulphamoyl, C1-6alkylsulphonylamino and C1-6alkylsulphonyl-N-(d.6alkyl)amino;
R is hydrogen or C1-6alkyl;
R1 is selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, Cι-6alkyl, C2_6alkenyl, C -6alkynyl, d.6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1-6alkyl)2amino, C1-6alkanoylamino,
N-(C1-6alkyl)carbamoyl, NN-(C1- alkyl)2carbamoyl, d.6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, d.6aikoxycarbonylamino, N-(Cι.6alkyl)sulphamoyl, NN-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, C1-6alkylsulphonyl-N-(C1_6alkyl)amino, C3.8cycloalkyl, C3-8cycloalkylC1-6alkyl, aryl, arylC1-6alkyl, heterocyclic group and (heterocyclic group)C1-6alkyl; wherein R1 may be optionally substituted on carbon by one or more groups selected from P and wherein if said heterocyclic group contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from R;
R2 is selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, d.6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1.6alkyl)2amino, C!,.6alkanoylamino, ^(Cϊ-ealky^carbamoyl, NN-(C1-4alkyl)2carbamoyl, N-(C1.6alkyl)-N-(C1-6alkoxy)carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, Cι-6alkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, NN-(C1.6alkyl)2sulphamoyl, sulphamoylamino,
N-(d.6alkyl)sulphamoylamino, NN-(C1-6alkyl)2sulphamoylamino, d-6alkylsulphonylamino, d.6alkylsulphonylaminocarbonyl, d_6alkylsulphonyl-N-(C1-6alkyl)amino and a group -E-F-G-H; wherein E and G are independently selected from a direct bond, -O-, -S-, -SO-, -SO2-, -OC(O)-, -C(O)O-, -C(O)-, -ΝRa-, -NRaC(O)-, -C(O)NRa-, -SO2NRa-, -NRaSO2~, -NRaC(O)NRb-, -OC(O)NRa-, -NRaC(O)O-, -NRaSO2NRb-, -SO2NRaC(O)- and -C(O)NRaSO2-; wherein Ra and Rb are independently selected from hydrogen or C1-6alkyl which is optionally substituted by a group V ;
F is Ci-βalkylene optionally substituted by one or more Q or a direct bond; H is selected from aryl, C3-8cycloalkyl and heterocyclic group; wherein H may be optionally substituted on carbon by one or more groups selected from S and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from T;
R3 is hydrogen or d-βalkyl; n is selected from 0-4; wherein the values of R1 may be the same or different; and wherein the values of R3 may be the same or different;
P, S and Q are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, d_6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(d-6alkyl)amino, NN-(C1.6alkyl)2amino, d.6alkanoylamino, N-(d.6alkyl)carbamoyl,
NN-(d_6alkyl)2carbamoyl, N-(C1-6alkyl)-N-(C1_6alkoxy)carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, d-βalkoxycarbonyl, d-ealkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, NN-(C1.6alkyl)2sulphamoyl, Ci_6alkylsulphonylamino, C1-6alkylsulphonyl-N-(C1-6alkyl)amino, C3-8cycloalkyl, aryl and heterocyclic group; wherein P, S and Q may be optionally and independently substituted on carbon by one or more groups selected from N and wherein if said heterocyclic group contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from U; V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl, N-methyl-N-ethylsulphamoyl, morpholino, morpholinocarbonyl, N- benzylcarbamoyl, and 4- hydroxypiperidinocarbonyl; R, T and U are independently selected from C1-4alkyl, C1- alkanoyl,
C1-4alkylsulphonyl, d-4alkoxycarbonyl, carbamoyl, N-(C1_4alkyl)carbamoyl, NN-(d_ alkyl)carbamoyl, phenyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl wherein R, T and U may be optionally and independently substituted on carbon by one or more groups selected from V; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof; with the provisos: i) when -X-Y-Z- is -S-CH=CH-, R2-(CR1R3)n- cannot be amino, l-phenyl-5-methyl-lH-l,5- benzodiazepine-2,4(3H,5H)dion-3-yl, l-methyl-5-phenyl-2-oxo-2,3-dihydro-lH- benzo(E)( 1 ,4)diazepin-3-yl, 2-(4-phenyl- 1 ,2,5,6-tetrahydropyrid- l-yl)ethyl, 3-(4- phenyl- 1 ,2,5 ,6-tetrahydropyrid- 1 -yl)propyl, 2-(4-phenylpiperazin- 1 -yl)ethyl, 2-(N- methylamino)ethyl, 2-morpholinoethyl or 2-(N-methyl-N-benzylamino)ethyl; ii) when -X-Y-Z- is -CH=CH-S-, R2-(CR1R3)n- cannot be amino or l-methyl-5-phenyl-2-oxo- 2,3-dihydro-lH-benzo(E)(l,4)diazepin-3-yl; iii) when -X-Y-Z- is -CH=C(SO2ΝH2)-S-, R2-(CR1R3)„- cannot be methyl or isobutyl; and iv) when -X-Y-Z- is as initially defined, n is 1, R1 is arylmethyl, substituted arylmethyl, (heterocyclic group)methyl and substituted (heterocyclic group)mefhyl and R3 is hydrogen then R2 is not a group -C(=O)-A or a group -CH(OH)-C(=O)-A in which A is NRdRd, - NRaCH2CH2ORa, or
Figure imgf000124_0001
each Ra and Rb is independently hydrogen or -d-Csalkyl; each Rd is independently hydrogen, d-C8alkyl, d-C8alkoxy, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; each Rc is independently hydrogen, -C(=O)ORa -ORa, -SRa, or -NRaRa; and each n is independently 1-3, and
X1 is NRa, -CH2-, O or S.
2. A compound of formula (I) according to claim 1 wherein: -X-Y-Z- is selected from -S-CR4=CR5- or -CR4=CR5-S-; wherein R4 and R are independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2-6alkenyl, C .6alkynyl, C1-6alkoxy, C1-6alkanoyl, d_6alkanoyloxy, N- d-όalky amino, NN-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(Ci-6alkyl)carbamoyl, NN-(d.6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1.6alkoxycarbonyl, Ci-ealkoxycarbonylamino, N-(d-6alkyl)sulphamoyl, NN-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino and C1_6alkylsulphonyl-N-(C1.6alkyl)amino; n is 0; R2 is a group -E-F-G-H; wherein E, F and G are each a direct bond;
H is a C3-12cycloalkyl which is optionally fused to a benz ring wherein H may be optionally substituted on carbon by one or more groups S which are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2-6alkenyl, d-ealkynyl, d-6alkoxy, d-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1-6alkyl)2amino, d.6alkanoylamino, N-(d-6alkyl)carbamoyl, NN-(d-6alkyl)2carbamoyl, N-(C1-6alkyl)-N-(C1,6alkoxy)carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, C1-6alkoxycarbonylamino, ^(Cϊ-όalky sulphamoyl, NN-(d_6alkyl)2sulphamoyl, d.6alkylsulphonylamino, C1_6alkylsulphonyl-N-(C1_6alkyl)amino, C -8cycloalkyl, aryl and heterocyclic groups; wherein S may be optionally substituted on carbon by one or more groups selected from V;
V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl, N-methyl-N-ethylsulphamoyl, morpholino , morpholinocarbonyl , N- benzylcarbamoyl, and 4- hydroxypiperidinocarbonyl ; or a pharmaceutically acceptable salt thereof.
3. A compound of formula (I) as claimed in claim lwherein:
-X-Y-Z- is selected from -S-CR4=CR5- or -CR4=CR5-S-; wherein R4 and R5 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2-6alkenyl, C -6alkynyl, d_6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(d_6alkyl)amino, NN-(C1-6alkyl)2amino, d.6alkanoylamino, N-(d-6alkyl)carbamoyl, NN-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, C1.6alkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, NN-(d-6alkyl)2sulphamoyl, d„6alkylsulphonylamino and C1-6alkylsulphonyl-N- (C1-6alkyl)amino; n is 0;
R2 is a group -E-F-G-H; wherein E, F and G are each a direct bond; and
H is a cyclic amide of formula
Figure imgf000125_0001
in which k is 0, 1, 2 or 3 and 1 is 0, 1, 2 or 3 such that the sum of k and 1 is 2 or 3 and wherein one of the carbon atoms governed by k or 1 may be replaced by sulphur and wherein H is optionally substituted on carbon by one or more groups selected from S and may be independently optionally substituted on nitrogen by a group selected from T;
S is selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1-6alkyl)2amino, d-ealkanoylamino, N-(C1-6alkyl)carbamoyl, NN-(C1.6alkyl)2carbamoyl, N-(C1-6alkyl)-N-(C1-6alkoxy)carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, Cι.6alkoxycarbonyl, d-βalkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, NN-(d.6alkyl)2sulphamoyl, d-ealkylsulphonylarnino, C1-6alkylsulphonyl-N-(d_6alkyl)amino, C3-8cycloalkyl, aryl and heterocyclic group; wherein S may be optionally and independently substituted on carbon by one or more groups selected from V and wherein if said heterocyclic group contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from U;
T and U are independently selected from C1-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N-(C1-4alkyl)carbamoyl, NN-(C1-4alkyl)carbamoyl, phenyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl wherein R, T and U may be optionally and independently substituted on carbon by one or more groups selected from V; V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl, NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl, N-methyl-N-ethylsulphamoyl, morpholino, morpholinocarbonyl, N- benzylcarbamoyl and 4- hydroxypiperidinocarbonyl ; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
4. A compound of formula (I) as claimed in claim 1 wherein:
-X-Y-Z- is selected from -S-CR4=CR5- or -CR4=CR5-S-; wherein R4 and R5 are independently selected from hydrogen, halo or Cι_6alkyl. n is 1;
R1 is hydrogen or arylC1-6alkyl;
R2 is selected from a group -E-F-G-H; wherein E, F and G are each a direct bond;
H is an unsaturated five membered heterocyclic group containing at least one nitrogen atom and one or two ring atoms selected from oxygen and sulphur and wherein H may be optionally substituted on carbon by one or more groups S which are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C1-6alkyl, C2_6alkenyl, C2-6alkynyl, C1-6alkoxy, d_6alkanoyl, C1-6alkanoyloxy, N-(d-6alkyl)amino, NN-(d-6alkyl)2amino, d-6alkanoylamino, N-(d-6alkyl)carbamoyl, NN-(C1-6alkyl)2carbamoyl, N-(C1-6alkyl)-N-(C1_6alkoxy)carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, Cι_6alkoxycarbonylamino, N-(C1-6alkyl)sulphamoyl, NN-(Ci_6alkyl)2sulphamoyl, d-6alkylsulphonylamino, C1.6alkylsulphonyl-N-(C1.6alkyl)amino, C3.8cycloalkyl and aryl groups;
R3 is hydrogen or C1-6alkyl; or a pharmaceutically acceptable salt thereof.
5. A compound of formula (I) as claimed in claim 1 wherein:
-X-Y-Z- is selected from -S-CR4=CR5- or -CR4=CR5-S-; wherein R4 and R5 are independently selected from hydrogen, halo or C1-6alkyl. n is 0;
R2 is a group -E-F-G-H; wherein E is a direct bond;
F is methylene; wherein G is -C(O)ΝRa-, wherein Ra is selected from hydrogen or C1-6alkyl which is optionally substituted by a group V ;
H is aryl which may be optionally substituted on carbon by one or more groups selected from S;
S is selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, d-ealkyl, C2-6alkenyl, C2-6alkynyl, d-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, NN-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, NN-(C1-6alkyl)2carbamoyl, N-(C1-6alkyl)-N-(C1.6alkoxy)carbamoyl, C1.6alkylS(O)a wherein a is 0 to 2, d.6alkoxycarbonyl, d-βalkoxycarbonylamino, N-(Cι.-6alkyl)sulphamoyl, N N-(C i -6alkyl)2sulphamoyl , C \ .6alkylsulphonylamino, C i -6alkylsulphonyl-N-(C1 -6alkyl) amino , C3-8cycloalkyl, aryl and heterocyclic group; wherein S may be optionally and independently substituted on carbon by one or more groups selected from V ;
V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, NN-dimethylcarbamoyl,
NN-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, NN-dimethylsulphamoyl, NN-diethylsulphamoyl, N-methyl-N-ethylsulphamoyl, morpholino, morpholinocarbonyl, N- benzylcarbamoyl , and 4- hydroxypiperidinocarbonyl; or a pharmaceutically acceptable salt thereof.
6. A compound selected from
2,3-dichloro-5-[N-(2-phenoxyethyl)carbamoyl]-4H-thieno[3,2-t]pyrrole; 2,3-dichloro-5-{N-[2-(2-thienyl)ethyl]carbamoyl}-4H-thieno[3,2-t>]pynole;
2,3-dichloro-5-{N-[2-(2-methoxyphenyl)ethyl]carbamoyl}-4H-thieno[3,2-_j]pyrrole;
2,3-dichloro-5-[N-(2-phenyl-l-cyclopropyl)carbamoyl]-4H-thieno[3,2-t>]pynole;
2,3-dichloro-5-{N-[2-(4-fluorophenyl)ethyl]carbamoyl}-4H-thieno[3,2-t ]pynole;
2,3-dichloro-5-[N-(N-phenylcarbamoylmethyl)carbamoyl]-4H-thieno[3,2-t]pynole; 2,3-dichloro-5-(N-{2-[(2-pyridyl)amino]ethyl}carbamoyl)-4H-thieno[3,2-/3]ρyrrole;
2,3-dichloro-5-{N-[2-(N-methylmethanesulphonamido)-l-(thiazol-2-yl)ethyl]carbamoyl}-4H- thieno[3 ,2-5]pynole;
2,3-dichloro-5-{N-[2-(thiomorpholino)ethyl]carbamoyl}-4H-thieno[3,2-Z>]pyrrole;
5-[N-(benzoylmethyl)carbamoyl]-2,3-dichloro-4H-thieno[3,2- >]pyrrole; 3-chloro-5-[N-(N-phenylcarbamoylmethyl)carbamoyl]-4H-thieno[3,2-b]pyrrole;
3-chloro-5-{N-[2-(thiomorpholino)ethyl]carbamoyl}-4H-thieno[3,2-b]pyrrole;
3-chloro-5- {N- [2-(N-methylmethanesulphonamido)- 1 -(thiazol-2-yl)ethyl]carbamoyl } -4H- thieno [3 ,2-Z?]pyrrole ; 3-chloro-5-[N-(benzoylmethyl)carbamoyl]-4H-thieno[3,2-δ]pyrrole;
3-chloro-5-{N-[2-(2-methoxyphenyl)ethyl]carbamoyl}-4H-thieno[3,2-δ]pyrrole;
3-chloro-5- (N- [2-(2-thienyl)ethyl]carbamoyl } -4H-thieno [3 ,2-δ]pyrrole;
3-chloro-5-[N-(2-phenyl-l-cyclopropyl)carbamoyl]-4H-thieno[3,2-δ]pyrrole; 3-chloro-5-{N-[2-(4-fluorophenyl)ethyl]carbamoyl}-4H-thieno[3,2-&]pyrrole;
3-chloro-5-[N-(2-phenoxyethyl)carbamoyl]-4H-thieno[3,2-b]pyrrole;
3-chloro-5-{N-[2-(l-phenylmethanesulphonamido)ethyl]carbamoyl}-4H-thieno[3,2-t>]pyrrole;
3-chloro-5-[N-(4-oxo-2,3,4,5-tetrahydrobenz[l,5]thiazepin-3-yl)carbamoyl]-4H-thieno[3,2- bjpyrwle; 2-chloro-5-[N-(benzoylmethyl)carbamoyl]-4H-thieno[3,2-b]pyrrole;
2-chloro-5 - [N-(2-phenyl- 1 -cyclopropyl)carbamoyl] -4H-thieno [3 ,2-tVJpyrrole;
2-chloro-5-[N-(N-phenylcarbamoylmethyl)carbamoyl]-4H-thieno[3,2-6]pynole;
2-chloro-5-(N-{2-[(2-pyridyl)amino]ethyl}carbamoyl)-4H-thieno[3,2-t]pynOle;
2-chloro-5-{N-[2-(2-methoxyphenyl)ethyl]carbamoyl}-4H-thieno[3,2-δ]pyrrole; 2-chloro-5-[N-(2-phenoxyethyl)carbamoyl]-4H-thieno[3,2-t3]pyrrole;
2-chloro-5-{N-[2-(2-thienyl)ethyl]carbamoyl}-4H-thieno[3,2-έ]ρyrrole;
2-chloro-5-{N-[2-(4-fluorophenyl)ethyl]carbamoyl}-4H-thieno[3,2-t>]pyrrole;
2-chloro-5- {N-[2-(N-methylmethanesulphonamido)- 1 -(thiazol-2-yl)ethyl]carbamoyl } -4H- thieno [3 ,2-Z>]pyrrole; 2-chloro-5-{N-[2-(thiomorpholino)ethyl]carbamoyl}-4H-thieno[3,2-t ]pyrrole;
2,3-dichloro-5-[N-(2,3-dimethyl-5-oxo-l-phenyl-2,5-dihydro-lH-pyrazol-4-yl)carbamoyl]-
4H-thieno [3 ,2-/>]pyrrole ;
2,3-dichloro-5-[N-(4-sulphamoylphenylmethyl)carbamoyl]-4H-thieno[3,2-t)]pyrrole;
2,3-dichloro-5-[N-(2-hydroxy-l-phenethyl)carbamoyl]-4H-thieno[3,2-t]pyrrole; 2,3-dichloro-5-{N-(2-[(3-trifluoromethylpyrid-2-yl)amino]ethyl)carbamoyl}-4H-thieno[3,2- δjpynole;
2,3-dichloro-5-{N-[3-(5-tetrazolyl)propyl]carbamoyl}-4H-thieno[3,2-t3]pyrrole;
2,3-dichloro-5-[N-(5-oxo-3-phenyl-4,5-dihydroisoxazol-4-yl)carbamoyl]-4H-thieno[3,2- t)]ρynole; 2,3-dichloro-5-[N-(5-hydroxy-2-oxo-2,3,4,5-tetrahydro-lΗ-benz[t)]azepin-4-yl)carbamoyl]-
4H-thieno[3,2-δ]pyrrole;
2-chloro-5-{N-[3-(benzyloxycarbonylamino)ρropyl]carbamoyl}-4H-thieno[3,2-ό]pyrrole;
2,3-dichloro-5-{N-[(4-dimethylaminophenyl)methyl]carbamoyl}-4H-thieno[3,2-t>]pyrrole; 5- [N-( 1 -benzyl-2-hydroxyethyl)carbamoyl] -2,3 -dichloro-4H-thieno [3 ,2-b] pyrrole ;
2,3-dichloro-5-{N-[2-(phenylamino)ethyl]carbamoyl}-4H-thieno[3,2-ό]pyrrole;
2,3-dichloro-5-[N-(β-(i?)-hydroxy-α-methylphenethyl)carbamoyl]-4H-thieno[3,2-t>]pyrrole;
2,3-dichloro-5-[N-(β-hydroxyphenethyl)carbamoyl)-4H-thieno[3,2-_j]pyrrole; 2,3-dichloro-5-{N-[2-(4-hydroxyphenyl)ethyl]carbamoyl}4H-thieno[3,2-ό]pyrrole;
2,3-dichloro-5-{N-[(benzimidazol-2-yl)methyl]carbamoyl}-4H-thieno[3,2-Z]pyrrole;
2,3-dichloro-5- {N-[2-(4-chlorophenyl)-2-hydroxy- 1 -(methoxycarbonyl)ethyl]carbamoyl } -4H- thieno [3 ,2-6]pyιτole;
2,3-dichloro-5- {N-(imidazo[ 1 ,2-α]pyrid-2-yl)carbamoyl } -4H-thieno[3,2-ό]pynole; 5-{N-[(benzthiazol-2-yl)methyl]carbamoyl}-2,3-dichloro-4H-thieno[3,2-t]pynole;
2,3-dichloro-5-{N-[(6-trifluoromethylpyrid-3-yl)methyl]carbamoyl}-4H-thieno[3,2-t]pyrrole;
2,3-dichloro-5-{N-(2-[(2-pyridazinyl)methyl]carbamoyl}-4H-thieno[3,2-Z?]pyrrole;
2,3-dichloro-5-{N-[ N-(2-hydroxy-3-phenoxypropyl)carbamoylmethyl] carbamoyl }-4H- thieno[3,2-Z?]pyrrole; 2 ,3-dichloro-5- { N- [N-(3 -methylisothiazol-5 -yl)carbamoylmethyl] carbamoyl } -4H-thieno [3,2- έ]pyrrole;
2,3-dichloro-5-{N-[2-(pyridazin-3-yloxy)ethyl]carbamoyl}-4H-thieno[3,2-δ]pyrrole;
2-chloro-5-(N- { 2-[(3-trifluoromethylpyrid-2-yl)amino]ethyl } carbamoyl)-4H-thieno[3 ,2-
_>]pyreole; 2,3-dichloro-5-{N-[2-(4-sulphamoylphenyl)ethyl]carbamoyl}-4H-thieno[3,2-t3]pyrrole;
2,3-dichloro-5-{N-[2-(2-pyridyl)ethyl]carbamoyl}-4H-thieno[3,2-έ]pyrrole;
2,3-dichloro-5-{N-(2-[l-hydroxymethyl-2-(4-imidazolyl)ethyl]carbamoyl}-4H-thieno[3,2- έ]pyrrole;
2,3-dichloro-5-{N-(2-[(3-quinolyl)methyl]carbamoyl}-4H-thieno[3,2-ό]pynole; 5-{N-[3-(4-acetamidophenoxy)-2-hydroxypropyl]carbamoyl}-2,3-dichloro-4H-thieno[3,2- >]pyrrole;
2,3-dichloro-5-{N-[3-(N-methylsulphonylcarbamoyl)propyl]carbamoyl}-4H-thieno[3,2- yreole;
2,3-dichloro-5-[N-(2-{[2-(guanidino)thiazol-4-yl]methylthio}ethyl)carbamoyl]-4H-thieno[3,2- όjpyrrole;
2,3-dichloro-5-{N-[2-(2,4-dioxoimidazolidin-l-yl)ethyl]carbamoyl}-4H-thieno[3,2-t>]pynole; 5- { N-[2-benzylthio- 1 -(hydroxymethyl)ethyl]carbamoyl } -2,3-dichloro-4H-thieno [3,2- ό]pyrrole;
2,3-dichloro-5-{N-[2-(dimethyaminosulphonylamino)ethyl]carbamoyl}-4H-thieno[3,2- δ]pyreole; 2,3-dichloro-5-{N-[(6-methoxypyrid-3-yl)methyl]carbamoyl}-4H-thieno[3,2-t)]pynole;
(S -2,3-dichloro-5-{N-[(2-oxo-3-phenyl-2,3,4,5-tetrahydrooxazol-5-yl)methyl]carbamoyl}-
4H-thieno [3 ,2-δ]pynole;
2,3-dichloro-5-(N-{2-[3-(carbamoylmethyl)phenoxy]ethyl}carbamoyl)-4H-thieno[3,2- ό]pyrrole; 5-(N-{[6-(benzo[l,3]dioxol-5-yl)-4-methylmorpholin-2-yl]methyl}carbamoyl)-2,3-dichloro-
4H-thieno[3,2-/3]pyrrole;
5-(N-benzylcarbamoyl)- 2,3-dichloro-4H-thieno[3,2-t3]pyrrole;
2,3-dichloro-5-(N-phenethylcarbamoyl)-4H-thieno[3,2-t3]pyrrole;
2,3-dichloro-5-[N-(3-phenylpropyl)carbamoyl]-4H-thieno[3,2-έ]pyιτole; 2,3-dichloro-5-{N-[2-(2-hydroxyphenyl)ethyl]carbamoyl}-4H-thieno[3,2-t3]pyrrole;
2,3-dichloro-5-[N-( , -dimethylphenethyl)carbamoyl]-4H-thieno[3,2-t>]pyrrole;
2,3-dichloro-5-[N-(l-phenylcyclobutyl)methyl)carbamoyl]-4H-thieno[3,2-t>]pyrrole;
2,3-dichloro-5-[N-(β-methylphenethyl)carbamoyl]-4H-thieno[3,2-ό]pyrrole;
2,3-dichloro-5-[N-(l,2,3,4-tetrahydronaphth-2-yl)carbamoyl]-4H-thieno[3,2-δ]pyrrole; 5-[N-(N-benzylcarbamoylmethyl)carbamoyl]- 2,3-dichloro-4H-thieno[3,2-t>]pyrrole;
5-[N-(N-benzyl-N-methylcarbamoylmethyl)carbamoyl]-2,3-dichloro-4H-thieno[3,2-tj]pyrrole;
2,3-dichloro-5-[N-(N-methyl-N-phenylcarbamoylmethyl)carbamoyl]-4H-thieno[3,2-t)]pyrrole;
2,3-dichloro-5-{N-[N-(2-cyanoethyl)-N-phenylcarbamoylmethyl]carbamoyl}-4H-thieno[3,2-
&]pyrrole; 2,3-dichloro-5-{N-[N-(4-methoxyphenyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2- t>]pynole;
2,3-dichloro-5-{N-[N-(4-fluorophenyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2-ό]pynole;
2,3-dichloro-5- {N-[N-(4-nitrophenyl)carbamoylmethyl]carbamoyl } -4H-thieno[3,2-b]pyrrole;
2,3-dichloro-5-{N-[N-(2,6-dimethylphenyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2- έ]pyrrole;
2,3-dichloro-5-{N-[N-methyl-N-(4-methylphenyl)carbamoylmethyl]carbamoyl}-4H- thieno[3 ,2-δ]pyrrole; 2,3-dichloro-5- {N-[N-methyl-N-(3-methylphenyl)carbamoylmethyl]carbamoyl } -4H- thieno [3 ,2-t>] pynole ;
2,3-dichloro-5- {N-[N-(3-chlorophenyl) N-methylcarbamoylmethyl]carbamoyl } -4H- thieno [3 ,2-t>]pyrrole; 2,3-dichloro-5-{N-[N-(2-hydroxyethyl)-N-phenylcarbamoylmethyl]carbamoyl}-4H- thieno [3 ,2-δ]pyrrole;
2,3-dichloro-5-{N-[N-(l,l-dimethyl-2-hydroxyethyl)carbamoylmethyl]carbamoyl}-4H- thieno[3,2-ό]pynole;
2,3-dichloro-5-{N-[N-(2-hydroxyethyl)-N-methylcarbamoylmethyl]carbamoyl}-4H- fhieno[3,2-t)]pynole;
2,3-dichloro-5-{N-[N-(2-hydroxyethyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2- b]pyrrole;
2,3-dichloro-5-{N-[N-(3-hydroxypropyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2- ό]pynole; 2,3-dichloro-5-{N-[N-(4-hydroxybutyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2- b] pynole;
2,3-dichloro-5-(N-{N-[bis(hydroxymethyl)methyl]carbamoylmethyl}carbamoyl)-4H- thieno [3,2-b] pynole ;
2,3-dichloro-5-{N-[N-(2,3-dihydroxypropyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2- b]pynole;
2,3-dichloro-5-{N-[N-(4-hydroxymethylphenyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2- ό]pyrcole;
2,3-dichloro-5-{N-[N-(5-isoquinolyl)carbamoylmethyl]carbamoyl}-4H-thieno[3,2-&]pynole;
2,3-dichloro-5- {N-[N-(3-hydroxymethy)lphenyl]carbamoylmethyl]carbamoyl } -4H-thieno[3 ,2- δ]pynole;
2,3-dichloro-5-(N-{N-[4-(2-hydroxyethyl)phenyl]carbamoylmethyl}carbamoyl)-4H- thieno[3,2-t>]pynole;
2,3-dichloro-5- {N-[N-(2,4-difluorophenyl)-N-methyl-carbamoylmethyl]carbamoyl } -4H- thieno[3,2-b]pyrrole; 2,3-dichloro-5-{N-[(l,2,3,4-tetrahydro-l-quinolyl)carbonylmethyl]carbamoyl}-4H-thieno[3,2- b]pynole;
2,3-dichloro-5-{N-[N-(2-cyanoethyl)-N-methylcarbamoylmethyl]carbamoyl}-4H-thieno[3,2-
Z?]ρyrrole; 2,3-dichloro-5-{N-[N-(4-hydroxypiperidino)carbamoylmethyl]carbamoyl}-4H-thieno[3,2- t)]pynole;
2,3-dichloro-5-[N-(N- cyclopentylcarbamoylmethyl)carbamoyl]-4H-thieno[3,2-/3]pyrrole;
2,3-dichloro-5-[N-(N-isopropylcarbamoylmethyl)carbamoyl]-4H-thieno[3,2-ό]pyrrole; 2,3-dichloro-5-[N-(N-isopropyl-N-methylcarbamoylmethyl)carbamoyl]-4H-thieno[3,2- t>]pyrrole;
2,3-dichloro-5-[N-(thiomorpholinocarbonylmethyl)carbamoyl]-4H-thieno[3,2-t)]pyrrole;
2,3-dichloro-5-[N-(morpholinocarbonylmethyl)carbamoyl]-4H-thieno[3,2-&]pyrrole;
2 , 3 -dichloro-5- { N- [( 1 , 1 -dioxothiomorpholino)carbonylmethyl] carbamoyl } -4H-thieno [3 ,2t>] - pyrrole;
2,3-dichloro-5-{N-[(l-oxothiomorpholino)carbonylmethyl]carbamoyl}-4H-thieno[3,2- t>]pyrrole;
2-chloro-5-[N-(2-indanyl)carbamoyl]-6H-thieno[2,3-t ]pynole;
5-[N-(benz[l,2]oxazol-3-ylmethyl)carbamoyl]-2,3-dichloro-4H-thieno[3,2-t]pyrrole; 2,3-dichloro-5-(N-{2-[2-(hydroxymethyl)phenyl]ethyl}carbamoyl)-4H-thieno[3,2-έ]pynole;
2,3-dichloro-5-[N-(4-phenylisoxazol-3-ylmethyl)carbamoyl]-4H-tbieno[3,2-t ]pynole;
2,3-dichloro-5-(N-{2-[2-(2-morpholinoethoxy)phenyl]ethyl}caι-bamoyl)-4H-thieno[3,2- t>]pyrrole;
2,3-dichloro-5-(N-{2-[2-(methoxycarbonylmethoxy)phenyl]ethyl}carbamoyl)-4H-thieno[3,2- δ]pynole;
5-(N- { 2-[2-(carboxymethoxy)phenyl]ethyl } carbamoyl)-2,3-dichloro-4H-thieno[3,2-&]pynole;
2,3-dichloro-5-{N-[2-(3-methoxyphenyl)ethyl]carbamoyl}-4H-thieno[3,2-t)]pynole;
2,3-dichloro-5-[N-(2-oxo-l,2,3,4-tetrahydroquinol-3-yl)carbamoyl]-4H-thieno[3,2-δ]pynole;
2,3-dichloro-5-(N-{2-[2-(2-methoxyethoxy)ρhenyl]ethyl}carbamoyl)-4H-thieno[3,2- όjpyrrole;
5-(N-{2-[2-(carbamoylmethoxy)phenyl]ethyl}carbamoyl)-2,3-dichloro-4H-thieno[3,2- έ]pynole;
2,3-dichloro-5-(N-{2-[2-(N-methylcarbamoylmethoxy)phenyl]ethyl}carbamoyl)-4H- thieno [3 ,2-b] pynole ; 2,3-dichloro-5-(N-{2-[2-(N,N-dimethylcarbamoylmethoxy)phenyl]ethyl}carbamoyl)-4H- thieno[3,2-t)]pynole;
2,3-dichloro-5-(N-{2-[2-(morpholinocarbonylmethoxy)phenyl]ethyl}carbamoyl)-4H- thieno [3 ,2-b] pynole ; 5-(N- { 2-[2-(N-benzylcarbamoylmethoxy)phenyl]ethyl } carbamoyl)-2,3-dichloro-4H- thieno[3,2-_)]pynole;
2,3-dichloro-5-(N-{2-[2-(4-hydroxypiperidinocarbonylmethoxy)phenyl]ethyl}carbamoyl)-4H- thieno[3,2-δ]pyrrole; (S)-2-chloro-5-{N-[α-(5-ethoxycarbonyl-l,3,4-oxadiazol-2-yl)phenethyl]carbamoyl}-6H- thieno[2,3-t)]pynole;
(S)-2-chloro-5-{N-[ -(4-methoxycarbonyloxazol-5-yl)phenethyl]carbamoyl}-6H-thieno[2,3- δ]pyrrole;
2-chloro-5-{N-[ -(3-pyridyl)phenethyl]carbamoyl}-6H-thieno[2,3-t3]pynole; 2,3-dichloro-5-{N-[α-(3-pyridyl)phenethyl)]carbamoyl}-4H-thieno[3,2-t>]pynole;
(S)-2-chloro-5- {N-[α-(3-phenyl- 1 ,2,4-oxadiazol-5-yl)phenethyl]carbamoyl } -6H-thieno[2,3- δ]pyrrole;
2,3-dichloro-5-[N-(l-hydroxyindan-2-yl)carbamoyl]-4H-thieno[3,2-t)]pynole;
2,3-dichloro-5-[N-((iS2S)-l-hydroxyindan-2-yl)carbamoyl]-4H-thieno[3,2-ό]pyrrole; 2,3-dichloro-5-[N-((ii?)2i?)-l-hydroxyindan-2-yl)carbamoyl]-4H-thieno[3,2-t3]pynole;
2-chloro-5-[N-(l-hydroxyindan-2-yl)carbamoyl]-6H-thieno[2,3-έ]pyrrole;
2,3-dichloro-5- [N-( 1 -hydroxy- 1 ,2,3 ,4-tetrahydronaphth-2-yl)carbamoyl] -4H-thieno[3 ,2- ό]pynole;
2,3-dichloro-5-[N-(6-fluoro-l-hydroxyindan-2-yl)carbamoyl]-4H-thieno[3,2-t ]pynole; 2,3-dichloro-5-[N-(7-methoxy-l-oxo-l,2,3,4-tetrahydronaphth-2-yl)carbamoyl]-4H- thieno [3 ,2-έ]pynole;
2,3-dichloro-5-[N-(2-indanyl)carbamoyl]-4H-thieno[3,2-t>]pynole;
2,3-dichloro-5-[N-(3-methylisoxazol-5-yl)methyl]carbamoyl]-4H-thieno[3,2-δ]pyrrole;
2,3-dichloro-5-[N-(4-hydroxy-l,l-dioxotetrahydrothiophen-3-yl)carbamoyl]-4H-thieno[3,2- δ]pyrrole;
2,3-dichloro-5-(N-{N-methyl-N-[(l-oxo-l,2,3,4-tetrahydronaphth-2- yl)methyl]carbamoylmethyl } carbamoyl)-4H-thieno [3 ,2-ό]pyrrole;
2-chloro-5-[N-(2-oxo-l,2,3,4-tetrahydroquinol-3-yl)carbamoyl]-6H-thieno[2,3-έ]pynole;
2-chloro-5-[N-(l,2,3,4-tetrahydroquinol-3-yl)carbamoyl]-6H-thieno[2,3-t]pyrrole; 2-chloro-5-[N-(l-methyl-2-oxo-l,2,3,4-tetrahydroquinol-3-yl)carbamoyl]-6H-thieno[2,3- ό]pynole; 2-chloro-5-[N-(3-oxo-2,3,4,5-tetrahydro-lH-benz[2]azepin-4-yl)carbamoyl]-6H-thieno[2,3- δ]pynole;
2,3-dichloro-5-[N-(l-methoxyindan-2-yl)carbamoyl]-4H-thieno[3,2-/J»]pynole; 2,3-dichloro-5-(N- { 1 -[N-( 1 , 1 -dimethylethoxy)carbonylamino]indan-2-yl } carbamoyl)-4H- thieno[3,2-t)]pyreole;
5-[N-(l-aminoindan-2-yl)carbamoyl]-2,3-dichloro-4H-thieno[3,2-/J»]pynole; 5-[N-(l-acetamidoindan-2-yl)carbamoyl]-2,3-dichloro-4H-thieno[3,2-t)]pyrrole; 2,3-dichloro-5- { N- [ 1 -(methanesulphonamido)indan-2-yl]carbamoyl } -4H-thieno [3,2- δ]pynole; 2,3-dichloro-5-{N-[l-(methylamino)indan-2-yl]carbamoyl}-4H-thieno[3,2-έ]pyrrole; and 2,3-dichloro-5-{N-[l-(N-methylacetamido)indan-2-yl]carbamoyl}-4H-thieno[3,2-δ]pynole or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition which comprises a compound of the formula (I) as claimed in any one of claims 1-6, or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or canier.
8. The use of a compound of the formula as claimed in any one of claims 1 to 6 or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof as a medicament.
9. The use of a compound of the formula as claimed in any one of claims 1 to 6 or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of a glycogen phosphorylase inhibitory effect in a warm-blooded animal such as man.
PCT/SE2001/001880 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors WO2002020530A1 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
EEP200300083A EE200300083A (en) 2000-09-06 2001-08-31 Bicyclic pyrrole amides as glycogen phosphorylase inhibitors
CA002417594A CA2417594A1 (en) 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
US10/344,506 US20030232875A1 (en) 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
DK01961577T DK1317459T3 (en) 2000-09-06 2001-08-31 Bicyclic pyrrolylamides as glucogen phosphorylase inhibitors
JP2002525151A JP2004508376A (en) 2000-09-06 2001-08-31 Bicyclic pyrrolylamides as glycogen phosphorylase inhibitors
AU2001282833A AU2001282833B2 (en) 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
SI200130112T SI1317459T1 (en) 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
BR0113606-2A BR0113606A (en) 2000-09-06 2001-08-31 Compound, pharmaceutical composition, and use of a compound or pharmaceutically acceptable salt or in vivo hydrolysable ester thereof
HU0400784A HUP0400784A3 (en) 2000-09-06 2001-08-31 Bicyclic heterocondensated pyrrolcarboxamide derivatives, their use and pharmaceutical compositions containing them
AU8283301A AU8283301A (en) 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
NZ524011A NZ524011A (en) 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
PL01361024A PL361024A1 (en) 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
KR1020037003265A KR100802369B1 (en) 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
MXPA03001512A MXPA03001512A (en) 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors .
SK259-2003A SK2592003A3 (en) 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
DE60102710T DE60102710T2 (en) 2000-09-06 2001-08-31 BICYCLIC PYRROLYL AMIDE AS GLUCOSE PHOSPHORYLASE HEMMER
IL15429101A IL154291A0 (en) 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
UA2003021026A UA73781C2 (en) 2000-09-06 2001-08-31 Dicyclic pyrolylamides as inhibitors of glucogenphosphorylase
EP01961577A EP1317459B1 (en) 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
AT01961577T ATE263772T1 (en) 2000-09-06 2001-08-31 BIZYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS
IS6727A IS2110B (en) 2000-09-06 2003-02-24 Bi-ring pyrrolylamide as glucogenophosphorylase inhibitors
NO20031024A NO20031024D0 (en) 2000-09-06 2003-03-05 Bicyclic pyrrolyl amides as glucogenic phosphorylase inhibitors
BG107624A BG107624A (en) 2000-09-06 2003-03-10 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
HK03107519A HK1055299A1 (en) 2000-09-06 2003-10-16 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0021831.3 2000-09-06
GBGB0021831.3A GB0021831D0 (en) 2000-09-06 2000-09-06 Chemical compounds

Publications (1)

Publication Number Publication Date
WO2002020530A1 true WO2002020530A1 (en) 2002-03-14

Family

ID=9898927

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2001/001880 WO2002020530A1 (en) 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors

Country Status (31)

Country Link
US (1) US20030232875A1 (en)
EP (1) EP1317459B1 (en)
JP (1) JP2004508376A (en)
KR (1) KR100802369B1 (en)
CN (2) CN1264846C (en)
AT (1) ATE263772T1 (en)
AU (2) AU8283301A (en)
BG (1) BG107624A (en)
BR (1) BR0113606A (en)
CA (1) CA2417594A1 (en)
CZ (1) CZ2003616A3 (en)
DE (1) DE60102710T2 (en)
DK (1) DK1317459T3 (en)
EE (1) EE200300083A (en)
ES (1) ES2217183T3 (en)
GB (1) GB0021831D0 (en)
HK (1) HK1055299A1 (en)
HU (1) HUP0400784A3 (en)
IL (1) IL154291A0 (en)
IS (1) IS2110B (en)
MX (1) MXPA03001512A (en)
NO (1) NO20031024D0 (en)
NZ (1) NZ524011A (en)
PL (1) PL361024A1 (en)
PT (1) PT1317459E (en)
RU (1) RU2003104013A (en)
SK (1) SK2592003A3 (en)
TR (1) TR200401659T4 (en)
UA (1) UA73781C2 (en)
WO (1) WO2002020530A1 (en)
ZA (1) ZA200301013B (en)

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1125580A2 (en) * 2000-01-24 2001-08-22 Pfizer Products Inc. Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors
WO2002064565A1 (en) * 2001-02-13 2002-08-22 Aventis Pharma Deutschland Gmbh Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical
WO2003074485A2 (en) * 2002-03-06 2003-09-12 Astrazeneca Ab Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
WO2003074513A2 (en) * 2002-03-06 2003-09-12 Astrazeneca Ab Indole amide derivatives and their use as glycogen phosphorylase inhibitors
WO2003074532A1 (en) * 2002-03-06 2003-09-12 Astrazeneca Ab Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase
WO2003074531A1 (en) * 2002-03-06 2003-09-12 Astrazeneca Ab Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
WO2004041780A2 (en) * 2002-11-07 2004-05-21 Pfizer Products Inc. N-(indole-2-carbonyl) amides as anti-diabetic agents
WO2004092158A1 (en) * 2003-04-17 2004-10-28 Pfizer Products Inc. Carboxamide derivatives as anti-diabetic agents
WO2004113345A1 (en) * 2003-06-20 2004-12-29 Japan Tobacco Inc. Fused pyrrole compound and medicinal use thereof
WO2005013981A1 (en) * 2003-08-07 2005-02-17 Astrazeneca Ab Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity
WO2005013975A1 (en) * 2003-08-07 2005-02-17 Astrazeneca Ab Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
WO2004104001A3 (en) * 2003-05-21 2005-03-03 Osi Pharm Inc Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
WO2005018637A1 (en) * 2003-08-22 2005-03-03 Astrazeneca Ab Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity
WO2005019172A1 (en) * 2003-08-22 2005-03-03 Astrazeneca Ab Indol-2-amides as glycogen phosphorylase inhibitors
WO2005020985A1 (en) * 2003-08-29 2005-03-10 Astrazeneca Ab Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
WO2005020986A1 (en) * 2003-08-29 2005-03-10 Astrazeneca Ab Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
WO2005020987A1 (en) * 2003-08-30 2005-03-10 Astrazeneca Ab Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
JP2006505541A (en) * 2002-10-03 2006-02-16 アストラゼネカ アクチボラグ Methods and intermediates for producing thienopyrrole derivatives
WO2006053274A2 (en) * 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
WO2006059165A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase
WO2006082401A1 (en) * 2005-02-05 2006-08-10 Astrazeneca Ab Chemical compounds
US7138415B2 (en) 2002-03-06 2006-11-21 Astrazeneca Ab Indolamid derivatives which possess glycogenphosphorylase inhibitory activity
US7166636B2 (en) 2002-03-06 2007-01-23 Astrazeneca Ab Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity
US7179839B2 (en) 2001-02-13 2007-02-20 Sanofi-Aventis Deutschland Gmbh Acylated indanyl amines and their use as pharmaceuticals
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
EP1841426A1 (en) * 2005-01-19 2007-10-10 Merck & Co., Inc. Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
US7307174B2 (en) 2002-10-03 2007-12-11 Astrazeneca Ab Process and intermediates for the preparation of thienopyrrole derivatives
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
WO2010057141A2 (en) * 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Alphavirus inhibitors and uses thereof
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7893098B2 (en) 2003-12-29 2011-02-22 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
EP2298772A1 (en) * 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US8053603B2 (en) 2006-01-06 2011-11-08 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
US8097760B2 (en) 2006-03-31 2012-01-17 Sunovion Pharmacuticals Inc. Preparation of chiral amides and amines
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
US8669291B2 (en) 2007-05-31 2014-03-11 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
US8877975B2 (en) 2006-01-06 2014-11-04 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP2923706A1 (en) 2009-12-03 2015-09-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia
WO2016030534A1 (en) 2014-08-29 2016-03-03 Tes Pharma S.R.L. INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
WO2017004500A1 (en) * 2015-07-02 2017-01-05 Genentech, Inc. Bicyclic lactams and methods of use thereof
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2020104456A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
US10947226B2 (en) 2016-10-17 2021-03-16 Genentech, Inc. Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
US11634436B2 (en) 2018-04-20 2023-04-25 Genentech, Inc. Pyridine lactam compounds and methods of use thereof
EP4066896A4 (en) * 2019-11-27 2024-03-27 Riken G9a inhibitor
RU2827714C1 (en) * 2015-07-02 2024-10-01 Ф. Хоффманн-Ля Рош Аг Bicyclic lactams and methods of use thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10215907A1 (en) * 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-urea derivatives, processes for their preparation and their use
DE10215908B4 (en) * 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-urea derivatives and their use as medicaments
DE10225635C1 (en) * 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-benzoylureido-cinnamic acid derivatives, process for their preparation and their use
DE50311954D1 (en) * 2002-06-17 2009-11-12 Saltigo Gmbh Process for the preparation of mono-N-sulfonylated diamines
EP1523471B1 (en) * 2002-07-11 2009-09-16 Sanofi-Aventis Deutschland GmbH Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
WO2006082400A1 (en) * 2005-02-05 2006-08-10 Astrazeneca Ab Indan-amide derivatives with glycogen phosphorylase inhibitory activity
JP6974331B2 (en) * 2016-02-05 2021-12-01 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. Compounds, compositions and methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2081747A1 (en) * 1993-09-07 1996-03-01 Esteve Labor Dr Amide derivatives of thienopyrroles, their preparation and application as drugs
WO1996039384A1 (en) * 1995-06-06 1996-12-12 Pfizer, Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
EP0846464A2 (en) * 1996-12-05 1998-06-10 Pfizer Inc. Use of glycogen phosphorylase inhibitor for reducing non-cardiac tissue damage resulting from ischemia
WO1999046268A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP1088824A2 (en) * 1999-09-30 2001-04-04 Pfizer Products Inc. Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706810A (en) * 1970-09-15 1972-12-19 American Cyanamid Co N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides
US4692522A (en) * 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4599198A (en) * 1985-08-02 1986-07-08 Pfizer Inc. Intermediates in polypeptide synthesis
US4668769A (en) * 1985-08-02 1987-05-26 Hoover Dennis J Oxa- and azahomocyclostatine polypeptides
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
FR2601368B1 (en) * 1986-07-08 1989-04-07 Synthelabo NITROFURAN DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
DE3629545A1 (en) * 1986-08-30 1988-03-10 Bayer Ag DIHYDROPYRIDINE COMPOUNDS, METHOD FOR THEIR PRODUCTION AND THEIR USE
US4751231A (en) * 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
US5863903A (en) * 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
FR2723739B1 (en) * 1994-08-19 1997-02-14 Sanofi Sa GLYCINAMIDE DERIVATIVES, METHODS FOR THEIR PREPARATION AND MEDICINAL PRODUCTS CONTAINING THEM.
CO5271699A1 (en) * 2000-01-24 2003-04-30 Pfizer Prod Inc PROCEDURE FOR THE TREATMENT OF CARDIOMIOPATIA USING INHIBITORS OF THE GLUCOGENO FOSFORILASA
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2081747A1 (en) * 1993-09-07 1996-03-01 Esteve Labor Dr Amide derivatives of thienopyrroles, their preparation and application as drugs
WO1996039384A1 (en) * 1995-06-06 1996-12-12 Pfizer, Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
EP0846464A2 (en) * 1996-12-05 1998-06-10 Pfizer Inc. Use of glycogen phosphorylase inhibitor for reducing non-cardiac tissue damage resulting from ischemia
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
WO1999046268A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
EP1088824A2 (en) * 1999-09-30 2001-04-04 Pfizer Products Inc. Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

Cited By (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1125580A3 (en) * 2000-01-24 2002-11-27 Pfizer Products Inc. Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors
EP1125580A2 (en) * 2000-01-24 2001-08-22 Pfizer Products Inc. Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors
US6867184B2 (en) 2000-01-24 2005-03-15 Pfizer, Inc. Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors
US8163751B2 (en) 2001-02-13 2012-04-24 Sanofi-Aventis Deutschland Gmbh Acylated indanyl amines and their use as pharmaceuticals
WO2002064565A1 (en) * 2001-02-13 2002-08-22 Aventis Pharma Deutschland Gmbh Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical
US6949556B2 (en) 2001-02-13 2005-09-27 Aventis Pharma Deutschland Gmbh Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents
US7179839B2 (en) 2001-02-13 2007-02-20 Sanofi-Aventis Deutschland Gmbh Acylated indanyl amines and their use as pharmaceuticals
AU2002250920B2 (en) * 2001-02-13 2007-06-28 Sanofi-Aventis Deutschland Gmbh Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical
US7713963B2 (en) 2001-02-13 2010-05-11 Sanofi-Aventis Deutschland Gmbh Acylated indanyl amines and their use as pharmaceuticals
US7169927B2 (en) 2002-03-06 2007-01-30 Astrazeneca Ab Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
WO2003074531A1 (en) * 2002-03-06 2003-09-12 Astrazeneca Ab Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
US7115648B2 (en) 2002-03-06 2006-10-03 Astrazeneca Ab Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
WO2003074513A3 (en) * 2002-03-06 2003-12-31 Astrazeneca Ab Indole amide derivatives and their use as glycogen phosphorylase inhibitors
US7122567B2 (en) 2002-03-06 2006-10-17 Astrazeneca Ab Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
US7129249B2 (en) 2002-03-06 2006-10-31 Astrazeneca Ab Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase
US7332515B2 (en) 2002-03-06 2008-02-19 Astrazeneca Ab Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity
WO2003074485A2 (en) * 2002-03-06 2003-09-12 Astrazeneca Ab Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
WO2003074485A3 (en) * 2002-03-06 2003-12-04 Astrazeneca Ab Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
US7138415B2 (en) 2002-03-06 2006-11-21 Astrazeneca Ab Indolamid derivatives which possess glycogenphosphorylase inhibitory activity
WO2003074513A2 (en) * 2002-03-06 2003-09-12 Astrazeneca Ab Indole amide derivatives and their use as glycogen phosphorylase inhibitors
US7166636B2 (en) 2002-03-06 2007-01-23 Astrazeneca Ab Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity
WO2003074532A1 (en) * 2002-03-06 2003-09-12 Astrazeneca Ab Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
WO2004014842A1 (en) * 2002-08-07 2004-02-19 Aventis Pharma Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
CN1304365C (en) * 2002-08-07 2007-03-14 塞诺菲-安万特德国有限公司 Acylated arylcycloalkylamines and their use as pharmaceuticals
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
US7307174B2 (en) 2002-10-03 2007-12-11 Astrazeneca Ab Process and intermediates for the preparation of thienopyrrole derivatives
JP2006505541A (en) * 2002-10-03 2006-02-16 アストラゼネカ アクチボラグ Methods and intermediates for producing thienopyrrole derivatives
CN100378106C (en) * 2002-10-03 2008-04-02 阿斯利康(瑞典)有限公司 Process and intermediates for the preparation of the thienopyrrole derivatives
US7411074B2 (en) 2002-10-03 2008-08-12 Astrazeneca Ab Process and intermediates for the preparation of the thienopyrrole derivatives
US6992101B2 (en) 2002-11-07 2006-01-31 Pfizer, Inc. N-(indole-2-carbonyl) and H-thieno[2,3-b]pyrrole-5-carboxamide anti-diabetic agents
WO2004041780A2 (en) * 2002-11-07 2004-05-21 Pfizer Products Inc. N-(indole-2-carbonyl) amides as anti-diabetic agents
WO2004041780A3 (en) * 2002-11-07 2005-05-19 Pfizer Prod Inc N-(indole-2-carbonyl) amides as anti-diabetic agents
US6992092B2 (en) 2003-04-17 2006-01-31 Pfizer Inc. Anti-diabetic agents
WO2004092158A1 (en) * 2003-04-17 2004-10-28 Pfizer Products Inc. Carboxamide derivatives as anti-diabetic agents
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
US8158622B2 (en) 2003-05-21 2012-04-17 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
EA009215B1 (en) * 2003-05-21 2007-12-28 Прозидион Лимитед Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
WO2004104001A3 (en) * 2003-05-21 2005-03-03 Osi Pharm Inc Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
WO2004113345A1 (en) * 2003-06-20 2004-12-29 Japan Tobacco Inc. Fused pyrrole compound and medicinal use thereof
WO2005013981A1 (en) * 2003-08-07 2005-02-17 Astrazeneca Ab Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity
WO2005013975A1 (en) * 2003-08-07 2005-02-17 Astrazeneca Ab Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
WO2005018637A1 (en) * 2003-08-22 2005-03-03 Astrazeneca Ab Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity
WO2005019172A1 (en) * 2003-08-22 2005-03-03 Astrazeneca Ab Indol-2-amides as glycogen phosphorylase inhibitors
WO2005020986A1 (en) * 2003-08-29 2005-03-10 Astrazeneca Ab Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
WO2005020985A1 (en) * 2003-08-29 2005-03-10 Astrazeneca Ab Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
WO2005020987A1 (en) * 2003-08-30 2005-03-10 Astrazeneca Ab Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
US7893098B2 (en) 2003-12-29 2011-02-22 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
WO2006055462A1 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A3 (en) * 2004-11-15 2006-07-06 Bristol Myers Squibb Co 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055463A3 (en) * 2004-11-15 2006-12-28 Bristol Myers Squibb Co 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) * 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006059165A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase
US8664397B2 (en) 2004-12-02 2014-03-04 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase
EP1841426A4 (en) * 2005-01-19 2010-04-07 Merck Sharp & Dohme Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease
US8338614B2 (en) 2005-01-19 2012-12-25 Merck, Sharp & Dohme Corp. Tertiary carbinamines having substituted heterocycles which are active as β-secretase inhibitors for the treatment of alzheimer's disease
EP1841426A1 (en) * 2005-01-19 2007-10-10 Merck & Co., Inc. Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease
WO2006082401A1 (en) * 2005-02-05 2006-08-10 Astrazeneca Ab Chemical compounds
US9868718B2 (en) 2006-01-06 2018-01-16 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
US8877975B2 (en) 2006-01-06 2014-11-04 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
US10562878B2 (en) 2006-01-06 2020-02-18 Sunovion Pharamceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
US8053603B2 (en) 2006-01-06 2011-11-08 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
US8097760B2 (en) 2006-03-31 2012-01-17 Sunovion Pharmacuticals Inc. Preparation of chiral amides and amines
EP2351568A2 (en) 2006-05-04 2011-08-03 Boehringer Ingelheim International GmbH Uses of dpp-iv inhibitors
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
EP2298772A1 (en) * 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
US9586888B2 (en) 2007-05-31 2017-03-07 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
US8669291B2 (en) 2007-05-31 2014-03-11 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
WO2010057141A3 (en) * 2008-11-17 2010-09-16 The Regents Of The University Of Michigan Alphavirus inhibitors and uses thereof
WO2010057141A2 (en) * 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Alphavirus inhibitors and uses thereof
EP2923706A1 (en) 2009-12-03 2015-09-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP3708179A1 (en) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
EP4309673A2 (en) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
EP4424697A2 (en) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2016030534A1 (en) 2014-08-29 2016-03-03 Tes Pharma S.R.L. INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
US11254644B2 (en) 2014-08-29 2022-02-22 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US10513499B2 (en) 2014-08-29 2019-12-24 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
AU2016287581B2 (en) * 2015-07-02 2019-06-06 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
KR20180023988A (en) * 2015-07-02 2018-03-07 에프. 호프만-라 로슈 아게 Bicyclic lactams and their use
RU2827714C1 (en) * 2015-07-02 2024-10-01 Ф. Хоффманн-Ля Рош Аг Bicyclic lactams and methods of use thereof
RU2716136C2 (en) * 2015-07-02 2020-03-06 Ф. Хоффманн-Ля Рош Аг Bicyclic lactams and methods for use thereof
EP3760625A1 (en) * 2015-07-02 2021-01-06 F. Hoffmann-La Roche AG Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases
AU2019203444B2 (en) * 2015-07-02 2021-01-21 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
WO2017004500A1 (en) * 2015-07-02 2017-01-05 Genentech, Inc. Bicyclic lactams and methods of use thereof
US10988459B2 (en) 2015-07-02 2021-04-27 Genentech, Inc. Bicyclic lactams and methods of use thereof
KR102104911B1 (en) * 2015-07-02 2020-04-28 에프. 호프만-라 로슈 아게 Bicyclic lactam and its use method
TWI788830B (en) * 2015-07-02 2023-01-01 瑞士商赫孚孟拉羅股份公司 Bicyclic lactams and methods of use thereof
TWI763630B (en) * 2015-07-02 2022-05-11 瑞士商赫孚孟拉羅股份公司 Bicyclic lactams and methods of use thereof
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US10947226B2 (en) 2016-10-17 2021-03-16 Genentech, Inc. Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
US11634436B2 (en) 2018-04-20 2023-04-25 Genentech, Inc. Pyridine lactam compounds and methods of use thereof
WO2020104456A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
EP4066896A4 (en) * 2019-11-27 2024-03-27 Riken G9a inhibitor

Also Published As

Publication number Publication date
IS6727A (en) 2003-02-24
DK1317459T3 (en) 2004-07-12
AU8283301A (en) 2002-03-22
PT1317459E (en) 2004-08-31
CN1264846C (en) 2006-07-19
CA2417594A1 (en) 2002-03-14
ATE263772T1 (en) 2004-04-15
HK1055299A1 (en) 2004-01-02
HUP0400784A2 (en) 2004-07-28
DE60102710T2 (en) 2005-04-14
EP1317459A1 (en) 2003-06-11
CN1473163A (en) 2004-02-04
TR200401659T4 (en) 2004-09-21
JP2004508376A (en) 2004-03-18
BR0113606A (en) 2003-06-24
CN1896078A (en) 2007-01-17
NO20031024L (en) 2003-03-05
BG107624A (en) 2004-01-30
EP1317459B1 (en) 2004-04-07
MXPA03001512A (en) 2003-06-09
IS2110B (en) 2006-05-15
HUP0400784A3 (en) 2007-09-28
KR20030025305A (en) 2003-03-28
IL154291A0 (en) 2003-09-17
ZA200301013B (en) 2004-05-05
EE200300083A (en) 2004-12-15
DE60102710D1 (en) 2004-05-13
PL361024A1 (en) 2004-09-20
UA73781C2 (en) 2005-09-15
RU2003104013A (en) 2004-08-20
GB0021831D0 (en) 2000-10-18
SK2592003A3 (en) 2003-08-05
NZ524011A (en) 2004-08-27
CZ2003616A3 (en) 2003-05-14
KR100802369B1 (en) 2008-02-14
AU2001282833B2 (en) 2006-07-06
US20030232875A1 (en) 2003-12-18
ES2217183T3 (en) 2004-11-01
NO20031024D0 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
EP1317459B1 (en) Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
AU2001282833A1 (en) Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
US7129249B2 (en) Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase
AU2008273017C1 (en) Heterocyclic compounds useful as Raf kinase inhibitors
JP5639197B2 (en) Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions
EP1658069B1 (en) Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity
KR20030045187A (en) Tetrahydrobenzazepine Derivatives Useful as Modulators of Dopamine D3 Receptors(Antipsychotic Agents)
EP1658067B1 (en) Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
JP5814948B2 (en) Substituted fused imidazole derivatives, pharmaceutical compositions thereof, and methods of use
WO2003074531A1 (en) Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
WO2003074513A2 (en) Indole amide derivatives and their use as glycogen phosphorylase inhibitors
WO2013044360A1 (en) Inhibitors of protein tyrosine kinase activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 154291

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003/01013

Country of ref document: ZA

Ref document number: 200301013

Country of ref document: ZA

Ref document number: 524011

Country of ref document: NZ

Ref document number: 2417594

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 191/MUMNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 10344506

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/A/2003/001512

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2001282833

Country of ref document: AU

Ref document number: 2001961577

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2592003

Country of ref document: SK

Ref document number: PV2003-616

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020037003265

Country of ref document: KR

Ref document number: 03018834

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2002525151

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 10762401

Country of ref document: BG

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020037003265

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1-2003-500097

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2003104013

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: 018183220

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: PV2003-616

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001961577

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001961577

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 524011

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 524011

Country of ref document: NZ